Pre-Clinical Detection and Treatment Targeting in Colorectal Hepatic Metastases by Carter, Christopher Ross
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
PRE-CLINICAL DETECTION 
AND TREATMENT TARGETING IN 
COLORECTAL HEPATIC METASTASES
A thesis submitted to the University of Glasgow 
for the degree of M.D. in 
the Faculty of Medicine
C.Ross Carter M.B. Ch.B. F.R.C.S.
University Department of Surgery, 
Glasgow Royal Infirmary, 
Glasgow,
ProQuest Number: 10992158
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10992158
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOW
UNIVERSITY
LIBRARY
ACKNOWLEDGEMENTS
I wish to thank all my colleagues in Glasgow Royal Infirmary, University 
Department of Surgery, whose friendship I will never forget. More specifically,! will 
be eternally grateful to Professor Timothy Cooke and Wilson Angerson for their 
supervision,enthusiasm, guidance and endeavour.
I also appreciate the contributions of David Hemingway, whose established 
models I inherited, and particularly John H.Anderson, without whose help the 
complexities of the cross perfusion experiment would have overcome my 
determination.
I am indebted to Gordon Murray,Carol and Audrey of the University 
Department of Statistics for their guidance and assistance in analysing of the 
results.
I am grateful to Robert,who always managed to find what I needed;to Peter 
whose "Mac" was invaluable;to Bruce,David,Colin, and the boys whose healthy 
cynicism maintained my perspective;and to the girls in my "coffee room" for 
providing gossip and solace when required.
Last,but not least,my family - my father(Kevin),Pat and sister(Dawn),and 
particularly my wife(Lynne),who have all been patient and tireless in their 
encouragement. However it is to my mother,Anita,to whose memory this thesis is 
dedicated.
2
ABSTRACT
The prognosis for patients with colorectal metastases at the time of 
presentation is poor. Recently published reports have suggested that moderate 
improvements in survival are possible in patients with colorectal carcinoma, using 
5-FU based chemo-therapeutic regimes given either as adjuvant therapy or in the 
presence of established metastases. The benefit is stage specific,less than 50% of 
patients being suitable candidates,the treatment of all patients therefore resulting in 
unnecessary morbidity, increasing the importance of accurate peri-operative staging.
Most currently available imaging techniques are "density dependent", 
detecting a difference in the density of tumour deposits,relative to the surrounding 
liver,but these rarely detect lesions less than 1 cm in diameter,and will consequently 
miss patients with micrometastatic disease. Dynamic hepatic scintigraphy is an 
indirect method of measuring liver blood flow and can distinguish the relative 
contribution of the portal venous and hepatic arterial components of liver blood flow. 
The ratio of the hepatic arterial contribution to total liver blood flow is termed the 
"Hepatic Perfusion lndex"(HPI).
The HPI has been shown to be raised in the presence of overt metastases 
and also in a proportion of those patients who are apparently clear at the time of 
presentation but who subsequently develop hepatic metastases. The reproducibility 
of the standard hepatic scintigraphy technique(80 MBq administered activity) has 
been questioned and the technique has not become established in clinical practice.
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A high administered activity(400 MBq) modification of dynamic scintigraphy 
technique has been assessed showing improved correlation following repeated 
analysis of studies by a single observer,and also on separate analysis by two 
observers. A prospective imaging study comparing five imaging modalities 
(U/S,CT,Static scintigraphy,dynamic scintigraphy and intraoperative ultrasound) 
with intraoperative palpation confirmed that the HPI was as accurate as contrast 
enhanced CT in the detection of colorectal metastases. However,the specificity was 
poor.
The change in the HPI has been shown in a rat tumour model,to be as a 
result of a reduction in splanchnic vascular inflow due to an increase in the 
splanchnic vascular resistance. A similar effect has been shown in patients. A 
cross perfusion model was developed to determine if the increase in the splanchnic 
vascular resistance was due to a transmissible humeral agent. The perfusion 
pressure was similar in controls and tumour bearing animals,but the flow produced 
was reduced during periods of perfusion with tumour bearing blood due to a 
significant increase in the vascular resistance,confirming the presence of a 
circulating agent.
Using a reference microsphere technique.the splanchnic vascular flow was 
shown to reduce in animals with both intrahepatic and extrahepatic(flank) 
tumour.The hepatic arterial flow was reduced in animals with extrahepatic tumour 
but not intrahepatic tumour,suggesting the change in the HPI in the presence of 
intrahepatic tumour was due to local(hepatic arterial) protection of flow despite 
splanchnic vascular vasoconstriction.
The efficacy of present chemotherapeutic regimes is limited by toxicity. By 
localising the drug in the target tissue,dose escalation is possible due to reduced
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systemic exposure. First order targeting(to the organ)usually requires a major 
surgical procedure to insert a gastroduodenal artery catheter. Organ targeting may 
in theory be achieved biochemically taking advantage of the normal biochemical 
pathways of the body avoiding the morbidity of surgery. Three potential targeting 
vehicles of this type were assessed in a rat model of hepatic metastases.
In the first study,14C labelled 5-FU bound to a manose/gaurin conjugate with 
secondary galactose residues was assessed as a targeting system. There was little 
advantage over free drug in achieving hepatic targeting,and the venous 
pharmacokinetic profile was suggestive of rapid breakdown of the 5-FU/gaurin 
complex.
A similar series of experiments, using a 125l labelled hydroxymethyacrylamide 
(HPMA) polymer, again with secondary galactose residues, confirmed organ 
specific targeting could be achieved in this way, with up to 60% of the polymer 
localising in liver within 30 minutes. Levels within intrahepatic tumour were 
disappointing. Regional delivery of the polymer had little effect on subsequent 
distribution,and although delivery via the hepatic artery increased the concentration 
within tumour tissue, levels were still less than 10% of surrounding liver 
parenchyma.
Porphyrin metabolism results in localisation within the reticulo-endothelial 
system and within tumour tissue. Again over 50% of a 14C-labeled 
haematoporphyrin derivative could be detected within the liver. With HpD tumour 
levels were better than with HPMA, being nearly half of that in surrounding liver. 
Further refinement is required to achieve positive tumour to liver ratios.
Regional administration of drugs via a surgically implanted catheter is 
designed to improve drug delivery to tumour. This may be further refined by the
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coadministration of either degradable microemboli or arterial vasocontrictors,which 
divert drug from normal liver,and/or delay its washout. The benefit from 
vasocontrictors is known to be temporary, the effect being minimal 90 minutes 
following administration. The effect of combining these two approaches was studied 
in an animal model of colorectal metastases. The administration of the angiotensin II 
prior to the degradable starch microspheres proved the most effective method of 
targeting a radiolabelled marker substance. The combination significantly increased 
both the absolute retention of marker in tumour and the tumour : liver ratio over 
animals treated with DSM alone.
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CHAPTER 1
INTRODUCTION
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INCIDENCE OF COLORECTAL CARCINOMA
Colorectal carcinoma is the third most common carcinoma behind lung and 
skin cancer in men and breast and lung carcinoma in females. Each year in Britain 
there will be 22,000 new cases,900 in the West of Scotland (W.S.C.S.U.,1990),only 
9,000 of which will be cured by surgical resection.
The prognosis in patients is largely determined by the extent of spread at the 
time of diagnosis. Tumours confined to the bowel wall have a five year survival in 
excess of 90%(Grem, 1991),but these unfortunately account for less than 10% of 
cases(Umpleby et al,1984;Gill and Morris, 1978),the majority having spread at least 
through the bowel wall,and approximately 20% having palpable metastases at 
laparotomy,who have a median survival of less than 6 months(Wood et 
al,1976;Bengmark and Hafstrom,1969).
Local recurrence in the original tumour bed represents a major component of 
failure, however attention to the detail of the surgical procedure(McGlone et 
al,1982),or the addition of adjuvant radiation may produce improvements in local 
control. Patients with disease limited to the original tumour bed comprise less than a 
quarter of all patients dying of colorectal carcinoma,the remainder having 
disseminated disease. Two-thirds of these patients will have hepatic metastases.
In the last two decades the percentage of patients known to have metastases 
at presentation has increased from 18-19% (Oxley and Ellis, 1969;Bengmark and 
Hafstrom,1969) to around 30% (Finlay and McArdle,1986;Machi et al, 1987) due to 
improved imaging techniques. The proportion of patients that are undergoing
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"potentially curative" surgery in the presence of undetected micrometastases is 
therefore reducing. Despite this,more than 20% will subsequently develop recurrent 
disease,one third with local recurrence,one third with hepatic or distant 
metastases,the remainder with a combination of both(Rich et al,1983).
The development of hepatic metastases depends on the dissemination of 
malignant cells from the primary tumour into the mesenteric tributaries and 
subsequently into the portal vein,before embedding in the hepatic bed. In those 
patients in whom surgery fails, it is assumed that micrometastases exist that are 
responsible for metachronous metastases. Whether these metastatic deposits are 
already present at the time of surgery,but below the threshold of detection,or 
whether dissemination occurs at the time of surgery is unresolved. Radical surgery 
or employing early isolation,"no touch" technique has more effect on local 
recurrence than distant dissemination(McGlone et al,1982;Turnbull,1980). Either 
way, these microdeposits have a high growth fraction and should be therefore be at 
their most sensitive to cytotoxic agents.
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Table 1. Relative frequency of common cancers in the West of Scotland:
Males Females
Lung 140 Breast
Skin(Ex.melanoma) 53 Lung
Colon, Rectum 48 Colon, Rectum
Prostate 43 Skin(Ex.melanoma)
Bladder 34 Stomach
Stomach 27 Ovary
Oesophagus 15 Cervix
Lymphoma 13 Bladder
Pancreas 12 Pancreas
Kidney 11 Oesophagus
Leukaemia 10 Endometrium
Oral tumours 9 Lymphoma
Larynx 8 Leukaemia
Brain 6 Melanoma
Melanoma 6 Kidney
Rates per 100,000 population in the West of Scotland. (1987) 
Based on registrations received before April 1990.
(West of Scotland Cancer Surveillance Unit, 1990)
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Figure 1 : Fate of 100 patients with colorectal carcinoma
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BLOOD SUPPLY TO THE LIVER
The normal liver has a dual blood supply via the portal vein (which collects 
blood from the viscera;the stomach,spleen, intestine and pancreas) and the hepatic 
artery which delivers blood directly from the heart.Both vessels enter the porta 
hepatis separately, before dividing into branches to the right and left lobes. 
(Rappaport,1973).
The separation of the liver into right and left lobes on the basis of surface 
anatomy does not fully reflect the vascular anatomy. Eight segments,each with 
separate hepatic arterial,portal venous and biliary radicles,may be identified. The 
hepar may therefore be divided more correctly into right (segments 5,6,7,8) and 
left(segments 2,3,4) livers,the line of separation corresponding to the plane from the 
gallbladder fossa to the inferior vena cava. Segment 1 (the caudate lobe) is 
considered to be a "third liver" with independent vascular and biliary anatomy 
(Couinaud, 1957;Nakamura and Tsukuki, 1981;Bismuth, 1982).
The division of the portal venous and hepatic arterial radicles continues, until 
they unite at the origin of the hepatic sinusoids. Differences in pressure are thought 
to be compensated by sphincters(Rappaport,1973). There are also presinusoidal 
communications through which 30% of the arterial blood is shunted into the portal 
venous radicles before ultimately entering the sinusoids. These sinusoids are 
intimately associated with the hepatic parenchymal cells. Blood having passed 
through the sinusoids drain into hepatic venules that progressively coalesce to form 
the hepatic veins that ultimately drain into the inferior vena cava. The liver receives 
a quarter of the cardiac output,one third via the hepatic artery the remaining 
two-thirds are supplied by blood draining the splanchnic circulation into the portal 
vein(Lautt and Greenway, 1987).
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Figure 2: Segmental anatomy of the liver
Total liver blood flow has been estimated at approximately 1500 ml/min using 
colloidal techniques, BSP, indocyanine green and galactose clearance 
(Keiding,1988;Caesar et al,1961,Shaldon et al.1961; Bradley et al,1945). The flow 
within the liver is a function of the hepatic arterial vascular resistance and the portal 
vascular resistance. Alteration to systemic venous pressure does not appear to 
affect relative flow(Lautt and Greenway, 1987). The resistance offered by the 
splanchnic vascular bed far exceeds that of the normal liver and the splanchnic bed 
therefore has the predominant effect on portal venous flow. Intrahepatic control of 
flow is therefore limited to the hepatic artery which is under both neural and humoral 
influences(Greenway and Stark, 1971;Lautt and Greenway, 1987).
It has been shown in dogs that a decrease in portal venous flow leads to a 
compensatory increase in hepatic arterial flow. Similarly an increase in portal flow 
leads to a decrease in arterial flow,a feature that is enhanced in portal 
hypertension(Baker and Shields, 1974;Zimmon and Kessler, 1980). The mechanism 
remains unclear, but the present consensus is that these changes in arterial flow 
serve to buffer the homeostatic environment of the liver(Lautt and Greenway, 1987) 
although the hepatic artery cannot always compensate quantitatively for reductions 
in portal flow.(Greenway and Stark, 1971)
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BLOOD SUPPLY TO LIVER METASTASES
Morphological studies on the structure of blood vessels that nourish hepatic 
metastases suggest that they are small tortuous vessels,arranged in a haphazard 
manner principally around the periphery of the deposit(Ackerman and 
Hechmer,1978). They are also immature lacking smooth muscle 
elements,endothelial tight junctions etc. and are therefore different from the 
surrounding host vessels in terms of physiological and pharmacological 
activity(Mattson et al, 1977;Mattson et al,1978). Determining the source of the blood 
entering these vessels is important for the regional delivery of chemotherapeutic 
agents,to ensure maximum delivery to tumour cells.
There have been many methods used to determine the relative importance of 
the hepatic arterial and portal venous components of hepatic metastatic blood flow. 
These include the delineation of the vascular tree using barium 
sulphate(Segall, 1923), India ink (Breddis and Young, 1954) and other colloidal 
dyes(Fisher et al,1961), corrosion casting methods(Healey, 1965;Lien and 
Ackerman, 1970; Ackerman, 1974),radioactive marker or stable isotope clearance 
techniques (Taylor et al,1979(133Xenon);Ridge et al, 1987(13N),arteriography (Kido, 
1970),and radio-active microsphere methods(Ackerman et al, 1969;Ackerman, 
1972; Hemingway et al,1991).
Micrometastases appear to have a dual supply,the portal supply being 
initially more prominent as in surrounding parenchyma. With growth the hepatic 
arterial contribution increases until the arterio-portal ratio is reversed, and in animal 
models tumours as small as 0.5mm have an established internal vasculature 
perfused predominately by the hepatic artery (Archer and Gray, 1989). Once
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established, human colorectal metastases would appear to be hypovascular relative 
to the surrounding liver parenchyma(Taylor et al,1978),although vascularity may 
vary between synchronous metastases(Bledin et al,1982;Civellari et al, 1991 ;Daly et 
al, 1985).
Histologically identifiable blood conduits are limited to the periphery of the 
metastases,central supply being haphazard and sparse resulting in ischaemic 
necrosis. In the physiological situation the portal contribution is minimal, a collateral 
circulation exists permitting portal venous filling of these vessels following arterial 
occlusion(Lien and Ackerman, 1970). Despite the existence of these collateral 
vessels,radiolabelled macro-aggregated albumen microsphere experiments have 
failed to show significant shunts between the hepatic artery and hepatic veins in 
human colorectal carcinoma(Goldberg et al,1987).
In summary,human hepatic metastases from colorectal primaries appear to 
derive their blood supply almost entirely from the hepatic artery,are predominately 
hypovascular relative to surrounding liver parenchyma,and are associated with 
minimal arteriovenous shunting.
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CONTROL OF INTESTINAL BLOOD FLOW
Intestinal blood flow is determined by three principal mechanisms: local 
myogenic or metabolic responses,sympathetic nervous control, and the effect of 
circulating vasoactive agents. Although discussed separately,these interact to 
maintain the homeostatic environment of the intestine.
The immediate control of flow is determined principally by local mechanisms 
largely independent of neural control(Johnson, 1964). In practice,phenomena 
resulting in a failure of the circulation to meet the 0 2 demands of the tissues 
produce the formation of metabolites responsible for arteriolar vasodilation, with a 
consequent increase in blood flow.Potassium, H+,serum osmolality,adenosine and 
adenine nucleotides,in addition to interstitial p02> have all been proposed as the 
local mediator(Granger et al,1980). Myogenic influences are dependent on the 
effect of stretch on vascular smooth muscle(Bayliss,1902), increases in transmural 
pressure leading to arteriolar vasoconstriction and reduced flow.
It is evident from this that there is considerable autoregulation of the 
intestinal circulatory environment. The principal site of this would appear to be the 
precapillary arterioles((Johnson and Hanson, 1962). The extent to which the 
intestine is able to maintain constant flow is limited,flow reducing markedly when 
perfusion pressure falls below physiological values.The intestine is richly innervated 
by post-ganglionic vasoconstrictor fibres reaching the gut via the splanchnic nerves, 
stimulation of which reduces blood flow to the intestine(Bunch,1899). Continued 
stimulation results in a compensatory metabolic vasodilatation resulting in 
"autoregulatory escape"(Folkow et al,1964). Stimulation of parasympathetic nerves 
has little direct effect on intestinal blood flow,in mammals its action being principally 
on gut motility.(Kewentner,1965).
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Numerous hormones alter intestinal blood flow either by directly affecting the 
resistance vessels or indirectly by affecting the perfusion pressure,sympathetic 
drive or by altering the local metabolic environment. Table 2 summarises the effect 
of hormonal stimulation on intestinal blood flow.
The most significant alteration to intestinal blood flow occurs with the 
response to food - the functional hyperaemia. Within a few minutes of ingestion 
splanchnic vascular resistance decreases.flow increasing by more than 100%(Burns 
and Worthington, 1969). This hyperaemia appears to be as a result of a 
combination of neural,hormonal,myogenic and metabolic stimuli the precise 
interaction of which remains the subject of much research.
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Table 2 : Effect of hormonal stimulation on splanchnic vascular 
resistance and blood flow(Granger et al,1980).
Hormone Vascular Splanchnic
Resistance blood flow
Glucagon - +
Prostacyclin - +
Gastrin - +
Secretin - +
CCK/PZ - +
VIP - +
Bradykinin -(minimal) ?
5-HT +(minimal) ?
Dopamine + -
p g a 2 + -
Acetylcholine + -
Histamine + -
Vasopressin + -
Phenylephrine + -
Angiotensin + -
Noradrenaline + -
Adrenaline + -
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METHODS OF DETECTING HEPATIC METASTASES
In the last decade,as evidence has increased that the ultimate survival in 
patients with colorectal metastases may be modified by surgery or 
chemotherapy,the detection of metastatic disease has assumed greater clinical 
importance. The simple detection of liver metastases is no longer sufficient,the 
evaluation of size,number and location may also affect future management.
Clinical manifestations of colorectal metastases,such as hepatomegaly, 
pain,weight loss or icterus occur relatively late in the clinical course,and are 
therefore of little use in detecting patients at a stage where they are still amenable 
to treatment. There are no specific tumour markers for colorectal tumours or their 
metastases. Carcinoembryonic Antigen(CEA) is disappointingly insensitive as a 
screening tool, but may have a role in the post-operative monitoring of metastases 
negative patients to detect preclinical recurrence.(Northover, 1986;Wood et 
al,1980). The measurement of biochemical indices(Aspartate transaminase(AST), 
Alanine transaminase(ALT),gamma-Glutamyl transpeptidase(gamma-GT),Alkaline 
phosphatase) is of limited value in the detection of metastatic disease.(Jonsson et 
al,1984;Schreve et al,1984;Hugieur and Lacaine,1981;Kemeny et al,1982)
Metastases may be confirmed at laparotomy by palpation allowing biopsy. 
Alternatively,they may detected by imaging techniques which may be separated 
into two types. Firstly there are those that depend on a difference between the 
composition or density of the normal liver parenchyma compared to that of the 
abnormal lesion.
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The four investigations of this type are computerised tomography (CT),real 
time ultrasonography(US),static hepatic scintigraphy,and magnetic resonance 
imaging(MRI),although MRI is still within Britain principally a research tool. 
Secondly there are those that attempt to exploit haemodynamic changes that occur 
in the presence of colorectal metastases. These changes may be determined by 
dynamic hepatic scintigraphy or by Doppler flow studies. Both investigations have 
yet to be accepted as being clinically relevant.
SECTION I - DENSITY DEPENDENT METHODS:
Real time ultrasonography was first developed in 1966,by Donaldson,an 
obstetrician in Glasgow;computerised tomography and albumen static scintigraphy 
were developed in the 1970's and MRI in the 1980's. The technology involved in 
these techniques has progressed rapidly in the intervening years, improving the 
precision of diagnostic imaging of hepatic metastases,and casting doubt on the 
relevance of studies of sensitivity and specificity performed in their infancy.(table 3). 
In all density dependent methods, detection may be complicated by the presence of 
diffuse abnormalities of the liver parenchyma,such as cirrhosis or fatty change.
Ultrasonography:
Real time ultrasonography depends on the detection of differences in the 
selective amplification of low level echos from an ultrasonic source directed at an 
organ. Metastases are detected due to a variations in the velocity of sound 
transmission through the normally homeogeneous liver parenchyma (Bryan et 
al,1977). Although with modern equipment lesions between 1 and 2cm can be 
diagnosed with confidence, and differentiation between solid and cystic lesions
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readily made, a negative scan does not exclude metastases and the sensitivity of 
ultrasonography remains low,falling below 80% under study conditions(Kemeny et 
al, 1982).Up to 10% of scans may be technically inadequate due to restricted 
anatomical access or overlying bowel gas(Schreve et al,1984). Another major 
drawback of sonography is its operator dependency,and in clinical practice 
accuracy has been reported to be as low as 20%(Charnley et al,1988).
Intraoperative Ultrasonography:
Percutaneous ultrasonography is hampered by the existence of "visually 
dead" areas due to the costal margin,bowel gas or simple obesity. The development 
of small,easily sterilised,high frequency ultrasound probes had led to the 
intraoperative examination of the liver which allows a more complete examination of 
the liver,with improved detection rates for intrahepatic lesions,especially in cirrhotic 
patients(lgawa et al,1985).
Originally described in 1980(Lane and Glazer, 1980),several authors have 
claimed this to be the most effective method of detecting liver tumours(lgawa et 
al,1985;Gossetti et al,1985) detecting over 90% of liver metastases. The technique 
is time consuming and may require a "water cushion" to detect superficial 
lesions,although this may be considered unnecessary as these are easily detected 
manually.
Any test that takes intraoperative time to perform must potentially result in 
alterations in management to justify the effort. The detection and localisation of 
additional lesions in patients with multiple bilobular metastases is therefore of little 
interest. The possibility of detecting metastases in patients in whom all other 
investigations have been negative has been suggested(Gossetti et 
al,1985),although the efficacy of screening apparently clear livers by intraoperative
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ultrasonography is yet to be fully established,as authors have tended to report the 
sensitivity in patients known to have intrahepatic lesions. Occasionally 
intraoperative ultrasound may be of benefit in distinguishing "Pseudotumours",such 
as focal hyperplasia in patients with coexistent hepatic parenchymal disease(Clain 
etal.1984)
The principle role of intraoperative ultrasonography would appear to be in 
patients in whom a liver resection is being contemplated. Currently only solitary 
lesions or less than three lesions localised to one area of the liver are considered 
suitable for resection. In these patients intraoperative ultrasonography has a dual 
role. The detection of previously occult lesions may render the patient an unsuitable 
candidate.avoiding an unnecessary resection. In addition by delineating the spacial 
relationship of the lesion to the principle intrahepatic vascular and biliary 
radicles,segmental resection may be performed with greater safety.
Computerised tomography
CT is a well established modality for the detection of liver metastases, the 
optimal technique having evolved with advances in scanning time and improved 
understanding of contrast media pharmacology. Early scanners required prolonged 
scanning times necessitating iodine infusions to prevent the rapid intravascular 
clearance of contrast media.Rapid scanning allows arterial or portal phase 
enhancement with improved detection, CT portography having the highest 
sensitivity in metastatic detection(Rossi et al, 1981).Bolus dynamic CT.CT 
arteriography and delayed iodine scanning, may also increase the information 
obtained over standard techniques.(Halvorson and Thompson, 1991)
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The detection of liver lesions is again dependent on the difference in 
attenuation or density between the background liver parenchyma and each lesion. 
Consequently isodense lesions,or lesions in a liver rendered of low density 
secondary to fatty change,are more difficult to detect.CT remains the most accurate 
currently available imaging technique for the detection of liver metastases with a 
sensitivity of up to 90%(Alderson et al,1983; Rossi et al, 1981;Halvorson and 
Thompson, 1991).
Magnetic Resonance Imaging
The spinning charges in an atom,the protons and electrons, convey magnetic 
properties to that atom. In general particles are paired in such a way that their spins 
cancel and materials with an even number of particles exhibit very weak magnetic 
properties. Magnets are a special class of materials in which the atoms contain 
several unpaired particles,giving these permanent magnetism.
The atoms of most importance for magnetic resonance imaging are those of 
low atomic number,having unpaired spinning particles within the nucleus. Each 
nucleus behaves like a small magnet,but as a whole lack columnation.the tissue 
having a neutral magnetic effect. By applying magnetic energy across the 
tissue,these nuclei can be orientated. On release from the external magnetic 
field,the orientation of the nuclei again becomes random, releasing energy. The 
amount of energy is a measure of the number of charged nuclei present and the 
rate of decay gives information about their environment. The release of this energy 
forms the basis of magnetic resonance imaging(Dendy and Heaton, 1987).
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Consequently by measuring the magnitude and kinetics of energy emanating 
from tissue exposed to and then released from an external magnetic field,a 
tomographic image can be created,providing anatomical detail. Thus the difference 
between liver parenchymal tissue and tumour tissue may allow identification of a 
colorectal metastatic deposit.The role of MRI in the detection of liver masses 
remains controversial. Respiratory artifact limits the application of MRI in some 
older machines. Stark's results (Stark et al,1987) suggested that MRI was superior 
to CT in the detection of metastases. In this study,he compared a state of the art 
MRI scanner to older CT equipment. By contrast other authors have found CT to be 
consistently superior to MRI(Nelson et al,1988).
In Britain,the limited availability of MRI has prevented its inclusion into 
clinical practice,and at present MRI remains a research tool. The sensitivity and 
specificity of CT and MRI with modern equipment are probably similar, these 
investigations being complementary rather than mutually exclusive.
Static scintigraphy
The detection of liver metastases by scintigraphy relies on the ability of the 
normal liver parenchyma to concentrate systemically administered " m'Tc labelled 
albumen colloid,metastases resulting in defects in the hepatic image.Hepatic 
scintigraphy is feasible in nearly all patients,and requires minimal medical input 
(Bryan et al,1977) and it is therefore a particularly useful screening tool when 
resources are limited. Scintigraphy is associated with a relatively high false positive 
rate due to large pendulous breasts,intrahepatic gallbladder,renal indentations,or 
lesions close to the porta hepatis(Knopf et al,1982). Scintigraphy also provides 
physiological information on liver function,but anatomic definition is poor and 
positive findings require corroboration.
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SECTION II - HAEMODYNAMIC TECHNIQUES:
Changes in hepatic blood flow with the development of intrahepatic tumour:
Accurate measurement of accurate organ blood is difficult in the clinical 
situation,and classical techniques for measuring liver blood flow fail to distinguish 
between the hepatic arterial and portal venous components. This has led to a 
dependence on the findings from animal studies. The knowledge that hepatic 
metastases derived the majority of their blood supply from the hepatic artery 
.coupled with the observation that the hepatic artery contributes a greater proportion 
of total liver blood flow(as determined in the hepatic perfusion index) in the 
presence of hepatic metastases, led to the assumption that absolute hepatic arterial 
flow increased with the development of metastases(Boyd et al,1978;Leveson et 
al, 1985;Sarper et al, 1981).
Using the Walker cell model of colorectal metastases,using radioactive 
microspheres and electromagnetic flowmetry.Nott demonstrated that this 
fundamental assumption was wrong,and that although the HPI increases,this is due 
to a decrease in portal venous flow rather than increased arterial demand(Nott et 
al, 1989). He suggested that the reduction in portal venous inflow was secondary to 
the development of significant arteriovenous shunts, increasing portal venous 
resistance,and therefore reducing flow.
Human metastases are slow growing,generally hypovascular,and are not 
associated with significant systemic shunting,and consequently, this model has 
been criticised in that it is fast growing,hypervascular and exhibits significant 
arteriosystemic shunting. Hemingway,using the hypovascular HSN sarcoma model, 
which is more representative of human colorectal metastases, confirmed the that 
portal venous inflow fell and hepatic arterial inflow remained static with the
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development of intrahepatic tumour(Hemingway et al, 1991).In contrast to the 
Walker cell model,these haemodynamic changes occur in the HSN model without 
the development of arteriovenous shunts,the portal venous resistance being 
unchanged. This suggested that the reduction in portal venous flow must be due to 
an increase in splanchnic vascular resistance,with a consequent reduction in 
splanchnic vascular, and therefore, portal flow.
As described earlier the control of splanchnic vascular resistance and 
therefore blood flow is multifactorial. Although immediate control would appear to be 
as a result of local mechanisms,persistent alterations in the haemodynamic pattern 
of the splanchnic bed appear to result from a combination of humoral and neural 
control. Many tumour products are vasoactive,however,if the tumour is producing an 
active substance why are the changes only apparent with the development of 
intrahepatic tumour? Although the accuracy of measuring blood flow using duplex 
sonography has yet to be confirmed .early results suggest that the changes may be 
due to a combination of reduced splanchnic vascular flow and increased hepatic 
arterial flow but the numbers investigated are as yet small(Leen et al,1991).
In summary it would appear that with the development of metastases,total 
liver blood flow does not increase and may even fall,primarily due to a reduction in 
portal venous flow which is partially compensated for by a minor increase in arterial 
inflow.
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Dynamic hepatic scintigraphy
In 1981 Sarper and Biersack described techniques whereby they could 
distinguish the arterial and portal phases of liver blood flow by the dynamic analysis 
of liver and right renal images following in a bolus injection of ssmjc sulphur 
colloid(Biersack et al,1981;Sarper et al,1981). In this technique,posterior images 
are obtained every 2 seconds for 2 minutes,using a large field of view gamma 
camera. Images corresponding to the heart and lungs,liver,spleen and kidneys may 
be identified. By the creation of time activity curves,blood flow to each organ can be 
deduced from the rate of delivery of ^ T c  sulphur colloid to that organ.
Analysis of the renal time activity curve reveals a single peak, corresponding 
to colloid reaching the kidney via the renal artery, followed by a gradual fall as 
colloid passes into the venous circulation. By contrast the hepatic time activity curve 
has two phases of uptake,an initial phase corresponding to hepatic arterial delivery 
of colloid and a second steeper phase due to colloid reaching the liver having 
initially passed through the splanchnic vascular bed. The end of the arterial phase 
and start of the portal phase may be determined as the point at which counts over 
the reference organ(kidney or spleen) are maximal.
Initially the right renal image was used as a reference organ,but the 
technique was modified by Wraight in 1982 using a splenic image to mimic arterial 
flow(Wraight et al,1982). The following year Parkin,in Leeds,used the left renal peak 
for analysis to avoid hepatic overlap with the right renal image,which results in 
artificially high values(Perkins et al, 1987),and described the ratio of the contribution 
of the hepatic arterial flow to total liver blood flow as the" Hepatic Perfusion Index".
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Figure 3: Time activity curves of liver and left kidney following
an intravenous bolus of 99mTc albumen colloid.
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The Leeds group showed that 97% of patients with metastases proven at 
subsequent laparotomy had an abnormal preoperative HPI (Parkin et al,1983). 
Some apparently metastases-free patients had an abnormal HPI at the time of 
laparotomy.Follow-up of these patients confirmed that at one year 18 of 29 patients 
with an abnormal HPI had developed metastases,whereas none of 21 with a normal 
pre-operative HPI had gone on to develop metastases(Leveson et al,1985). 
Subsequently,the ability of the HPI to predict the metachronous development of 
metastatic disease was confirmed(Cooke et al,1987), and the HPI was also shown 
to increase on serial scanning with disease progression in 86% of 
patients.(Ballantyne et al,1990)
Despite these encouraging and potentially clinically important results,the 
hepatic perfusion index(low administered activity(80 MBq)),has not been accepted 
into surgical practice. This has been as a result of other workers experiencing 
technical difficulties or problems with the reproducibility of the technique. Some 
authors have found up to 14% of patients unsuitable for analysis,although this may 
be reduced using the left kidney image for analysis(Perkins et al,1987). Laird 
confirmed the HPI to be a sensitive method of detection of liver dysfunction,but 
found abnormalities in patients with parenchymal liver disease,in addition to those 
with metastases (Laird et al,1987).
The standard technique involves the injection of 80-100 MBq of 99"Tc. This 
produces relatively small counts in each region of interest,and previous studies from 
the Glasgow Royal Infirmary have demonstrated a range of values on reprocessing 
studies by a single observer(Goldberg et al,1989). This is because the inherent 
statistical errors associated with small accumulated counts lead to relatively poorly 
defined uptake curves.
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In addition to this intra-observer variability,Perkins reported that significant 
interobserver variation occured on sequential analysis of time activity 
curves(Perkins et al, 1987),with one observer consistently achieving higher results 
than another,possibly due to differences in the size of regions of interest selected.
Standardised methodology is of paramount importance in that bolus 
quality,the length of time over which the slopes are averaged,transit times through 
the liver,splenic and mesenteric circulations and the degree of tracer extraction will 
all effect the calculated HPI(Tindale and Barber,1987). Errors are most likely within 
the abnormal range,and higher values are obtained using the right rather than the 
left renal image(Perkins et al,1987). We have previously found that reliability was 
improved in animal studies,measuring the HPI using a high administered activity of 
radiocolloid(80 - 100MBq/rat)(Hemingway et al,1991). This has led to the evaluation 
of the Hepatic Perfusion Index in patients using a high administered activity of 
radiocolloid(400MBq / patient) in an attempt to improve the reproducibility of the 
technique,and the results of this assessment are presented later in this thesis.
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Duplex ultrasonography
More recently advances in the technology of duplex sonography are being 
applied in Glasgow Royal Infirmary as a technique for the estimation of hepatic 
arterial and portal venous flow(Leen et al,1991). The technique is less invasive than 
dynamic scintigraphy and again allows the calculation of a doppler perfusion 
index,defined in analogy with the hepatic perfusion index as the ratio of the hepatic 
arterial inflow to total liver blood flow. The inter- and intra-observer variation and 
clinical correlation have yet to be evaluated. Another potential advantage of Doppler 
sonography is the additional information that may be obtained regarding the 
morphology of the apparently normal liver parenchyma. False positive HPI's occur 
in the presence of cirrhosis (Parkin et al,1983) which may be detectable on 
ultrasound. This allows the calculation of a "congestive index" which compensates 
for other morbid conditions.
Summary:
Over the last 15 years,there have been many published studies examining 
the relative sensitivity of various methods of detection of liver metastases (table 3). 
Imaging technology is an area of rapid evolution, rendering sensitivities obtained on 
1970's equipment irrelevant. All techniques, and in particular ultrasound and 
doppler perfusion scanning,have an element of operator dependance,techniques 
such as dynamic scintigraphy being dependant more on computer analysis rather 
than a subjective impression. Finally, most reports on new imaging techniques are 
by protagonists,and therefore have a tendency toward subconscious bias,and a 
techniques clinical application is determined by its accuracy in the hands of those 
less familiar with its use.
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It would appear that not only is dynamic scintigraphy the most sensitive 
technique for the detection of colorectal metastases, consistently having a 
sensitivity in excess of 90%(Cooke et al,1987;Sarper et al,1981;Parkin et 
al,1983;Leveson et al, 1985),but in addition has the ability to provide prognostic 
information in patients undergoing apparently curative surgery. Consequently if 
problems of reproducibility are overcome the measurement of the HPI may have a 
central role in the investigation and management strategy of patients with colorectal 
carcinoma.
43
Table 3: Accuracy of methods of detecting hepatic metastases.
Sensitivity of detection techniques(%)
Static U/S CT Palp MRI HPI Bioch IOU/S
Bryan(1977) 79 85 88 30
Sarper(1981)85 100
Finlay(1982) 29 47 88 30
Kemeny(1982) 82 75 80 65
Alderson(1983) 86 82 93
Parkin(1983) 97
Schreve(1984) 79 85 88 30
lgawa(1985) 91
Gossetti(1985) 80 74 98
Leveson(1985) 94
Stark(1987) 51 64
Nelson(1988) 86 62
Charnley(1988) 21 50 64 86
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METHODS OF TREATING METASTASES.
Eighty percent of patients that die of colorectal carcinoma have liver 
metastases at the time of death(Taylor et al,1985). In the absence of liver or lung 
metastases spread to other organs is rare. Treatment may be designed to prevent 
their occurrence (adjuvant therapy) or towards eradication or control of established 
disease. Chemotherapy or radiotherapy may be employed in either a therapeutic or 
adjuvant setting,whereas surgery is indicated only in the presence of established 
metastases.
(1) CHEMOTHERAPY:
SECTION I - TREATMENT of ADVANCED DISEASE 
Systemic therapy:
Chemotherapy is the only feasible option when faced with a patient with 
advanced disease. Many feel that subjecting these patients to the morbidity 
associated with chemotherapy is unjustified when the median survival may be as 
short as 3 months(Wood et al, 1976). Systemic 5FU is still the most effective agent 
producing objective responses in 10-20% of patients but does not affect 
survival(Kemeny, 1987;Laurie et al,1989).Most regimes are limited by systemic 
toxicity.Consequently two alternative approaches toward improving the efficacy of 
chemotherapy have been employed: tumour targeting and biochemical modulation 
of 5FU activity.
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TREATMENT TARGETING:
The targeting of therapy toward a tumour may be considered on three levels(Widder 
etal.1979):
(1) to the affected organ
(2) to the tumour mass within that organ
(3) to the tumour cells within the tumour mass
First Order targeting:
(a) Surgical methods of targeting;
In 1964 Watkins published and his collegues from Boston published their 
initial experience (Watkins and Sullivan, 1964) with regional infusion of 
fluorodeoxyuridine into the hepatic artery; long term follow-up of these patients 
(Watkins et al,1970) suggested a favorable symptomatic response and also 
prolongation in survival when compared to historical controls. In the next 20 years 
several phase I and II trials of 5-FU,FUDR and mitomycin (Patt et al,1980;Ansfield 
et al,1977) reported objective response rates as high as 83% but the percutaneous 
catheter technique resulted in a high complication rate.
The development of an implantable port, through which intraarterial infusions 
could be administered (Shiley-lnfusaid, 1981) stimulated a further phase II trial of 
intra-arterial FUDR therapy which again reported an 83% response rate(Ensminger 
et al,1982). Unfortunately the phase III study that followed this allowed crossover 
following failure of systemic therapy preventing analysis of survival data(Holn et 
al,1989). A similar trial(Kemeny,1987) again showed improved hepatic response 
rates but again the cross-over design obscured survival data. Infusion therapy 
would appear to be more effective than interval bolus administration (Lokich et 
al,1989).
46
In both forms of therapy the limiting factor was patient 
tolerability;approximately double the maximum systemically tolerated 
dose(300mg/m2/d)(Lokich et al,1989) was required to produce significant biliary 
morbidity in the intra arterial group. Nearly twice as many patients developed 
extrahepatic disease in the intraarterial group (62.5%:35%(Kemeny,1987)).
(b) Biochemical methods of targeting:
An alternative approach for first order targeting is to utilise inert drug carriers 
for site specific delivery to the target organ. Human albumen and dextrans(Baurain 
et al,1983) have been evaluated as potential carriers,but the potential 
immunogenicity limits their clinical usefulness. Consequently synthetic carriers, 
consisting of a polymer backbone to which can be linked both targeting residues 
and antitumour agents,have been suggested as potential alternatives.
The galactose recognising receptor of hepatocytes has been proposed to 
enable liver specific chemotherapy to be systemically administered.Previous in-vitro 
experiments using N-(2-hydroxylpropyl)methacrylamide copolymers containing 
galactosamine have confirmed that binding occurs to both hepatocytes and 
hepatoma cell lines(0'Hare et al, 1989),and hepatic targeting occurs in murine 
distribution experiments. Little is known regarding its distribution in tumour bearing 
livers.
An alternative method of biochemical targeting to liver is to utilise porphyrin 
metabolism. When haemoglobin is broken down the "globin" portion is reutilised 
either as such or by joining the amino acid pool. The "haem" or porphyrin portion is
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broken down and the Fe2+ removed to form biliverdin which is subsequently reduced 
to bilirubin. This occurs in the reticuloendothelial cells of the liver spleen and bone 
marrow. Exogenous porphyrins are metabolised in a similar manner,resulting in 
organ specific targeting to the liver and spleen.
An additional attraction of porphyrins is the spontaneous localisation in 
tumour tissue,first noticed by Policard in 1924. Haematoporhyrin derivative(Lipson 
et al,1961) and later dihaematoporphyrin ether/Photofrin ll(Dougherty et al,1983) 
have been developed for their improved tumour localising properties. If a cell in the 
presence of a photosensitiser is stimulated.classically by light in the near infra red,a 
number of reactions occur, the most important of which is the production of singlet 
oxygen(Dougherty et al,1978) which results in membrane damage and cell death 
due to photooxygenation of membrane proteins(Van Steveninck et al,1986).
Consequently in porphyrins we have the potential for organ selectivity, 
tumour localisation and local cytotoxicity. Unfortunately the poor tissue penetration 
of visible light(5mm at 630nm)coupled with the inaccessability of the liver prevent 
standard photodynamic therapy having a clinical application for the treatment of 
liver metastases. In theory any non-ionising electromagnetic radiation has the 
potential to excite a photosensitiser, raising the possibility of intrahepatic excitation 
with external beam radiation. This innovative approach is as yet theoretical.
The principal advantage of biochemical targeting by either galactose bearing 
polymers or porphyrins is the avoidance of major surgery with its attendant 
morbidity and mortality. At present this alternative strategy remains in its infancy.
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Second order targeting:
Although first order targeting reduces the systemic morbidity and allows 
modest dose escalation,colorectal hepatic metastases are relatively hypovascular 
relative to the surrounding liver parenchyma, favoring drug delivery to normal 
liver.The development of significant hepatotoxicity prevents dose escalation to 
achieve cytotoxic levels within the tumour deposits.
Tumour vessels are immature and,lacking smooth muscle elements (Mattson 
et al, 1977;Mattson et al,1978),are unable to respond to vasoactive agents. Any 
response following administration of a vasoconstrictor will occur predominately in 
the normal liver parenchyma inducing a temporary tumour hypervacularity,favoring 
delivery of drug to tumour rather than liver. The use of biodegradable emboli such 
as albumen or starch microspheres have also been shown to increase the retention 
of drug in tumour tissue(Cooke and Chang, 1990). The temporary embolisation 
within the liver delays the systemic distribution and leading to reduced systemic 
exposure due to a prolonged first pass effect(Lindell et al,1978).
Both vasoactive agents and degradable emboli have been used 
clinically(Civellari et al,1991;Goldberg et al, 1989;Hunt et al, 1990),to produce 
second order targeting of chemotherapeutic agents. Excellent objective responses 
have been achieved,but this has as yet to be shown to improve survival.
The available evidence would suggest that while first and second order 
targeting may produce symptomatic and objective intra-hepatic responses, any 
survival advantage is limited by the subsequent development of extrahepatic 
disease. Titration of the intrahepatic dose to allow sufficient spillover into the 
systemic circulation to achieve adequate systemic levels is at present being 
investigated.
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Biochemical enhancement of 5-FU activity
Because of the relative insensitivity of colorectal metastatic disease to all 
currently available chemotherapeutic agents,there has recently been considerable 
interest in the potentiation of the achieved antitumour effect through biochemical 
modulation. Experimental studies investigating the mechanism of action of 
5-FU(Evans et al,1981;Waxman and Bruckner, 1982) have suggested that the 
inhibition of thymidylate synthetase is one of the major anti-metabolic sites of action 
of the drug. The duration of inhibition appears to depend on the 5-FU 
metabolite,flourodeoxyuridylate, forming a ternary complex with thymidylate 
synthetase and the folate cofactor 5-10 methylene tetrahydrofolate. Other folate
Table 4: Trials of 5-FU plus Folinic acid versus 5-FU alone.
Erlichman (1988): Improved response rate
Prolonged disease free interval
Prolonged survival
Poon (1989): Response rate best with low dose FA
Prolonged disease free interval
Prolonged survival
Doroshaw (1989): Improved response rate
Prolonged disease free interval
? trend toward prolonged survival
Petrel I i (1989) Response rate best with high dose FA
? trend towards prolonged survival
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analogues also stimulate the binding of flourodeoxyuridylate to thymidylate 
synthetase. The addition of folinic acid,is thought to increase or substitute for 5-10 
methylene tetrahydrofolate.so that more ternary complexes may develop producing 
an anti-metabolic effect of greater magnitude.
Encouraging results from phase I and II studies(Machover et 
al,1986;Madajewicz et al,1984) of combination therapy,were confirmed in larger 
comparative trials (Erlichman,1988,Doroshaw et al,1990) both in terms of objective 
responses and survival. Studies investigating the effect of folinic acid dose 
escalation produced conflicting results, Petrelli(Petrelli et al,1989) suggesting dose 
escalation to be beneficial, while Poon (Poon et al, 1989) suggested this made little 
difference. Both trials confirmed that the addition of folinic acid potentiated the 
response over 5-FU alone.
An alternative pathway for biochemical modulation is to use PALA( 
N-Phosphonacetyl-L-aspartate) which is an inhibitor of aspartate transcarbamylase, 
an essential enzyme in pyrimidine synthesis.This indirectly results in increased 
activation of 5-FU to 5-fluorouridine triphosphate resulting in increased RNA 
incorporation. Early clinical trials have suggested response rates in excess of 40% 
may occur with this regime((Ardalan et al,1988; O'Dwyer et al,1989). Combination of 
5-FU with methotrexate appears to act in a similar manner(Marsh et al,1989). Other 
combinations with cisplatin or dipyridamole are in their infancy. The improved 
understanding of the mechanism of action of these agents suggests further 
advances will be made in the treatment of these relatively chemoresistant tumours.
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SECTION II
TREATMENT OF MICROMETASTATIC DISEASE(Adjuvant therapy):
(1) Systemic:
Adjuvant systemic therapy is designed to prevent recurrent disease 
developing in patients thought to have had a curative resection,by treating the 
patients with minimal tumour bulk at the micro-metastatic stage. A recent review of 
27 randomised trials of adjuvant chemotherapy suggested that whereas the majority 
of regimes had little effect,those containing 5FU as the principal agent resulted in a 
small benefit in terms of survival(Buyse et al.1988).
An additional approach is the addition of the immunomodulator 
levamisole,however the initial study from Glasgow showed no benefit(Bancewicz et 
al,1980). Larger studies have confirmed that levamisole is of no benefit when used 
alone(Arnaud et al, 1989), but it may be of benefit when used in combination with 
5-FU.Three major studies (Windle et al, 1985;Laurie et al,1989; Moertel et al,1990) 
involving 1700 patients with stage B or C carcinoma of the colon, have shown that a 
significant improvement in survival can be achieved using adjuvant therapy with 
combination 5-FU and levamisole,although the benefit appears to be limited to 
those patients with lymph node involvement.
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(2)Regional:
Between 10 and 30 percent of patients undergoing radical resections for 
carcinoma subsequently develop liver metastases (Russell et al, 1984;Finlay and 
McArdle, 1982),and of these a third are apparently confined to the liver. These 
presumably arise by haematogenous spread along the portal vein. In an attempt to 
reduce the morbidity associated with chemotherapy,and target the drug to the 
liver,short term portal venous infusion of 5-FU has been used with minimal toxicity. 
In a prospective randomised trial Taylor reported a significant improvement in 
survival in patients treated with postoperative portal venous infusion. The benefit 
was limited on retrospective analysis to subgroups within the study cohort(Taylor et 
al, 1985). Several interim reports of other studies have been less conclusive. The 
AXIS (Adjuvant Xray and 5-FU Infusion Study)is currently addressing this 
controversy.
In summary,some progress has been made in the treatment of advanced 
colorectal carcinoma and in the adjuvant setting. Of the many drugs have been tried 
over the last 30 years,5-FU remains the mainstay of treatment.The most promising 
results would appear to be achieved using 5-FU in combination with a biochemical 
or immunological modulator,rather than in combination with other cytotoxics. 
Objective responses and improvements in survival are possible in patients with 
advanced disease, adjuvant therapy appears to be more promising as regards the 
potential for long term survival. Systemic or host organ toxicity remains a major 
problem limiting the administered dose. Identifying the "at risk" population and 
improving the targeting of treatment to minimise toxicity may provide improved 
results with available agents.
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(2)RESECTI0N OF METASTASES
Resection of liver metastases was first performed by Garre over 100 years 
ago(Hunt et al, 1990),however its role in current management remains controversial. 
Adson, 1976;Cady and McDermott, 1985). Resection in patients with solitary 
metastases or small multiple deposits in one area of the liver may improve 
survival,resulting in between a 25 - 40% five year survival rate with a less than 5% 
operative mortality rate(Adson et al,1984;lwatsuki et al,1986). It must be 
remembered that there is potential for prolonged survival in patients with low 
volume disease without treatment(See table 5).
Table 5: Survival in patients with untreated potentially
resectable metastases
Type of metastases
Median
Survival % 5YS
Wood (1976) "resectable" 8%
Pettavel (1978) Solitary/small 22 mths
Wanebo (1978) solitary 19 mths
Goslin (1982) <4 24 mths
Wagner (1984) Solitary 21 mths
Daly (1985) < 20% PHR >24 mths
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The development of more sophisticated imaging techniques has revealed an 
increasing number of patients with multifocal or extrahepatic disease, casting doubt 
as to whether any metastases are truly solitary.Adson showed that at least 50% of 
metastases thought to be solitary had synchronous lesions(Adson et al,1984). Even 
with improvements in postoperative care perioperative mortality remains around 5 - 
10%,(Ekberg et al, 1986;Fortner, 1988, Wanebo et al, 1978),with morbidity rates as 
high as 25%(August et al, 1985;Logan et al, 1982), requiring a substantial 
improvement in survival to offset the risks of surgery. The recurrence rates following 
hepatic resection are also high.varying between 35 and 90%(Cady and 
McDermott, 1985;August et al,1985;Joishy and Balasegaram,1980). The variation 
being at least partly as a result of small numbers in each study.
Table 6: Results of resection of liver metastases:
Author No of patients Recurrance
Joishy (1980) 10 90%
August (1985) 33 50%
Cady (1985) 18 35%
Rajpal(1982)* 30 50%
Fortner (1988)* 77 58%
excluding operative mortality.
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Correct patient selection is obviously of utmost importance and currently only 
solitary or up to three metastases localised to one area of the liver are considered 
suitable for resection. More extensive procedures are associated with significantly 
increased morbidity and have as yet to be shown to benefit the patients. Even if 
estimates that up to 10% of patients with metastases may benefit from resection are 
justified,this relates to a relatively small number of patients. In the U.K., thirteen 
thousand patients die as a result of colorectal cancer each year. Approximately 
3750 will have metastases apparently confined to the liver at the time of death. 
Even if 10% (and the true figure is probably closer to 4%) of these are suitable, this 
relates to only 15 patients a year in the West of Scotland as being potential 
candidates for resection in the entire region.
Because 20-30% of the patients dying from colorectal cancer have metastatic 
disease apparently confined to the liver, hepatic transplantation has been 
suggested as a possible treatment. Starzl and his colleagues from Pittsburg have 
shown that transplantation has no advantage over resection,except in patients with 
end stage hepatic parenchymal disease(personal communication).
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(3)HEPATIC ARTERY LIGATION
The rationale of hepatic arterial ligation stems from the observation that 
hepatic metastases derive their blood supply from the hepatic artery rather than the 
portal vein,while the normal hepatic parenchyma can withstand interruption of this 
supply. Reinhoff and Woods in 1953 described the effect of hepatic arterial ligation 
on metastases from an oesophageal primary. Nilsson (Nilsson and 
Zettergen, 1967(1);Nilsson and Zettergen, 1967(2)) demonstrated that hepatic 
arterial ligation was effective in reducing the size of experimental rodent hepatic 
tumours. There is some experimental evidence that distal embolisation rather than 
proximal ligation may be more effective (Doppman et al,1978).
In human colorectal tumours,despite evidence that ligation or embolisation 
leads to necrosis of the majority of tumour cells,with an objective response rate of 
up to 30% of patients(Chuang and Wallace, 1981), the effect is temporary with the 
development of collateral channels within a week of surgery(Bengmark and 
Rosengren,1970), and the treatment has little effect on survival (Almersjo et 
al,1972). Bengmark and his colleagues from Lund introduced an implantable 
inflatable cuff to permit intermittent hepatic arterial occlusion and have shown 
significant objective responses without the development of arterial collaterals. The 
combination of hepatic arterial ligation with intraportal chemotherapy as first 
described by Fortner (Fortner and Pahnke, 1976),only produced objective response 
rates of 20% and no effect on survival (Gerard et al,1991).
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(4)RADI0THERAPY
Although colorectal adenocarcinoma is potentially radiosensitive,as 
suggested by evidence that adjuvant radiotherapy may reduce the rate of local 
recurrence in patients with rectal cancer.whether given preoperatively(Gerard et 
al,1985;S.R.C.G,1987) or post operatively(G.T.S.G, 1985),its role in the treatment of 
advanced disease is limited by the local toxicity.
Palliation of abdominal pain,nausea and vomiting can be demonstrated in up 
to 90% of patients undergoing external radiotherapy for hepatic 
metastases(Sherman et al,1978;Borgelt et al,1981)but this treatment has not been 
associated with a prolongation of survival (Sherman et al,1978;Turek-Maischeider 
and Kazem,1975). If a dose exceeding 3500 rads is administered severe 
irreversible radiation hepatitis results.
The exposure of the normal hepatic parenchyma to radiation may be reduced 
by the regional delivery of glass microspheres, containing yttrium-OO^Y). These 
are prepared as 89Y,which is then activated by neutron bombardment to ^Y, a beta 
emitter with a half life of 64 hrs. Each microsphere therefore irradiates the tissue 
surrounding it,with tissue penetration limited to less than 0.85mm. Herba showed 
that both symptomatic improvement and objective responses could be achieved in 
up to 60% of patients without significant hepatic morbidity(Herba et al,1988).
5.8
Following administration into the hepatic artery,microspheres are not 
distributed according to blood flow. Due to an unknown mechanism,there is 
preferential delivery toward tumour tissue(Cooke and Chang, 1990),with consequent 
sparing of the normal hepatic parenchyma from the effects of the beta irradiation. 
This technique has been further refined in a recent phase 1 study in Glasgow Royal 
Infirmary, University Department of Surgery,combining regional delivery with 
angiotensin targeting.
This study has shown that up to 15,000 rads can be delivered to an individual 
patient,without the development of significant toxicity. Using this technique 
significant objective tumour responses have been achieved but financial and logistic 
difficulties limit the universal acceptance of this form of therapy.
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AIMS OF THESIS
Colorectal carcinoma is a common clinical problem, and as such advances in 
this field have wide applications. This review of the literature has covered many 
aspects of the current methods of detection and management options for colorectal 
hepatic metastases,and has highlighted some of the areas in which improvements 
in treatment are being sought. It is clear that whatever treatment option is 
chosen,early accurate diagnosis of metastases,holds the key to effective treatment.
Current treatment options for patients with colorectal metastases are limited. 
In the majority of patients, cytotoxic therapy provides the only hope for improved 
survival.The benefit from chemotherapeutic regimes is greatest when the tumour 
load is small,treatment being given at a micrometastatic stage as an adjuvant 
therapy,however,given in this manner,more than half of those treated, will receive 
their chemotherapy unnecessarily.
Advancing technology has ensured that the accuracy of density dependent 
detection techniques has steadily improved over the last 15 years. There is a 
threshold below which metastases are undetectable leading to incorrect staging of 
patients. Methods dependent on the haemodynamic changes that occur in the 
presence of colorectal metastases hold great promise, as they may be able to 
detect micrometastatic spread of disease. The accuracy,reproducibility and 
mechanism underlying these changes has not yet been clarified.
Having identified a treatment population, the effect of current chemotherapy 
is limited by systemic toxicity. Hepatic targeting aims to increase the effective dose 
to tumour tissue while at the same time reduce systemic exposure. This has 
traditionally involved surgical catheter placement, however it may be possible to 
manipulate biochemical pathways to achieve tumour localisation.
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In this thesis I have carried out two broad lines of investigation into the 
detection and treatment of liver metastases. The aims were as follows;
(1)to evaluate the reproducibility.the intra and interobserver variation of the high 
administered activity Hepatic Perfusion Index and prospectively compare the HPI 
with the other currently available imaging techniques for the detection of hepatic 
metastases.
(2)to evaluate the mechanisms that underlie the changes in the HPI with the 
development of hepatic tumour,and
(3)to evaluate potential methods of biochemically or pharmacologically targeting 
chemotherapeutic agents to a rodent model of colorectal metastases.
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CHAPTER 2
METHODOLOGY
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In this chapter I will describe details of the methods employed to investigate 
the aims of the thesis. In this, and in subsequent chapters,this is divided into three 
subsections:
(1) CLINICAL STUDIES:
Firstly I will describe the modifications in the methodology of the Hepatic 
Perfusion Index(HPI) made in Glasgow Royal Infirmary, and my subsequent 
evaluation of its reproducibility. I will then discuss the technique we have utilised for 
our intraoperative ultrasonography, followed by an assessment of how both 
techniques performed in a prospective clinical study of the detection of colorectal 
metastases.
(2)HAEMODYNAMIC STUDIES:
In the second section I will describe the methods involved in the production 
of the animal model of colorectal metastases used in this thesis. I will also describe 
the methods employed in experimental studies on the vascular changes that 
accompany the development of hepatic metastases. These were performed in an 
attempt to prove that the reduction in splanchnic vascular inflow and increase in 
splanchnic vascular resistance was due to a humoral and therefore transmissible 
vasoactive agent. Two experiments were performed; a cross perfusion study and a 
reference microsphere study.
(3)TARGETING STUDIES
In this section, I will describe the experiments studying three potential 
methods of biochemically targeting the delivery of drugs to hepatic parenchymal 
tissue and lastly an experiment investigating how two methods of second order 
targeting may be combined to achieve the maximal response.
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SECTION I - CLINICAL STUDIES
HEPATIC PERFUSION SCINTIGRAPHY(high administered activity)
Patients were fasted for 12 hours. The first description involved the injection 
of 300MBq of 99mjc sulphur colloid(Boyd et al,1978),the technique being modified to 
a "low administered activity" technique in the early 1980's,to minimise patient 
exposure. This involved the injection of 80 MBq(Perkins et al, 1987), 111 MBq (Sarper 
et al, 1981;Parkin et al.1983) or 150MBq (Wraight et al,1981),however,we have 
found a resultant reduction in image quality,due to poor count statistics, with a 
consequent increase in interobserver variation (Goldberg et al,1987).
In an attempt to improve the reproducibility, a modified "high administered 
activity" technique was employed,each patient receiving a rapid intravenous bolus 
injection of 400 MBq of 99mTC albumen colloid via the antecubital vein. Posterior 
images were obtained every 2 seconds on a 64 x 64 matrix using a large field of 
view gamma camera,fitted with a high sensitivity parallel hole collimator, interfaced 
with a computer. Regions of interest were drawn around the liver and both kidneys 
avoiding overlap with the lungs and aorta. Using the left kidney arterial peak (Tp) as 
the demarcation of the hepatic arterial and portal venous components of liver 
perfusion,the gradients of the eight second periods before(G-|) and after(G2 ),but 
excluding the frames overlapping Tp.were calculated using a least squares 
analysis.
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The Hepatic Perfusion Index(HPI) is therefore defined as the ratio between 
the hepatic arterial gradient(Gi) and the total liver blood flow(gradient + G2 ).
G1
i.e. HPI = ------------ --------
G1 + G2
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Figure 4: Idealised curves for the derivation of the HPI(Leveson et al,1985)
VALIDATION OF THE MODIFIED TECHNIQUE
The inter- and intraobserver variation were assessed on eighteen 
consecutive patients presenting with colorectal cancer. Each underwent dynamic 
scintigraphy using the modified high administered activity technique described 
above. To assess intra-observer variation, each study was reprocessed four 
times,creating four sets of regions of interest and time activity curves.Each study 
was independently reprocessed by a second observer,creating a fifth set of values. 
The inter-observer variation was calculated by taking the first value of observer 1 
and the value of observer 2,assessing both the positive difference and the root 
mean square difference of the values. In addition the correlation coefficient of the 
inter-observer values was calculated.
In clinical practice,the difference between the obtained values is often more 
important than the degree of similarity or "correlation". This may be assessed using 
the Bland Altman technique. In this if there is no significant difference,the difference 
between the values divided by the mean will equal zero,or the ratio of the values 
divided by the mean will equal one. Whether the difference between or the ratio of 
the values is used, is dependent on whether the magnitude of the difference 
increases as the value increases(in which case the ratio should be used). 
Finally,having established the reproducibility of the technique,the clinical correlation 
was then assessed on 50 consecutive patients with colorectal carcinoma.
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COMPARISON OF METHODS OF DETECTING COLORECTAL
METASTASES
Patients referred to the University Department of Surgery were studied. All 
had a presumptive diagnosis of colorectal carcinoma,which in all but 2 cases was 
subsequently confirmed on biopsy. All patients were investigated for the presence 
of hepatic metastases.their subsequent clinical management being determined by a 
combination of their physical fitness and stage of disease.
Figure 5 is a fiow diagram illustrating the clinical fate of patients included in 
the study. All were investigated with a minimum of an ultrasound scan,CT scan of 
the abdomen,static liver scintigraphy and dynamic hepatic scintigraphy(hepatic 
perfusion index). Latterly,patients also had measurement of blood flow in the 
hepatic artery and portal vein by duplex Doppler ultrasonography, but his was not 
available for the whole duration of the study. Those patients that proceeded to 
elective surgery had the presence or absence of metastases assessed by palpation 
and in the case of palpably clear livers by intraoperative ultrasound.
Patients were considered to be metastases positive if they were confirmed at 
laparotomy,biopsy or shown to have disease progression during the followup 
period.The accuracy with which each of the above investigations identified the 
presence or absence of hepatic metastases has been prospectively compared,and 
in particular the clinical application of intraoperative ultrasound has been assessed.
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All patients presenting to the University Department of Surgery Glasgow 
Royal Infirmary with colorectal carcinoma after January 1990, have been included in 
an imaging programme,to detect the presence or absence of hepatic metastases. 
Those patients that presented as an emergency were screened in the 
post-operative period. The remainder presented with symptoms to the emergency 
department or outpatient clinic,and were investigated prior to elective surgery or 
laser palliation. In those patients that were unfit for laparotomy or those treated by 
intraperitoneal chemotherapy via a "tenchkoff" catheter where adequate access is 
prevented, intraoperative ultrasonography was not performed.
Ultrasonography and contrast enhanced computerised tomography and static 
hepatic scintigraphy were supervised and reported by consultants in radiology and 
nuclear medicine. The dynamic scintigraphy was analysed by myself,Mr D 
Hemingway or G McCurragh. The intraoperative ultrasound was performed by 
myself or Mr D. Hemingway after an initial training period six months prior to the 
study to validate the technique.
68
Figure 5: Clinical course of patients within study
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INTRAOPERATIVE ULTRASONOGRAPHY.
The intraoperative ultrasonography was performed using a waterproof 
T-shaped probe,with a 5 MHz frequency,sterilised by immersion in 2% 
glutaraldehyde ("cidex") for 10 minutes prior to use. The natural humidity of the 
liver avoids the need for contact surface gel. Access to the liver parenchyma is 
limited by the fibrous attachments of the liver to the abdominal wall and 
diaphragm(falciform ligament.right and left coronary ligaments and the bare area).
The potential advantage intraoperative ultrasound holds over transabdominal 
ultrasound lies in the requirement for less tissue penetration. Penetration reduces 
as the frequency increases,and the resolution increases with frequency. 
Consequently whereas a transabdominal probe would usually be 2 - 3 MHz(15cm 
penetration), with a minimum resolution of 4-5 mm, a intraoperative probe usually 
employs a 5MHz probe,with less penetration (approximately 8 cm) but better 
resolution(2-3mm).
In one patient dense fibrous adhesions prevented adequate access to the left 
lobe. There is also a "blind zone" 1 - 2 cm from the surface. This can be minimised 
by altering the frequency,or visualisation via a water cushion if doubt exists. Lesions 
in this region are usually clinically apparent,and the additional time required to use 
the cushion unnecessary.
The probe is placed transversely on the anterosuperior aspect of the right 
lobe to visualise the confluence of the three hepatic veins with the inferior vena 
cava. These can then be followed to identify the segmental venous drainage. The 
portal venous radicles are then identified,being distinguishable from the hepatic 
veins by their echogenic fibrous envelope derived from "Glisson's capsule" These 
are then followed down to the porta hepatis. The gallbladder and hepatic pedicle
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are then studied by turning the probe longitudinally lying anteriorly on the caudate 
lobe. Segments II and III are then visualised to the left of the falciform  ligament. 
Metastases (Figure 6) are identified by their heterogenous echo pattern, and their 
segmental location noted. Abnormalities may be recorded on a Sony AX 24 
printer,integrated with the ultrasound machine.
Figure 6: Intraoperative ultrasound of a two metastases lying in segment 
VII of the liver.
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COMPARATIVE STUDY OF METHODS FOR DETECTING COLORECTAL
METASTASES.
All six detection modalities were completed in 40 patients. Having completed 
all investigations,patients were considered positive for metastases if they had 
histological or post mortem evidence of colorectal metastases, or had retrospective 
evidence of disease progression on serial followup investigations. The 
sensitivity(The number of true positives as a percentage of the total with 
metastases),specificity(the number of true negatives divided by the number that are 
disease free),and positive (proportion of true cases among those with a positive 
result) and negative(proportion of true negative cases among those with a negative 
result) predictive value of each investigation was calculated.
In a further 33 patients one or more investigations was not performed for 
reasons described earlier,however, the accuracy of the performed investigations 
was assessed,to determine whether the figures obtained from the comparative study 
were maintained in this larger cohort of patients.
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SECTION II - HAEMODYNAMIC STUDIES
CELL CULTURE TECHNIQUES AND ANIMAL MODELS:
One of the principal objectives of this thesis was to investigate the 
mechanisms that underlie the changes in the hepatic perfusion index that occur with 
the development of intrahepatic tumour. The methods available for the assessment 
of hepatic anatomy and blood flow are either unsuitable for use in-vivo (colloidal 
dyes,casting techniques), provide information on total liver blood flow but do not 
distinguish between hepatic arterial flow and portal flow(indocyanine green, 
galactose clearance,BSP),or assess relative portal and hepatic arterial flow but are 
not quantitative(HPI,DPI).
Similarly,methods for studying drug distribution are limited in clinical research 
by the availability of tissue for analysis. Consequently despite the difficulties in 
correlating animal based studies with clinical practice,we chose to employ an animal 
model of hepatic metastases.
Throughout this series of experiments the following rodent model of 
colorectal metastases has been employed. The cell line used is the HSN 
fibrosarcoma,and although established within the University Department of 
Surgery,was originally gifted by Dr. S Eccles, Institute of Cancer Research,Royal 
Marsden Hospital. Previous experiments in the department have shown that this cell 
line grew well in immunocompetent rats, producing discrete tumours two to three 
weeks following inoculation, and,as in a proportion of human colorectal 
metastases,these tumours were hypovascular relative to surrounding liver 
parenchyma,and derived the majority of their blood supply from the hepatic 
artery(Nott et al, 1989,Hemingway et al, 1991).
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Preparation of the cell suspension for inoculation:
Approximately 10 ml of culture medium (50 mis fetal calf serum, 10 ml 
penicillin/streptomycin solution(Sigma),10 ml Glutamine (200mmol solution),and 
500ml Dulbecco's Modified Eagles Medium) was aspirated from a flask containing a 
confluent monolayer of HSN cells and was discarded. The cells were washed in 
sterile PBS which was again aspirated and discarded. Ten ml of 0.1% trypsin 
solution (Sigma) was added and the flask incubated at 37°C. The cells were 
inspected under phase contrast microscopy intermittently until the cells were seen 
to have gone into suspension. The trypsin was inactivated by the addition of 5 mis 
fetal calf serum,the suspension being placed in a universal container. Following 
centrifugation the supernatant was discarded and the pellet resuspended in fresh 
medium,the viability being confirmed microscopically by the addition of trypan blue, 
additional medium adjusting the concentration to 106 cells per ml.
Tumour induction:
Male hooded Lister rats weighing approximately 200 - 250g, are 
anaesthetised by an intraperitoneal injection of sodium pentobarbitone (Sagatal,30 
mg/kg). An upper midline laparotomy was performed and the antero-superior 
surface of the liver exposed. An intrahepatic injection of 105 HSN Sarcoma cells 
suspended in 0.1 ml of fetal calf serum as previously described was given into the 
right and left lobes of the liver,taking care to avoid spillage.Haemostasis was 
achieved using pressure applied with cotton buds soaked in ethanol,to avoid 
peritoneal contamination. The abdomen was closed in two layers using 2.0 dexon 
sutures. All experiments were performed between 15 and 25 days following 
inoculation to correspond with the rapid growth phase of the HSN cell line growth 
curve.
74
Figure 7: HSN tumour at 20 days.
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CROSS-PERFUSION EXPERIMENT
As discussed in the introduction,persistent alterations in splanchnic blood 
flow are determined by neural and humoral influences. This experiment was 
designed to investigate the hypothesis that the relative reduction in portal flow was 
caused by the presence of a circulating vasoactive agent. The blood from a tumour 
bearing animal may therefore result in similar hepatic haemodynamic changes when 
perfused through a second,otherwise normal,animal.
Preparation of the experimental animal:
After an overnight fast,a rat weighing approximately 400g,was anaesthetised 
by an intraperitoneal injection of sodium pentobarbitone (Sagatal 30mg/kg),and a 
transverse dorsal neck incision performed. The platysma was divided and the strap 
muscles split in the midline to expose the trachea. A transverse tracheotomy was 
performed and a 6FG tracheostomy inserted and secured. The plane between the 
strap muscles and the sternomastoid was developed to expose the carotid artery 
which was stretched and cannulated with a specially constructed cannula, the tip of 
which had an external diameter of 1 mm(internal diameter 0.85mm).
After 15mm the cannula diameter expanded to 2mm,to minimise the 
resistance of the extracorporeal circuit. It was connected to a staggered multiport 
connector which permitted continuous monitoring of the systemic arterial pressure 
and subsequent extracorporeal autoperfusion of the intestinal segment. The jugular 
vein was cannulated with a 5FG flexible cannula.
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Maintenance of anaesthesia:
The animal was mechanically ventilated with an inspired gas mixture of 
50/50 N 0/02,a stroke volume of 25ml and a respiratory rate of 40/minute 
determined by blood gas analysis to maintain the p02 above lOOmmHg and the 
pC02 below 40mmHg. Repeated 0.1 ml boluses of 8.4% NaHC03 were required at 
30 minute intervals to prevent the development of a metabolic acidosis. Further 
intravenous boluses of sodium pentobarbitone(O.lml) were given if the depth of 
anaesthesia showed any signs of lightening. Using an oesophageal temperature 
probe and heat lamps the animals temperature was maintained above 36°C.
Preparation of the segment:
The animal was anticoagulated using sodium heparin (200 units/1 OOg) and a 
midline laparotomy performed. The small bowel was wrapped in cling film and 
retracted to the right to allow access to the distal colon which was mobilised and 
divided at the level of the pelvic brim. The colon was then followed proximally to the 
level of the duodenal-jejunal flexure to identify the left colic vessels which were 
divided. The terminal ileum was then tied and divided at the level of the terminal 
arcade,the ileocolic vessels being tied distal to the last vessel to the ileum. The 
plane between the colon and small bowel mesentery was then developed up to the 
level of the right colic vessels. The colon was then reflected caudally to allow 
dissection of the pancreas from the mesocolon. Having achieved this the colic 
vessels were divided and the colon removed.
The spleen was then retracted caudally and the stomach cephalad.the 
adventitial tissue between these being divided up to the level of the short gastric 
vessels, which were tied in continuity before division. There is no surgical plane 
between the pancreas and stomach, both being fed by vessels of the right
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gastroepiploic artery. The gastroepiploic was therefore divided along the inferior 
border of the stomach to the level of the pylorus.
The lesser omentum was then opened allowing the pylorus to be ligated and 
divided, the duodenum being retracted laterally. This allows identification of the 
coeliac artery arising from the aorta. The coeliac artery was followed distally, to 
where it gives off the hepatic artery which was dissected off the portal vein and 
divided.
The coeliac artery itself was tied flush with the aorta and then divided. A 
plane can be identified between that part of the pancreas supplied by the coeliac 
artery and that supplied by the superior mesenteric artery. By developing this plane 
the portal vein can be identified, vessels draining the distal pancreas arising to the 
left of the portal vein and those from the head of the pancreas emerging from the 
right. These vessels were carefully identified, diathermied and divided. The spleen 
and pancreas were removed, and the small bowel divided at the level of the 
duodeno-jejunal flexure to skeletalise the superior mesenteric artery and portal vein.
The superior mesenteric artery was then quickly cannulated,using another 
tapering cannula connected to the multiport connector,with a terminal internal 
diameter of 1mm. The arterial half of the extracorporeal circuit was allowed to 
perfuse for 5 minutes to ensure adequate oxygenation of the segment. The portal 
vein was then cannulated using a 6 FG flexible cannula,the emerging blood being 
collected in a measuring reservoir before being recirculated using a rotary pump 
into the internal jugular vein. (See figure 8)
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Figure 8: Establishment of an extracorporeal circuit to perfuse the
isolated segment.
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Preparation of the donor animals
Two donor animals,syngeneic Hooded Lister rats, were anaesthetised using 
an intraperitoneal injection of sodium pentobarbitone(Sagatal 30mg/kg). One of 
these had undergone intrahepatic tumour induction three weeks earlier as 
described previously, the other was a control. In each animal a tracheostomy was 
performed and the carotid artery cannulated using a 2-1mm tapering cannula. A 
5FG cannula was inserted into the right jugular vein for the return of blood from the 
reservoir, the animals being heparinised with an intravenous injection of sodium 
heparin (200units/1 OOg).
^  To pressure recorder
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TumourControl Tumour
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Figure 9 : Connection of the donor animals to the circuit.
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Establishment of the cross perfusion circuit.
The cross perfusion circuit is summarised in figure 10. Using a staggered 
multiport vascular access "traffic light" the carotid cannulae were connected prior to 
establishment of the cross perfusion to allow rapid crossover limiting interval 
ischaemia. The initial blood emerging from the segment following crossover was 
discarded to minimise venous mixing.
Two syngeneic rats,one tumour bearing,one control, were anaesthetised and 
heparinised as previously described. A midline laparotomy was performed and the 
aorta cannulated. The animals were exsanguinated providing fresh,heparinised 
blood to prime the reservoirs and the venous return cannulae.
The isolated small bowel segment was then perfused by one of the "donor" 
rats followed by the other the order being determined by a computerised random 
number sequence. The blood flow through the segment was measured over three 
30 second periods,each 90 seconds apart,collecting the blood emerging from the 
portal venous catheter in a measuring chamber before returning the blood to the 
reservoir. A five minute equilibration period was allowed to elapse before measuring 
the flow attributable to each animal.The flow achieved at each time point was 
combined with the simultaneous mean arterial pressure to calculate the mean 
vascular resistance of the segment using the formula:
PRESSURE
RESISTANCE = ---------------
(mmHg.mM.min-1) FLOW
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Further cross perfusions were performed on each segment but due to the 
inevitable minor mixing of tumour and control blood only the first measurements for 
each animal were used for statistical analysis. The significance of the observed 
differences were assessed using the Mann-Whitney U test, and the Wilcoxon rank 
sum test for paired data.
To pressure recorder
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TumourControl Tumour
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Figure 10: Experimental animal excluded from the cross perfusion
circuit
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Figure 11 : Photograph of cross perfusion experiment.
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REFERENCE MICROSPHERE EXPERIMENTS
If the mechanism underlying these haemodynamic changes is as the result of 
a reaction between the tumour and host,this raises the question as to why the HPI 
alters only with the development of secondary tumour and is not effected by the 
primary tumour. This experiment was designed to assess the effect of extrahepatic 
tumour on liver blood flow.
Hooded Lister rats weighing 200-250 g were used throughout the experiment. 
Three groups of animal were studied:
(1) Control animals that had undergone a laparotomy and intrahepatic injection of 
dead tumour cells.
(2) animals that had undergone intrahepatic tumour induction as described 
previously.and
(3) animals that had subcutaneous tumour induced by a subcutaneous injection of 
106HSN sarcoma cells, producing 10-15mm tumours three weeks after inoculation.
The animals were anaesthetised by an intraperitoneal injection of sodium 
pentobarbitone(Sagatal 30 mg/kg)and a left groin incision performed. The left 
common femoral artery was isolated and ligated distally before being stretched and 
cannulated with a 1mm internal diameter cannula. The cannula was flushed with 
heparinised saline, and connected to a 2ml syringe in a withdrawal pump calibrated 
at 1ml/min.
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Figure 12 : The Reference Microsphere Sample Technique
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A transverse neck incision was then performed and the platysma divided 
allowing access to the strap muscles which were split in the midline. A 6 FG 
tracheostomy tube was inserted to ensure a patent airway,the animal breathing 
spontaneously using an enriched-oxygen inspired air mixture. The right internal 
carotid artery was identified lying in the groove between the strap muscles and the 
sternomastoid. This was ligated distally and cannulated with a 0.75mm internal 
diameter cannula. This, when connected to a pressure monitor,allowed placement 
of the catheter into the left ventricle, its position being confirmed by the 
establishment of a ventricular type pressure tracing.
The 15 pm diameter resin microspheres (Nentrac,Dupont Ltd) labelled with 
153Gd,in a concentration of approximately 5 x 105 microspheres/ml, were suspended 
in saline and agitated for two minutes. Having ensured that the femoral cannula was 
flowing,a 0.2 ml intraventricular bolus injection of the microsphere suspension was 
performed, blood being withdrawn from the femoral cannula over the subsequent 60 
second period.
The animal was humanely killed and the organs(Liver,tumour,kidneys, 
spleen,heart,lungs,stomach,pancreas,small bowel and colon) weighed, divided and 
placed in a well gamma counter for analysis. Counts per organ were measured and 
the blood flow for each calculated from the amount in the known reference 
sample(1ml/min). Animals were excluded from analysis if the flow to the left and 
right kidney differed by over 15%, as this was taken to reflect incomplete mixing of 
microspheres with arterial blood.
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Figure 13: Reference microsphere study design:
The radioactivity in the liver reflected only the hepatic arterial component of 
blood flow. The portal venous inflow was calculated as the sum of flows to the 
stomach,spleen,pancreas,small bowel and colon. These data allowed estimation of 
the hepatic perfusion index(hepatic arterial inflow/ hepatic arterial + portal inflow) for 
each animal. The flow per gram of tumour tissue relative to the normal liver 
parenchyma was also calculated.
The significance of the observed differences were assessed using the 
Kruskal-Wallis analysis of variance,Mann-Whitney U test, and the Wilcoxon signed 
ranks test as appropriate.
SECTION III - DRUG DELIVERY/TARGETING
Hepatic targeting of chemotherapeutic agents aims to improve delivery of 
drug to tumour and at the same time reduce side effects by reducing systemic 
exposure. All experiments used the HSN model of colorectal metastases as 
previously described.This series of experiments involved the assessment of 
methods of either first order localisation,^ which I have evaluated the possibility of 
targeting an intravenous bolus injection towards the liver by exploiting the affinity of 
galactose residues or porphyrins for hepatocytes or second order targeting,where I 
have investigated how physical microembolisation and vasoactive agents may be 
combined to improve regional delivery of drugs.
PART 1 - FIRST ORDER TARGETING:
Two potentially useful polymeric compounds conjugated to galactose have 
been assessed,onto which chemotherapeutic agents could be incorporated,should 
targeting to either liver or tumour be demonstrated. One polymer used a 
guarin/polysaccaride backbone the other a hydroxymethacrylamide backbone. Both 
were radiolabelled allowing systemic distribution to be evaluated following 
administration. If hepatic targeting of a polymer was demonstrated the effect of 
regional administration was assessed.
Porphyrins naturally accumulate in tumour and hepatic tissue. In a study by 
Bugelski.the initial distribution of haematoporphyrin derivative(HpD) matched that of 
radiolabelled albumen before being cleared from most normal tissue after 6 
hours,whereas the levels in tumour tissue remained stable for several 
days(Bugelski et al, 1981). Uptake into hepatocytes was minimal, but accumulated in 
the Kupffer cells,and other cells of the reticulo-endothelial system.
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Correct timing of sampling therefore produces positive tumour to normal 
tissue concentration ratios for cutaneous tumours,however the ratio attainable with 
intrahepatic tumour is unknown. The distribution of radiolabelled haematoporphyrin 
derivative was assessed following intravenous administration into animals 
inoculated with intrahepatic HSN tumour deposits.with particular reference to 
variations in the relative tumour and liver tissue concentrations with time following 
injection.
The significance of the observed differences were assessed using the 
Kruskal-Wallis analysis of variance,Mann-Whitney U test, and the Wilcoxon signed 
ranks test as appropriate.
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Flowchart summarising the first order targeting experimental plan:
Guarin/5-FU
i.v.1
HPMA polymer 
i.v.1
HpD
i.v.l
▼
Drug distribution at 
10,30 and 60 mins
\
\
Drug distribution at 
5,10 and 30 mins
i
T
Distribution
at
1,3,5,7,9,11 days
i
No hepatic 
localisation
i
Good hepatic 
localisation 
Poor tumour uptake
1
Good hepatic 
and tumour uptake
i
No further 
experiments
i.a + i.p.
Effect of regional 
administration
Future work
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5-FLUOROURACIL/GUARIC ACID POLYMER
Labelling of the polymer:
The 5-flourouracilacetic acid(5-FUAA)/guarin conjugate was developed in the 
Institute of Medical and Chemical Bioengineering, University of Liverpool. The 
polymer is a linear manose chain with secondary galactose residues.the 5FU being 
covalently bonded via the primary carbon of the acetyl linkage, using radiolabelled 
14C-5FU obtained from Amersham International .which was acetylated prior to 
conjugation. The activity of the 5-FUAA used was 3.48x10® cpm/g;the activity of the 
resulting conjugate was 9.6 x 10® cpm/g,giving a load of 2.76% in the polymer.
The polymer was prepared as a vacumn dried powder having been purified 
twice in methanol. This was only slowly soluble in water due to its high molecular 
weight,initially swelling to give a gel,subsequently becoming more fluid with gentle 
agitation in a water bath at 37°C over a 24 hour period to leave a colourless 
solution.
A recovery experiment was performed to ensure that the volume of tissue in 
each sample did not effect the sample counts(Appendix 5a). This was performed 
using free 14C-5-FU acetic acid. The liver from a recently sacrificed animal was 
divided into cubes of varying sizes(100mg - 600mg approx). Ten microlitres of the 
5-FUAA was then injected into the centre of each cube,which was then placed in a 
scintillation vial,solubilised using 2ml of "soluene" and decolourised with 30% H20 2 
Having waited a minimum of 6 hours to allow any chemofluorescence to decay, 
10ml of "Optiphase" scintillant fluid was added,and the vials counted in a beta 
scintillation counter,each sample being counted over a ten minute period. Quench 
correction was performed using the external standard channels ratio technique. The 
counter was regularly calibrated using a set of commercial standards to generate 
the quench correction curve.
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Animal experiment:
This experiment investigated the differences in organ distribution between 
free drug(5-FUAA) and the galactose polymer conjugate. Tumour bearing animals 
were anaesthetised using intra-peritoneal "Sagatal" and a transverse neck incision 
performed. The trachea was mobilised and a tracheostomy inserted and secured. 
The internal carotid artery was ligated and cannulated with a 3FG cannula for blood 
sampling. The right jugular vein was cannulated and each animal then given an 250 
lil intravenous bolus injection of either free 5FU acetate or the conjugate. Blood 
samples were obtained every 2,5 or 10 minutes respectively by collecting dropped 
blood in a Epindorph vial. Animals were killed after either 10 minutes.30 minutes or 
60 minutes.
Thirty microlitre samples of the dropped blood were obtained using a Gilson 
pipette,new tips being used for each sample to avoid contamination. These were 
dropped onto a filterpaper disc, to which was added 0.4 ml of 30% H20 2 to bleach 
the sample. Frothing was avoided by adding the peroxide dropwise. The blood 
pharmacokinetic profile following intravenous injection was assessed by plotting the 
venous blood concentration(expressed as the percentage of the injected dose per 
ml) against time and the log concentration against time. In addition, any difference 
in potential total drug exposure following administration of each compound was 
assessed by comparing the ratio of the plasma AUC's(area under the time 
concentration curve for blood);the larger the ratio,the greater the relative total drug 
exposure.
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The liver,tumour, kidneys,heart Jung and spleen were dissected, subdivided 
into 200-300mg segments. These were placed in scintillation vials to which was 
added 2ml of "soluene". The vials were placed in a agitating waterbath for 24 hours 
to solublise the tissue before adding 1 ml of H20 2. All of the samples were left 
overnight to allow any chemoflourescence to settle before adding 10 of "Optiphase" 
scintillant fluid to each vial. The samples were counted over a ten minute period,to 
ensure a minimum of 200 counts per sample.
A 25ptl reference sample was taken at the same time as the bolus injection,to 
which was added "soluene",H20 2,and "Optiphase" scintillation fluid prior to 
counting. The counts were summated for each organ and expressed as a 
percentage injected dose per gram of tissue. Because the guarin conjugate showed 
little tendency to accumulate in the liver or tumour no regional administration 
experiments were performed.
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N-(2-HYDR0XYPR0PYL)METHACRYLAMIDE POLYMER
Labelling of the polymer:
The polymer was provided unlabelled from Professor Ruth Duncan,Keele 
University. A 2mg sample of the polymer was placed in a sealed vial to which was 
added 1 ml of phosphate buffered saline,iodobeads(Pierce Chemical Company), 
and 300 pCi of Na 125l. After incubation for 20 minutes the 1ml solution was placed 
in a "Centricom 10" centrifuge tube and centrifuged for 30 minutes at 3000 rpm. The 
supernatant was discarded and the sample washed from the filter membrane using 
sterile water with reversed centrifugation at 300 rpm for 10 minutes. A drop of the 
polymer containing fluid was placed on thin layer chromatography paper, and using 
85% methanol as a mobile phase separation of the bound and unbound 125l was 
performed. Activity of the source and solvent front was determined in a well gamma 
counter,allowing a percentage labelling index to be calculated. The centrifugation 
was repeated until a labelling index in excess of 90% was achieved(Appendix 5b).
Animal experiments:
The aim of these experiments was to again assess the distribution of the 
polymer following intravenous administration, and then assess whether the targeting 
of polymer to liver or tumour could be further improved by regional administration. 
As in the other distribution experiments the HSN model of colorectal metastases 
was used.
The polymer was administered in three ways. The distribution following an 
intravenous bolus injection was assessed to determine a baseline to which the 
distribution following either intraarterial or intravenous administration could be 
compared. From pilot studies performed in mice in Keele it was known that the
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uptake in the liver was maximal in the first 10 minutes following injection. 
Consequently animals were sacrificed at 5 minutes, 10 minutes and 30 minutes 
following injection.
Each animal was anaesthetised using an intraperitoneal injection of "Sagatal" 
and a transverse neck incision performed. The jugular vein and internal carotid 
artery were cannulated and a tracheostomy performed as previously described. 
Systemic arterial blood pressure was monitored via the carotid cannula. Through a 
left groin incision the femoral artery was cannulated for blood sampling. Those 
animals in the intraarterial and intraportal groups had either the gastroduodenal 
artery or a distal mesenteric vessel cannulated respectively.
The labelled polymer was administered by a 100 pi bolus injection over 20 
seconds.Drop blood samples were collected in Epindorph vials at set intervals prior 
to sacrifice. One hundred microlitre samples of the dropped blood were obtained 
using a Gilson pipette.new tips being used for each sample to avoid contamination. 
Each blood sample was made up to 1 ml using normal saline prior to counting in a 
well gamma counter. The blood pharmacokinetic profile following intravenous 
injection was assessed by plotting the venous blood concentration(expressed as the 
percentage of the injected dose per ml) against time and the log concentration 
against time. As in the 5-FU distribution studies any regional advantage provided by 
the different modes of administration was assessed by calculating the median 
AUC(area under the concentration curve) for each group of animals,and calculating 
a ratio between intravenous and both intraarterial and intraportal administration..
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After the animals were killed, the liver, tumour,kidneys .spleen,heart and 
lungs were dissected from the carcass. The carcass and each organ was weighed 
before being placed 1M NaOH. This was then heated to 85°C dissolving all solid 
tissue. The solvent volume was measured and five 1ml samples placed in vials 
allowing calculation of the counts per organ, the results being expressed as a % 
recovered dose per organ, and % recovered dose per gram of tissue.
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14C-HAEMAT0P0RPHYRIN DERIVATIVE DISTRIBUTION STUDIES:
Labelling of the HpD:
The haematoporphyrin was obtained from Professor S.B. Brown of Leeds 
Radioporphyrins. This 14C-polyhaematoporphyrin is equivalent in composition to 
the clinically used photosensitiser/'Photofrin II". Because of the complexity of the 
labelling process,the radiolabelled HpD is extremely expensive limiting the number 
of possible experiments.The drug is supplied as a freeze dried powder,which is 
reconstituted in saline. The dose of Hpd was 5mg/kg(as in the clinical 
application),each animal receiving 1 mg Hpd (labelled with 0.5 pCi 14C to provide 
sufficient counts to be available despite excretion). The freeze dried powder was 
then reconstituted in 0.9% saline for injection.
Animal experiments:
The aim of these experiments was to assess the distribution of the HpD 
following intravenous administration,and evaluate how the distribution and more 
particularly the tumour to normal liver ratios varied with the duration following 
injection. As in the other distribution experiments the HSN model of colorectal 
metastases was used. Fifteen days following the induction of intrahepatic 
tumour,each animal was anaesthetised using an intraperitoneal injection of 
"Sagatal" and a transverse neck incision performed. The jugular vein was exposed 
and the Hpd given by slow intravenous injection.
The animals were allowed to recover and 2 animals subsequently killed at 
1,3,5,7,9,and 11 days following injection. The liver, tumour,kidneys, spleen, heart 
and lungs were dissected from the carcass. In addition a section of the pelt was 
removed and weighed. The carcass and each organ was weighed before being
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placed in 1M NaOH. This was then heated to 85°C dissolving all solid tissue. The 
solvent volume was measured and five 0.5 ml samples placed in scintillation vials. 
To each vial 1 ml of 30% H20 2 was added to bleach the solublised tissue. Having 
left the samples over night to allow any chemoflourescence to settle, 10ml of 
"Optiphase" scintillant fluid was added. Each sample was counted over a ten 
minute period,to ensure a minimum of 200 counts per sample.Quench correction 
was performed using the external standard channels ratio technique. The counter 
was regularly calibrated using a set of commercial standards to generate the 
quench correction curve.
The mean counts measured for each organ was corrected for the solvent 
volume allowing the total counts per organ to be calculated, the results being 
expressed as a % recovered dose and % recovered dose per gram of tissue.
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PART 2 - SECOND ORDER TARGETING
In the presence of overt hepatic deposits drug delivery may be enhanced by 
regional delivery into the hepatic artery. Previous work from within the department 
had demonstrated that delivery could be further enhanced by manipulation of blood 
flow by either vasoactive agents (Hemingway et al, 1991) or physical embolisation 
using degradable starch microspheres(Cooke and Chang, 1990). I have 
investigated the theory that these methods could be combined to further improve 
drug delivery to tumour.
Liver tumours were induced in male hooded lister rats as previously 
described. Animals 20 days following tumour induction were anaesthetised by an 
intraperitoneal injection of sodium pentobarbitone(Sagatal 30 mg.kg'1) and the 
gastroduodenal artery cannulated. Care was taken to ensure that the tip of the 
cannula lay at the junction of the coeliac and hepatic arteries. A trial injection of 
saline ensured that the injectate flowed along the hepatic artery and not in a 
retrograde manner down the coeliac artery. The right common carotid artery was 
then cannulated for continuous measurement of the systemic arterial blood 
pressure,via a strain gauge transducer driving a pen recorder(Gould Medical, 
Lutterworth, UK.).
The dose of Angiotensin ll(50pl of angiotensin II 5pg.mM obtained from 
Ciba-Geigy (i.e 25pl bolus)) and DSM (20pl of DSM solution, lOOmg.mM (i.e 2mg 
bolus)) were chosen allow comparison with previous experiments(Hemingway et 
al,1991;Cooke and Chang, 1990). Distribution studies were performed using 
"mic-labelled methylene diphosphonate (MDP),a marker of similar molecular 
weight as Adriamycin.
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Pilot study:
A pilot study, three animal per group, was performed to ascertain the most 
effective mode of administration of the targeting agents. The following schedules 
were compared using:
(1) DSM followed by angiotensin II and MDP; or
(2) Angiotensin II followed by DSM and MDP; or
(3) DSM,Angiotensin II,and MDP given simultaneously.
The results of this study suggested that the most effective combination was 
achieved by the slow bolus injection of Angiotensin II, followed one minute later by 
degradable starch microspheres and 30^1 of 99mTc-labelled MDP (100 MBq/ml) over 
30 seconds. This schedule was therefore used in the main comparative study.(See 
figures 48 and 49)
Comparative study:
Three experimental groups receiving regional delivery of 99mTc-labelled 
methylene diphosphonate(MDP),100 MBq.mM,were compared. Control animals 
(two groups of nine) received an intra-arterial injection of 30pl of MDP in 
physiological saline over 30 seconds. Two groups of animals (n=12) were given a 
20jil intra-arterial injection of degradable starch microspheres (lOOmg.mM) mixed 
with 30pil of MDP as described by Cooke (Cooke and Chang, 1990).
In two further groups of experimental animals(12 per group) 50pl of 
angiotensin II (5jig.mM),was injected into the gastroduodenal artery over 30 
seconds(Hemingway et al, 1990),Systemic arterial blood pressure was monitored 
and one animal was rejected from further analysis when a rise in mean arterial
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blood pressure did not occur. One minute later, chosen as the time point at which 
the pressor effect is maximal, an injection of degradable starch microspheres(2mg) 
with 30(^ 1 of MDP was performed.
Animals were sacrificed 1 and 90 minutes following injection. The liver was 
removed and the tumour tissue carefully dissected from the surrounding normal liver 
tissue. The liver was divided into lobes to ensure there was no intrahepatic 
distribution variation. The tissue was divided,weighed and placed in vials for 
immediate counting in a well gamma counter. A reference sample of the w^Tc MDP 
was taken at the time of the hepatic injection and counted prior to the samples. 
Counts were corrected for decay of the ""Tc.
The results were expressed both as a percentage of the injected dose per 
gram of tissue,and as a ratio of the relative counts detected in tumour and normal 
liver tissue. The significance of the observed differences were assessed using the 
Kruskal-Wallis analysis of variance, Mann-Whitney U test, and the Wilcoxon signed 
ranks test as appropriate.
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CHAPTER 3
RESULTS
102
As in the previous chapters,this is divided into three sections. Firstly I will 
describe the results of the clinical studies on the reproducibility of the modified (high 
administered activity) hepatic perfusion index technique,a comparative study of the 
sensitivity of modern imaging techniques. I will then describe the results to the 
investigations of the tumour model itself ,and then the results of the animal 
experiments investigating why the HPI changes with the development of liver 
tumour.
Lastly I will describe the results of the animal experiments of drug 
targeting, investigating firstly,biochemical carriers for organ specific targeting given 
systemically or regionally,and secondly the combination of physical embolisation 
and a vasoactive agent to improve the retention of a regionally delivered marker 
within tumour deposits.
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SECTION 1
CLINICAL STUDIES
(l)Reproducibility of the Hepatic Perfusion Index:
Eighteen consecutive patients with colorectal carcinoma were suitable for 
analysis,and both observers were able to able to generate regions of interest and 
generate time activity curves for all patients. Ten patients were male and eight 
female with a median age of 72(range 49-82 yrs).The values obtained are detailed 
in appendix 1.
Six patients had pathological or radiological evidence of hepatic metastases. 
The median HPI value obtained in these patients was 0.56(0.38-0.91) compared to 
0.33(0.15-0.57) in the other 12 patients without evidence of metastases. Six of 
these had a value greater than normal(0.37(Parkin et al, 1983)),although four of 
these were within 5% of a normal value. Clinical followup is ongoing.
For a single observer,the median range of reprocessings was 0.035 and the 
maximum range was 0.11. The median difference between two observers was 
0.04(range 0.01-0.11),and the root mean square difference in the HPI
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measurements was 0.028,which is 7.5% of the overall median HPI value for 
observer one. The correlation coefficient between the two observers was 
0.98(p<0.001). The gradient of the regression line was 0.92 with an intercept at 
0.07(see figure 14),indicating that observer two was obtaining values slightly 
greater than observer one.
0 .8 -
Observer 1 o.6- r=0.98
0.4-
0 .2 -
0.0 0.2 0.4 0.6 0.8
Observer 2
Figure 14 : Correlation between value obtained for the HPI by two 
observers.
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As can be seen from the Bland Altman plot(figure 15),the difference between 
the values does not increase proportionately with the magnitude of the value. In this 
case,therefore,the difference between the values,rather than the ratio should be 
used to determine to what extent the values differ. For two observers, the mean 
difference between observations was 0.037, with a Standard Error of 0.0096 and 
Standard Deviation of 0.041. The plot also illustrates,that observer two consistently 
obtained values greater than observer one.
0.2
0.1 -
difference
0.0
- 0.1
o  o  o  
o
s
J - 1---------- 1-----------«- 1 ■ I
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mean
Figure 15 : Bland Altman plot assessing differences between observed values.
Clinical correlation:
The clinical correlation of the modified technique was then assessed on the 
next fifty consecutive patients presenting with colorectal carcinoma. Twenty-seven 
were male and 23 female with a median age of 66 yrs(range 48 - 79). Twenty-nine 
patients had radiological or pathological evidence of metastases. This high 
percentage(58%) reflects the secondary referral of patients with metastases to the 
University Department for hepatic chemotherapy or palliative laser treatment. 
Twenty-one patients were considered disease free. Of the patients with metastases 
97% had an abnormal HPI.whereas only 46% considered disease free had a normal 
value. The prognostic value of an abnormal HPI in patients without evidence of 
metastases is currently under evaluation.
Hepatic
Perfusion
Index
100 i
80-
60-
0.3740-
2 0 -
metastases no metastases
(n=29) (n=21)
Figure 16 : Clinical correlation of the HPI in patients with colorectal 
carcinoma
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(2)Comparative study of imaging techniques:
Seventy-three consecutive patients with colorectal carcinoma were studied. In 
33 patients,one or more imaging modalities were omitted because of emergency 
presentation(n=14) or subsequent palliative non operative treatment(n=19) 
preventing intraoperative palpation or ultrasonography. Consequently percutaneous 
ultrasound, computerised tomography, hepatic scintigraphy, and the hepatic 
perfusion index,were performed on 73 patients, intra-operative palpation in 54,and 
intraoperative ultrasound in 40 patients.
Patients were considered positive if they had histological or post-mortem 
confirmation of metastases,or retrospective evidence of disease progression on 
serial followup imaging. Of the 73 patients 36(49%) were considered to have 
definitive evidence of hepatic metastases,the high percentage reflecting the 
Departments use as a referral centre. The relative clinical accuracy of these 
techniques in the detection of hepatic metastases are summarised below and 
detailed in Appendix 3.
The comparative study was limited to those patients in whom all techniques 
had been employed(n=40). One dynamic hepatic scintigraphic study was unable to 
be processed due to focal uptake. Computerised tomography and dynamic 
scintigraphy were the most sensitive imaging techniques,both detecting over 90% of 
hepatic lesions. Real time ultrasonography was disappointing, having a sensitivity 
of only 77%. These scans were performed on routine lists this may simply reflect 
inter-operator variability. Intraoperative ultrasound had a sensitivity of only 77% in 
the detection of metastases,but with 100% specificity. In two cases,because 
superficial metastases were easily palpable.it was considered inappropriate to
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attempt to visualise these lesions through an "aqueous window"fwhich would have 
increased the recorded sensitivity. The other two missed lesions were small 
metastases near the bare area of the liver. The sensitivity of intraoperative 
palpation(82%) was higher than expected and must reflect an unusually high 
number of superficial metastases.
Table 7: Prospective imaging study
Comparative Study(n=40)
Im a g in g
•
TECHNIQUE SENSITIVITY SPECIFICITY +VE PRED. -VE PRED.
VALUE VALUE
Ultrasound (13/17)77% (23/23)100% (13/13)100% (23/27)85%
CT (16/17)94% (21/23)91% (16/18)89% (21/22)95%
Static scan (15/17)88% (19/23)82% (15/19)79% (19/21)90%
Dynamic scan (16/17)94% (8/22)36% (16/30)53% (8/9)89%
Palpation (14/17)82% (23/23)100% (14/14)100%(24/26)92%
Intraop. U/S (13/17)77% (23/23)100% (13/13)100% (24/27)89%
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Figure 17: Sensitivity of modalities of imaging
Specificity in all tests apart from the HPI was at least 81%, indicating a 
hesitancy to report possible metastases. The low recorded specificity of the HPI 
may reflect its reported ability to predict the occurrence of metachronous 
metastases. If this is so, with time, the specificity of the HPI will improve,with a 
corresponding reduction in the sensitivity and specificity of the other techniques. It 
will therefore be several years before the prognostic value of an abnormal HPI in 
these apparently disease free patients can be accurately assessed.
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Table 8 demonstrates the effect of the inclusion of the results of the other 33 
patients in whom one or more of the tests was not performed.and it is apparent that 
this does not significantly alter the relative accuracy of each test. This further 
strengthens the findings of this study.
Table 8 : Comparison of imaging techniques including patients that did
not undergo all imaging techniques(n=73):
Im a g in g
TECHNIQUE S ensitivity Specificity +VE PRED. -VE PRED.
VALUE VALUE
Ultrasound (27/36)75% (37/37)100% (27/27)100% (38/46)83%
CT (34/36)94% (34/37)92% (34/37)92% (34/36)94%
Static scan (29/36)80% (31/37)81% (29/36)80% (31/37)84%
Dynamic scan (34/36)94% (16/36)44% (34/54)63% (16/18)89%
Palpation (23/25)92% (29/29)100% (23/23)100% (29/31)94%
Intraop. U/S (13/17)77% (23/23)100% (13/13)100% (24/27)89%
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Figure 18 : Specificity of modalities of imaging:
SECTION 2
ANIMAL MODELS AND HAEMODYNAMIC STUDIES 
The HSN sarcoma cell tumour model:
Prior to inoculation the viability of the cells was confirmed by the addition of 
trypan blue. Tumour was achieved in all animals undergoing inoculation with live 
cells. Intrahepatic tumour deposits were usually undetectable (median 
diameter=0mm(0-1)) at five days following induction,becoming more obvious 
between ten days (2mm(0-3)) and fifteen(4mm(2-7)). By twenty days 8mm(6-10) 
they entered their rapid growth phase,reaching 23mm(18-28) by twenty-five and 
28mm(21-42) by thirty days.
mm
5
4
3
2
1
0
days post innoculation
Figure 19: Growth curve of cell line.
All experiments were performed between 20 and 25 days following 
inoculation to correspond with the rapid phase of the growth curve when tumours of 
between 1-3 mg were present. The median % hepatic replacement of these tumours 
at this stage was 15.6% (range 2 - 42%) (See Appendix 4). These tumours are 
relatively hypovascular with a median blood flow to liver tissue, as determined by 
the reference microsphere sample technique, of 0.124ml/min/g(range 0.095-0.159) 
compared to 0.085(0.045- 0.17) with a median tumour to liver blood flow ratio of 
0.503 (0.28-1.70).
0.21
ml/min
0 . 1  -
o.o
liver tumour
Figure 20: Relative blood flow of liver and tumour tissue.
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Cross perfusion experiment:
As discussed earlier this was performed to attempt to prove that the
alterations in splanchnic haemodynamics are as a result of a circulating,and
therefore transmissible,vasoactive agent. A total of 62 experiments were performed.
The initial experiments were plagued by instability created by the complexity of the
model. Consequently more than two thirds of the experiments were principally
concerned with overcoming technical problems and the development of a stable 
»
model,with physiological temperature (36-38°C),electrolytes(Na2+ (130-145),K+ 
(3.0-5.0) ,CI"(90-105), Urea(<10),blood gases (p02(100-150mmHg) C02 (40-50 
mmHg) and acid/base balance(pH(7.30-7.50).
Segmental 2" 
flow 
(ml/min)
tumour control tumour control tumour control
Figure 21: Segmental flow in experiment 1 during alternate periods of
perfusion by tumour bearing and control animals
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Figure 22: B.P. tracing and associated flows of experiment 1
This is a photograph of the continuous blood pressure tracing obtained during a 
cross-perfusion experiment. The arterial trace (having previously been calibrated) 
records the perfusion pressure developed by the donor animal. The figures refer to 
the simultaneous blood flow achieved through the isolated segment, during 
alternating periods of perfusion by tumour-bearing animals(T) and synergistic 
controls(C).
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Cannulas reported to have been used in the literature(Anzueto, 1984) were
*
found to produce unacceptably high resistance to flow and "tapering" cannulas from 
2mm to 1 mm internal diameter were developed and used. Excessive fluid and 
temperature loss from the exposed small bowel was prevented by wrapping the 
segment with "clingfilm". Because of previously reported vascular homeostasis,only 
flows associated with a mean systolic blood pressure of between 80 and 130 
mmHg were accepted.
mmHg
1501
100 -
tumour control
Figure 23: Blood pressure during perfusion by control and tumour rats:
The median arterial blood pressure in control animals was 101.7mmHg 
(range 90 - 108.3) as compared to 99.2 mmHg(range 90 -120.7) in the tumour 
bearing rats(p=0.82). The median flow through the small bowel segments was 
greater during perfusion by a control animal (2.1ml/min (range 1.33-3.93)) than 
during perfusion by a tumour bearing animal (1.58 ml/min (range 0.4-3.6))(p=0.12). 
The median calculated splanchnic vascular resistance was less in the during control 
perfusion (49.7 mmHg/(ml/min) (range 25 - 117) than during tumour perfusion 
(64.8mmHG/(ml/min)(range 26.9-243)(p=0.03).
ml/min 3-
2 -
tumour control
Figure 24: Segmental blood flow during perfusion by control and tumour
bearing rats.
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On the second cross perfusion (Appendix 3b) four experiments were 
terminated because the mean systolic pressure was not above 80mmHg. In the 
remaining animals the median systolic pressure was 100mmHg(range 85 - 110) 
compared to 100 mmHg (95 - 110)in tumour bearing animals(p=0.78). Once again 
the flow was greater ( 2ml/min (range 0.8 - 3.3) cf. 1.25( 0.4-2.4))(p=0.32) and the 
resistance lower (51.2 (33-122.3) cf.76.1 (45.4-250)(p=0.13) during perfusion with 
control rats compared to tumour bearing animals.
2501
20 0 “
p<0.05
mmHg / 150- 
(ml/min)
1 0 0 -
50-
controltumour
Figure 25: Mean resistance during perfusion by control and tumour rats
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Reference microspheres:
In this section the results of the reference microsphere experiments are 
summarised and detailed in Appendix 4. This experiment was performed to 
investigate the effect of extrahepatic tumour on splanchnic haemodynamics.The 
mean recovered counts of the reference sample was 2830(range 1363-7878) with 
no significant difference between the three study groups. Tumour deposits were 
confirmed in two intrahepatic and flank sites in all animals inoculated with live 
cells.The livers in animals injected with dead cells showed only minimal fibrous 
scarring with no evidence of tumour.The mean tumour weight in animals with flank 
tumour was 1.75g(range 1.4-2.3) compared to 1.93g (range 1.2-2.6) in animals with 
intrahepatic tumour. Seventeen animals were excluded from analysis because the 
counts in the left and right kidney differed by more than 15%.
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Figure 26: Flow per gram of liver
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The calculated blood flow confirmed that.as in previous experiments 
intrahepatic tumour was hypovascular relative to surrounding liver parenchyma with 
a mean tumour to liver blood flow ratio per gram of tissue of 0.67 (range 0.33-1.7). 
When blood flow is calculated on a per gram basis, the hepatic arterial flow to liver 
parenchyma was similar in controls(0.123 ml/gm) and liver tumour bearing 
animals(0.124 ml/gm) but less in flank tumour bearing animals (0.078ml/gm). The 
flow per gram to the splanchnic organs was greater in control animals(0.789 ml/gm) 
compared to both liver tumour bearing (0.461 ml/gm) and flank tumour bearing 
(0.489 ml/gm) animals.
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Figure 27: Flow per gram of splanchnic tissue.
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Total blood flow to tumour bearing livers,including tumour blood flow, was 
greater than to either controls or animals with flank tumours(1.31 ml/min compared 
to 0.91 ml/min and 0.75 ml/min respectively). The splanchnic blood flow was 
reduced in both animals with tumour in the liver and flank(7.75 ml/min and 8.69 
ml/min) relative to control animals (11.36 ml/min).
2.0n
ml/min
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control flank liver
Figure 28: Flow to liver parenchyma in controls,and animals with tumour in
the liver and flank.
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. The calculated Hepatic Perfusion Index,excluding tumour blood flow, was 
significantly increased in animals with tumours within the liver (0.11(0.09-0.19)) 
compared to animals with flank tumours (0.08 (0.07- 0.10)) and control 
animals(0.08(0.06-0.09). The inclusion of the flow to tumour in calculating the 
HPI(0.13 (0.11-0.23) in the intrahepatic group further increased the magnitude of 
the change.
ml/min
control flank liver
Figure 29: Flow to splanchnic organs in controls, and animals with tumour
in liver and flank.
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Figure 30: Calculated hepatic perfusion index for controls, and animals with
tumour in liver and flank.
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Figure 31: Calculated Hepatic perfusion index(incl. tumour blood flow)
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SECTION 3
DRUG TARGETING
In this section I will first describe the results of experiments designed to 
assess the efficacy of three agents with potential use for hepatic targeting for 
adjuvant therapy and then the results of experiments looking at intrahepatic 
targeting in the presence of overt tumour.
FIRST ORDER TARGETING 
(1) 5-FU/GUARIC ACID POLYMER DISTRIBUTION STUDIES
The results are summarised here and detailed in Appendix 5. A recovery 
experiment confirmed that the counts were unaffected by the volume of dissolved 
tissue used(Appendix 5a). Venous pharmacokinetic sampling following an 
intravenous bolus injection of free 5-FU acetate confirmed a rapid plasma 
peak(tmax= 4min) followed by a rapid fall(t1/2 = 3 mins) to a low concentration, 
indicating a large volume of distribution. A similar pattern was seen following 
injection of the 5 FU polyrner(tmax=4 mins),but with a slightly prolonged half life 
(t1/2=7.5mins),indicating a little,if minimal,retention within the circulation.
Using the area under the plasma concentration curve for each animal,the 
median AUC for 5-FU(4.74 %I.D.mH.hr1) and 5-FU polymer( 6.21 %I.D..mM.hr1) 
treated animals was calculated,providing an AUC ratio(AUC5_FU:AUCpo,ymer) of 
1.309,indicating slightly increased total drug exposure using the polymer.
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Figure 32: Venous pharmacokinetics following bolus injection of 5FU
acetate
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Figure 33: Venous pharmacokinetics following injection of 5FU/Guaric acid
polymer
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There was a minor element of hepatic targeting,however only 7% of the 
injected dose was detectable in liver at 60 minutes (compared to 4.5% with free 
5-FU acetate). Less than 0.5% of the injected dose was detectable in tumour 
tissue,and this was not greatly altered by the compound used.(Acetate(0.32%) cf 
polymer(0.24%). Tissue levels per gram of tissue were highest in kidney 
tissue,being over four times greater than in liver tissue,and over 2 0  times greater 
than in tumour. Due to the minor degree of hepatic targeting,the tumour: liver ratio 
was worse using the polymer than free acetate.
^  V77/77? 7/X
liver tumour kidney Spleen Heart Lung
Figure 34: Distribution of 5 FU acetate(median % injected dose/g)
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Figure 35: Distribution of 5FU/Guaric acid polymer(median % inj. dose/g)
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Figure 36: Tumour:liver ratios at 10,30 and 60 minutes following injection of
5FU acetate
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Figure 37: Tumour:liver ratios at 10,30 and 60 minutes following injection of
5FU/Guaric acid polymer
(2) N-(2-HYDROXYPROPYL)METHACRYLAMIDE POLYMER
Initial recovery experiments comparing the reliability of the estimation of the 
injected dose when administered through polyethylene cannulae and 
needle,showed considerable variation and a mean recovered cannula to needle 
dose ratio of 0.57:1, indicating a degree of adherence of the polymer to the internal 
surface of the cannula. Consequently it was considered inappropriate to calculate 
the injected dose from a reference sample and all distribution experiments were 
calculated as a percentage of the recoverable dose in the animal.
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Intravenous administration:
The venous pharmacokinetic profile following an intravenous injection 
revealed a tmax of approximately 45 seconds, with a t1/2 of 3 minutes. The median 
AUC,V was 1.655%R.D.mM.hr1. Total body distribution confirmed targeting to 
hepatic parenchymal tissue, with a median of 55.8%(range 37-67%) of the 
recovered dose being present in liver at 5 minutes, rising tp 65% (range 56-76%) at 
10 minutes,thereafter remaining steady(figure 38). Median renal concentration at 5 
minutes(6 %) rose minimally to 6.5% at 30 minutes.
1 0 0 "
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% .
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Figure 38: Polymer distribution following intravenous administration
(median % I.D.)
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Despite the excellent targeting to hepatic parenchyma, localisation in tumour 
was disappointing with a median 1 .2 % of the polymer being recovered from tumour 
tissue,the concentration being similar at 5 minutes (1.18(0.47-1.74)), 10 minutes 
(1.22(0.51-2.85)) and 30 minutes (1.09(0.15-2.1)) following injection.
When expressed as a percentage of the recovered dose per gram of tissue 
the highest concentration of polymer was in liver with a median concentration of 
5%/g at 5 minutes, increasing to 5.5%/g at 30 minutes. The concentration in kidney 
was approximately half this(2.4%/g increasing to 2.7%/g). Tumour tissue 
concentration was 0.27%/g increasing slightly by 30 minutes to 0.36%/g giving a 
median tumour to liver ratio of 0.07 : 1.
Regional administration:
The effect of administering the polymer via the hepatic artery or portal vein 
on systemic pharmacokinetics and whole body distribution was studied. There was 
no significant difference in the pharmacokinetic profile following either intraarterial 
or intraportal administration, presumably reflecting a low "first pass" uptake by the 
liver. Maximum serum concentration of polymer (tmax) being obtained at 45 seconds 
following injection with a similar half life(t1/2) of three minutes(figure 39). Comparison 
of the median AUCIA(1.527%R.D.mM.hM)and AUCIP (1.609%R.D.mM.hM) with that 
following intravenous administration produced an AUCiV:AUC|A ratio of 1:0.92 and 
an AUC,v:AUC|p of 1: 0.97,indicating slightly less systemic total drug exposure 
following regional administration.
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Figure 39: Venous blood concentration following intravenous, intraarterial and 
intraportal HPMA polymer administration(median % I.D./ml)
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Figure 40: Log concentration against time following intravenous, intraarterial 
and intraportal HPMA administration.
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Table 9: Median tissue levels following intravenous,intraarterial,
and intraportal administration:
5 minutes 10  minutes 30 minutes
Liver i.v. 55.85 65.40 64.05
i.a. 56.55 56.05 60.15
i-P- 57.65 60.80 62.99
Tumour i.v. 1.18 1 .22 1.09
i.a. 2.93 2.19 2.16
i-P- 1.40 0.92 1.24
Heart i.v. 0.50 0.34 0.21
i.a. 0.81 0.67 0.50
i-P- 0.77 0.65 0.40
Lung i.v. 1.40 0.85 0.57
i.a. 0.90 1.19 0.65
i-P- 1.08 0.76 0.47
Kidney i.v. 6.14 2.45 6.44
i.a. 5.85 6.24 7.81
i-P- 4.95 3.68 4.29
Spleen i.v. 0.30 0 .2 0 0.29
i.a. 0 .8 8 0.81 0.51
i-P- 0.65 0.48 0.41
Carcass i.v. 34.70 27.60 26.65
i.a. 30.35 30.60 27.25
i-P- 33.20 30.75 26.35
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With regional administration,as can be seen in table 9, because of the similar 
systemic availability of the alternative routes of administration, polymer distribution 
was not significantly affected by intraarterial or intraportal administration. Once 
again there was excellent hepatic targeting, nearly 60% of the labelled polymer 
localising within the liver in 5 minutes. The levels detected in kidney,spleen,heart, 
lung,and carcass(figures 41 and 42) were similar to intravenous administration.
100 i
80 -
%
60"
40-
2 0 -
■ liver tumour heart lung kidney spleen Carcass
Figure 41: Polymer distribution following intraarterial administration
(median % I.D.)
136
When expressed as a percentage of the recovered dose per gram of tissue, 
the levels in liver parenchyma(approx 6 %/g) were over twice that of renal 
tissue(2.5%/g) and ten times that of heart (0.5%/g)and lung(0.5%/g). The relative 
concentrations obtained in tissue were unaffected by the mode of administration. 
(Appendix 5b)
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Figure 42: Polymer distribution following intraportal administration,
(median % I.D.)
Tumour levels in all groups were disappointing.As a result of the preferential 
arterial delivery to tumour tissue, there was slightly higher concentration of polymer 
in tumour at 5 minutes(figure 43) following intraarterial administration(0.61%/g 
(0.25-1.34)) than by either intravenous(0.27%/g(0.16-0.96)) or intraportal 
administration (0.31%/g(0.26-0.67)) This difference was maintained at 30 minutes 
(0.74(0.18-1.26) cf 0.36(0.11-0.57)) and 0.32(0.21-1.54). Despite the improvement 
in polymer delivery to tumour,the median tumour to liver ratio'was still only 0 .12:1 
(figure 44).
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Figure 43: Uptake into tumour and liver parenchyma following intravenous,
intraarterial and intraportal administration
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Figure 44: Tumour to liver parenchyma concentration ratio 30 minutes after
intravenous,intraarterialyand intraportal administration
(3)14C-LABELLED HAEMATOPORPHYRIN DERIVATIVE
The principal aim of this study was to determine firstly to what extent hepatic 
targeting occurred and secondly.whether the relative tissue concentrations varied 
with time;which would be useful in the temporal planning for the subsequent 
activation of the sensitiser. Localisation in the viscera was slow,58% of the 
recovered dose remaining in the carcass at 24 hours. There was progressive 
excretion of the radiolabelled porphyrin with 46% of the recovered dose on day 1 
remaining by day 1 1 .
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The distribution pattern of the HpD was similar to the HPMA polymer.the Hpd 
being concentrated in the liver.spleen,kidney and tumour.only small amounts being 
recovered in the other organs. Localisation in the liver took 3 days to reach a 
maximum concentration. Thereafter the percentage of the recovered dose remained 
around 50% with a gradual reduction in absolute counts within the liver.
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119753
days
Figure 45: Total recovered dose with time.
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By contrast,the uptake into tumour tissue was relatively rapid.the highest 
concentration 1.82 %/g) being recorded 24 hours following injection.
Consequently,because of the more gradual concentration in liver parenchyma,the 
tumour: liver ratio was greatest on day one (0.75:1).
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Figure 46: Tumour to liver ratios with time
When expressed as a percentage of the recovered dose per gram,the level 
detectable in the liver parenchyma remained steady throughout the study at 
4%/g,which was slightly less than that of the HPMA polymer. There was also a 
gradual localisation within the spleen presumably due to progressive metabolism 
and excretion via the reticuloendothelial system.
141
Despite the early targeting to the hepato-portal viscera,a significant level of 
drug was detected in the carcass throughout the study,more than 30% remaining 
by day 11. This presumably reflects the prolonged photosensitisation experienced 
by patients receiving HPD.
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Figure 47: Distribution of 14C-labelled Hpd at day 3
SECOND ORDER TARGETING
Pilot Study:
The results of the pilot study are illustrated below(figures 48 and 49) and 
detailed in appendix 6 . This suggested that the most effective combination was 
achieved by the injection of Angiotensin followed one rfiinute later by the 
degradable starch microspheres (2mg) and 30 pi of 99m'Tc methylene 
diphosphonate(MDP) given over 30 seconds. This schedule was therefore used in 
the comparative study.
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Figure 48: Pilot study. Liver and tumour distribution at one minute.
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Figure 49: Pilot study. Liver and tumour distribution at 90 minutes. 
Comparative study:
Comparison of the three study groups using the Kruskal-Wallis test 
confirmed that there was a significant difference in the retention of marker in tumour 
(p= 0.003) and liver (p= 0.001) at one minute.but only in tumour(p= 0,001) and not 
liver (p= 0.21) by 90 minutes. Whereas there was no significant difference in the 
tumour to liver ratio at one minute(p= 0.87) there was a significant difference by 90 
minutes (p=0.001). Comparison between groups used the Mann-Whitney U-test for 
non-parametric data. The results are detailed in appendix 6  and summarised 
below. All results are expressed as the median(and range) of the percentage of the 
injected dose per gram of tissue.
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ONE MINUTE:
Table 10: Uptake at one minute.(median(range))
Control DSM alone DSM/Angiotensin
Liver parenchyma 0.08(0.01-0.62) 0.94(0.73-1.18) 0.95(0.4-1.01)
Tumour tissue 0.06(0.01-0.4) 0.71(0.09-4.55) 0.52(0.16-1.99)
T:L ratio 0.72(0.1-6.2) 0.69(0.1-4.2) 0.72(0.2-2.2)
Within control animals, the percentage of the injected dose of MDP per gram 
of tumour tissue was 0.06(0.01-0.4) which was lower than in the surrounding liver 
tissue(0.08(0.01-0.62)) but this difference was not statistically significant.(p=0 .1). 
The median tumour to liver ratio was 0.72(0.1-6.2).
In animals that were treated with DSM alone, the median uptake in normal 
liver tissue was 0.94(0.73-1.18) which was significantly greater (p<0.001) than in 
the control animals. Similarly the uptake in tumour tissue was significantly greater at 
0.71(0.09-4.55) than in control animals(p=0.005). The median tumour to liver ratio 
was 0.69(0.1-4.2) which did not differ significantly from that of the control group. 
(p=0.87).
Combining Angiotensin with the DSM again significantly increased the 
normal liver uptake to 0.95(0.4-1.01 )(p=0.003),and to 0.52(0.16 -1.99) (p=0.003) in 
tumour tissue compared to control animals. The median tumour to liver ratio of 
0.72(0.2- 2.2)was again not significantly altered. Uptake achieved in both normal 
liver(p=0.49) and in tumour tissue(p=0.79) was not significantly different from 
animals treated with DSM alone.
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90 MINUTES:
In control animals the level of marker remaining in normal liver tissue was 
0.07(0.05-0.16) and in tumour tissue was 0.04(0.01-0.08) which was slightly less 
than in control animals at one minute due to washout of marker.There was relatively 
greater washout of marker from tumour tissue than in normal liver, with a median 
tumour to liver ratio of 0.49(0.2-1.1).
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Figure 50: Uptake of marker at one minute following injection of salineyDSMy
or angiotensin II followed by DSM
146
Table 11: Uptake at 90 minutes.(median(range))
Control DSM alone DSM/Angiotensin
Liver parenchyma 0.07(0.05-0.16) 0.12(0.04-0.69) 0.11 (0.03-0.24)
Tumour tissue 0.04(0.01-0.08) 0.19(0.06-0.75) 0.53(0.15-1.09)
T:L ratio 0.49(0.2-1.1) 2.09(0.1-3.6) 5.22(1.9-11,4)
In animals treated with DSM alone there was significantly increased retention 
of marker in tumour tissue(0.19(0.06-0.75)) (p<0.001)compared to control animals 
and also compared to surrounding liver tissue(0.12(0.04-0.69)(p=0.03)) with a 
significantly increased tumour to liver ratio of 2.09(0.1-3.6). There was no significant 
difference in the retention of marker in normal parenchyma between DSM treated 
animals and controls at 90 minutes(p=0.1)
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Figure 51: Uptake of marker 90 minutes following injection of saline,DSM
or angiotensin II followed by DSM.
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In animals treated with both DSM and angiotensin II, there was again 
significantly increased retention of marker(p=0 .0 0 2 ) in tumour tissue 
(0.53(0.15-1.09)) compared to surrounding liver parenchyma(0.11 (0.03-0.24)). The 
tumour to liver ratio was also significantly increased (p=0.001) at 5.22(1.9-11.4) 
compared to both control animals and those treated with DSM alone. The absolute 
retention of marker in tumour tissue was also significantly greater than in controls 
(p<0.001) and DSM treated animals (p=0.01). The retention of marker in normal 
liver was not significantly different from that in control or DSM treated animals 
(p=0.64).
Blood pressure:
In animals treated with Angiotensin II the pretreatment median systolic blood 
pressure was 114mmHg(106-120).Following administration of the Angiotensin there 
was a rise in median systolic pressure to 131mmHg(120-143). One animal was 
excluded from further analysis when a rise in systolic pressure failed to occur.
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SUMMARY OF FINDINGS
DETECTION OF METASTASES:
Section 1 - Clinical studies:
(1) Abnormalities in the hepatic blood flow pattern were detected in patients in 
patients with colorectal metastases.
(2) The high administered activity dynamic hepatic scintigraphy technique is 
reproducible when processed on more than one occasion by one observer or when 
separately processed by two independent observers.
(3) The HPI has a sensitivity of 94% in the detection of hepatic metastases. This is 
similar to computerised tomography and better than all other methods of detection. 
The specificity of the HPI ,in comparison to the other techniques, was poor(36%).
(4)The sensitivity of intraoperative ultrasound was disappointing (77%), although 
the specificity was excellent 100%). Intraoperative ultrasound only confirmed 
metastases that had been identified by other techniques, and was therefore found to 
have a similar threshold to standard techniques.
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Section 2 - Animal models and haemodynamic studies:
(5) Hepatic tumour was reliably induced in Hooded Lister rats by direct intrahepatic 
injection of 106 HSN sarcoma cells derived from cell culture.This produced two 
discrete tumour deposits with a median percentage hepatic replacement of 15.6 %.
(6 ) Abnormalities in the hepatic blood flow pattern were detected in animals with 
liver tumour.
(7) The HSN tumour model produces deposits that are hypovascular relative to the 
surrounding liver parenchyma.
(8 ) Perfusion with blood from a tumour bearing animal results in a reduction in flow 
through an isolated small segment due to an increase in vascular resistance.
(9) This increase in resistance was abolished by perfusion with blood from a control 
animal.
(10) Both tumour within and outwith the liver result in a reduction in splanchnic 
blood flow.
(11) Tumour outwith the liver results in a reduction in blood flow to both the liver and 
splanchnic vascular bed.
(12) Hepatic arterial blood flow does not change with the development of tumour 
within the liver.
(13) The calculated HPI was similar in animals with tumour in the flank compared to 
controls.
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(14) The calculated HPI was significantly altered in animals with intrahepatic tumour 
compared to animals with flank tumours and controls.
TREATMENT OF METASTASES:
Section 1 - First Order Targeting: 
(1)Guaric acid polymer:
(15) There was minimal demonstrable targeting of 5-FU to the liver using the gauric 
acid polymer. The pharmacokinetic profiles of the polymer and free drug were 
similar,suggesting rapid breakdown of the polymer/label complex.
(2)HPMA polymer:
(16) Using the HPMA polymer,60% of the recovered dose was present in the liver at 
5 minutes,increasing slightly at 10 and 30 minutes.
(17) Less than 1% of the HPMA polymer targeted to tumour tissue following i.v 
administration, with a tumour to liver ratio of 0.07:1.
(18) Regional administration had little effect on the distribution of the HPMA 
polymer, except that tumour tissue concentration was higher following intra-arterial 
administration. The tumour to liver ratio was still only 0.12:1
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(3)Haematoporphyrin derivative:
(19) Half of the administered haematoporphrin derivative remained 11 days 
following injection,the remainder having been excreted.
(20) The HpD was concentrated in the liver,spleen,kidney and tumour.The tumour to 
liver ratio was maximal on day 1 (0.75:1). There is a gradual relative concentration 
of HpD in the liver and spleen due to its metabolism via the reticuloendothelial 
system.
Section 2 - Second order targeting:
(21) Mean arterial blood pressure was significantly raised following the injection of 
angiotensin II.
(22) The intra-arterial injection of DSM significantly increased the retention of 
marker in both liver and tumour tissue one minute after injection. Similarly, the 
intra-arterial injection of angiotensin II plus DSM significantly increased the 
retention of marker in both liver and tumour tissue one minute after injection.
(23) The tumour to liver ratio was unaltered one minute following the injection of 
either DSM alone or angiotensin II plus DSM.(0.7:1)
(24) The intra-arterial injection of DSM significantly increased the retention of 
marker in tumour tissue 90 minutes after injection, whereas the retention of marker 
in the surrounding liver had returned to control values due to portal washout of 
marker. The intra-arterial injection of angiotensin II plus DSM significantly increased 
the retention of marker in tumour tissue 90 minutes after injection. At this time point 
the retention of marker in the surrounding liver had returned to control values.
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(25) The tumour : liver ratio was significantly raised 90 minutes following the 
injection of DSM alone(2.09:1).
(26) The tumour : liver ratio was significantly raised 90 minutes following the 
injection of angiotensin II plus DSM.(5.22:1)
(27) The administration of angiotensin II plus DSM results in a significantly better 
tumour: liver ratio than DSM alone.
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CHAPTER 4
DISCUSSION
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SECTION 1
IMAGING OF HEPATIC METASTATIC DISEASE:
Until recently the early detection of liver metastases arising from primary 
colorectal carcinoma was more of academic interest than of clinical importance to 
the patient. The recent confirmation that the subsequent survival following surgical 
treatment of the colorectal primary may be influenced by chemotherapy or 
surgery,particularly as these treatments are associated with significant morbidity 
and the benefit appears to be stage specific,has placed increased significance on 
the accurate staging of patients suffering from colorectal carcinoma.
Improvements in technology have rendered many of the early studies on the 
accuracy of imaging techniques obsolete,as sensitivities quoted may be surpassed 
using modern equipment. In addition the simple detection of metastases is no 
longer sufficient for treatment planning. Evaluation of number,size and location are 
essential if resection is considered. Consequently the pattern of investigations 
chosen may differ from patient to patient.
Since the early 80's computed tomography has been the preferred screening 
test for the detection of metastases.Advances in technology and technique,using 
fast scanning sequences and contrast CT angiography, have resulted in a 
sensitivity of up to 90%. Problems arise with single small metastases and 
metastases in patients with synchronous hepatic parenchymal disease. In these 
cases,lesions may be missed or additional investigations required to clarify the 
diagnosis. Therefore density dependent imaging techniques are insufficiently 
sensitive to identify a target population for effective chemotherapy.
155
Previous studies of chemotherapy have shown that although improvements in 
survival can be achieved in patients with established metastatic disease using 
either systemic or regional chemotherapy,the treatment is primarily palliative,the 
only potential for cure in patients with metastases being surgical resection. 
This,however,is a feasible option in less than 5% of these patients.
Adjuvant therapy on the other hand has been associated with a reduced 
incidence of overt metachronous metastases and increased long term survival 
presumably by treating the patients at a micrometastatic stage when the tumour 
load is small. Of those patients undergoing an apparently curative resection, only 
40-45% go on to develop metachronous metastases. Consequently if applied 
indescriminantly,adjuvant therapy,with its considerable morbidity, would be 
administered unnecessarily to over half of these patients.
This highlights the potential importance of the hepatic perfusion index in the 
management of patients with colorectal carcinoma. Not only is the sensitivity in 
excess of 90% in the detection of established metastases,the separation of patients 
undergoing apparently curative surgery into those at low or high risk of developing 
metachronous hepatic metastases would allow some selectivity regarding the 
administration of adjuvant chemotherapy.
The results of our present studies have confirmed that by the adoption of the 
high administered activity technique assessed in this thesis,several of the 
previously reported problems associated with the dynamic scintigraphy may be 
avoided. Whereas with the former technique up to 14%(Tindale et al, 1987) of 
studies were unsuitable for analysis,we have found only one study impossible to 
process due to complete overlap of the lung and liver regions of interest.
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Similarly the reproducibility of the analysis of studies is improved using the 
high administered activity technique(Goldberg et al, 1987), both on serial analysis or 
on analysis by two observers. Whereas the difference between the two techniques 
is not great,the reduction in variability may be of importance in improving accuracy, 
particularly in studies close to threshold value. It is possible that the greater 
statistical uncertainty associated with the lower administered activities, may account 
for some of the conflicting results in previous studies of the diagnostic and 
prognostic value of the hepatic perfusion index.
Although the sensitivity in the presence of proven metastases is excellent the 
specificity is poor due to the large number of apparently false positive results. 
Leveson.in 1985,demonstrated that 94% of patients with metastases at the time of 
surgery have an abnormal HPI,and that over 60% of those patients who had an 
abnormal HPI but no demonstrable evidence of disseminated disease on 
presentation, had developed metastases within one year. Consequently the 
specificity increases with time, an abnormal HPI identifying a subgroup that may 
have the most to gain from adjuvant therapy. This prognostic value of the HPI, 
initially reported by Leveson in 1985,has yet to be reproduced by other centres.and 
we are consequently following these patients to determine their outcome.
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BLOOD FLOW CHANGES ASSOCIATED WITH THE HEPATIC PERFUSION 
INDEX.
For over 10 years it has been known that abnormalities in liver perfusion 
occur with the development of metastases,detectable by dynamic hepatic 
scintigraphy(Parkin et al,1983;Leveson et al,1985;Sarper et al, 1981). Because of 
the difficulties in directly measuring organ blood flow in humans,animal models of 
hepatic colorectal metastases have been used to investigate changes in the blood 
flow pattern. Previous studies by Nott(Nott et al,1989) and Hemingway(Hemingway 
et al,1991) have demonstrated that the HPI is abnormal during both the micro­
metastatic and macroscopic stages of tumour development in both hypervascular 
and hypovascular rodent colorectal tumour models,the magnitude of that 
abnormality increasing with the growth of the tumour. Because of the progressive 
nature of the blood flow changes,the HPI may be within the normal range at the 
earliest stage of the development of slowly growing tumours(Cooke et 
al, 1987;Hemingway et al, 1991).
Whether patients that have an initially normal HPI,but develop metastases,do 
so because their intrahepatic disease is minimally advanced or seeded by cells 
shed at laparotomy,a repeat HPI at a later time may reveal abnormalities that would 
predict the subsequent development of overt liver metastases. Unfortunately due to 
the high administered activity we at present have not obtained 
ARSAC(Administration of Radioactive Substances Advisory Committee) approval 
for sequential studies. If the predictive value of the measurements is confirmed, 
temporal monitoring of the HPI may be possible in the future.
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There has been some controversy as to why the blood flow pattern to the 
liver altered in the presence of metastases. It has been known for over 30 years that 
the blood supply to metastases was principally derived from the hepatic 
artery(Breedis and Young, 1954;Ackerman et al, 1969;Lien and Ackerman, 1970; 
Ackerman, 1972). These anatomical studies were not quantitative,and the increase 
in the proportionate contribution of the hepatic artery to total liver blood flow has 
been assumed to be as a result of increased hepatic arterial demand(Boyd et 
al,1978; Leveson et al,1985;Wraight et al,1982).
Using a combination of dynamic scintigraphic and reference microsphere 
techniques,Nott demonstrated in the hypervascular Walker cell model of colorectal 
metastases, that the abnormality detected in the HPI was a result of reduced portal 
venous inflow and not an increase in hepatic arterial flow, which remained 
constant(Nott et al, 1989). These findings were confirmed by Hemingway using the 
HSN sarcoma cell model.who suggested that the alteration in hepatic proportionate 
flow was due to an increase in the splanchnic vascular resistance,with a 
consequent reduction in portal venous flow(Hemingway et al, 1991).
Whereas Nott had demonstrated the development of arterio-systemic 
shunting in the Walker model, Hemingway confirmed that the HPI was also 
abnormal in a non-shunting model. This disproved the initial theory that the 
reduction in portal venous flow was due to increased intrahepatic resistance 
secondary to the development of arterio-venous shunting. Furthermore, using the 
HSN model Hemingway was able to demonstrate that the changes occurred 
principally due to an increase in the splanchnic vascular resistance,resulting in a 
reduction in portal venous flow with only a small increase in intra-hepatic portal 
vascular resistance.
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Although the isolated small bowel cross perfusion experiment developed in 
this thesis is subject to many experimental pitfalls, with care and practice a stable 
model within physiological limits can be maintained. The homeostasis of intestinal 
perfusion is complex with more than one factor acting simultaneously. We observed 
a trend toward reduced perfusion with time presumably due to progressive 
metabolic disturbance. For this reason the order of perfusion by tumour bearing and 
control animals was randomised,and only the first pair of measurements was used 
for formal comparison, Changes in flow could be reproduced quantitatively for 
several subsequent measurement pairs in the majority of experiments. Similarly 
there was a significant range of flows obtained through different segments, as both 
control and tumour bearing animals perfused the same segment,the intersegmental 
variation should not effect the final result.
There was a significant trend towards greater intestinal blood flow during 
periods of perfusion by control animals with increased calculated vascular 
resistance during perfusion by tumour bearing animals. This provides strong 
evidence that there is a circulating agent in the blood of tumour bearing animals 
which results in splanchnic vasoconstriction.
If the tumour is producing a vasoconstricting agent,why does the hepatic 
perfusion index only become abnormal on the development of intrahepatic 
tumour,and not with the primary lesion? The results of the reference microsphere 
experiment, looking at the effect of intrahepatic and intrahepatic tumour may help to 
explain this phenomenon.
Calculated splanchnic blood flow fell in the presence of both intrahepatic and 
extrahepatic tumour relative to controls. Hepatic arterial flow fell in the presence of 
extrahepatic tumour but not with tumour within the liver. The contribution of the 
hepatic arterial flow in animals with intrahepatic tumour therefore increased in
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relative terms,leading to a raised hepatic perfusion index which concurs with the 
earlier findings of Nott and Hemingway (that the hepatic arterial flow remains 
constant with the development of intrahepatic tumour).
Taken together the findings of the cross-perfusion study and the reference 
microsphere study would suggest that both extra-hepatic and intrahepatic tumours 
may produce a vasoconstricting agent,but in the case of intrahepatic tumour there is 
local preservation of arterial flow.
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SECTION II
THE TREATMENT OF HEPATIC METASTASES
Surgery is the primary treatment modality for patients with colorectal cancer 
The majority of colorectal tumours are "operable", nearly 50% of patients develop 
recurrent disease,even if all the tumour is resected. Over the last 20 years,research 
has concentrated on chemotherapeutic prevention or treatment of tumour 
recurrence or metastases,with only minor improvements in survival. This potential 
benefit is small in relation to inter-surgeon variations in long term results and 
survival(McArdle and Hole, 1991). It is important to remember therefore the 
importance of adequate primary surgery in any discussion of the management of 
colorectal carcinoma.
Even in the most skilled hands, the recurrence rate in patients with colorectal 
cancer is high, the most common,and often only,site of overt disease at death being 
the liver. Several studies have demonstrated that chemotherapeutic regimes 
containing 5-FU provide significant improvements in survival whether given in an 
adjuvant setting(Windle et al,1985;Moertel et al, 1990; Laurie et al,1989) or in the 
presence of established metastatic disease(Poon et al,1989;Erlichman,1988). 
These treatments result in significant side effects in up to 30% of patients,some of 
which may be life- threatening.
The goal of those involved in surgical oncology has long been to develop 
treatments that would recognise and selectively kill tumour cells. Widder in 
1979,formalised the concept of targeting; to the organ,the tumour and the abnormal 
cells within that tumour. Tertiary targeting remains an area of experimental 
research,but first and second order targeting have been used in clinical practice to 
improve response rates and reduce systemic toxicity.
162
First order targeting:
Organ specific administration of chemotherapy has traditionally been 
achieved by surgical means. The choice of the chosen route of administration(portal 
or hepatic arterial) is dependent on whether the treatment is to be given in an 
adjuvant setting or in the presence of established metastases. Both portal venous 
and hepatic arterial catheterisation can result in significant surgical complications in 
addition to the morbidity associated with the chemotherapeutic regime, and 
therefore non-surgical means of achieving organ specific delivery provides an 
attractive alternative.
Galactose-terminating neoglycoproteins and glycoproteins (Duncan et 
al, 1983) accumulate in hepatocytes in-vitro and in-vivo due to a specific receptor 
mediated pinocytotic uptake mechanism (Ashwell 1982). The incorporation of 
chemotherapeutic agents with these carrier molecules will result in an alteration in 
the body distribution profile of a drug,resulting in concentration of that drug within 
the liver. In this thesis I have evaluated the targeting potential of two such galactose 
terminating polymers,in an animal model of colorectal metastases, to assess both 
organ and tumour selectivity.
The 5-FUAA/guaric acid polymer developed in the Liverpool University 
Department of Bioengineering,was a linear manose chain of molecular weight 
approximately 220,000 daltons. The radio-labelled portion ,the 5-FU, was covalently 
bonded via the primary carbon of an acetyl linkage. Intrahepatic targeting was 
disappointing, levels in liver and tumour being only slightly greater than that 
following the administration of free 5-FU.
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The blood pharmacokinetic profile following the systemic administration of 
the polymer was only slightly different than that following administration of free drug 
with a similar tmax (4 mins) and a prolonged t-j/2 of approximately 7.5 minutes,. The 
AUC5FU : AUCpojyme,. ratio of 1:1.3 suggest slightly greater total drug exposure 
following polymer exposure which could explain the minimally increased levels in 
liver rather than any organ specific targeting.
In addition there was also rapid excretion of radioactivity into the 
urine,inconsistent with continued attachment of the labeled 5-FU to a polymer 
molecule of that size (220,000 daltons). This suggests that although the stability of 
the 5-FU/guarin conjugate had been confirmed in-vitro,the covalent acetyl linkage 
may be quickly degraded in-vivo releasing free radiolabelled 5-FU,for systemic 
distribution. Because following disaggregation of the 5-FU/polymer conjugate the 
galactose/ manose backbone is unlabelled,there may well have been unrecognised 
intrahepatic accumulation. Further work is required to develop methods of labelling 
the backbone itself,initially for distribution studies,and, if localisation does occur, an 
alternative mechanism of linkage of the active drug to delay release until 
intrahepatic localisation has occurred.
By contrast the Keele University polymer, N-(2-hydroxypropyl) 
methacrylamide, has been developed to a much greater degree. Although originally 
developed as a plasma expander(Kopecek et al, 1973) a programme of research 
into potential hepatic selectivity in-vitro and in mice has resulted in the development 
of a drug carrier system suitable for hepatic targeting. Variables such as galactose 
content and side chain composition have been investigated to maximise delivery.
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The HPMA polymers have oligopeptide linkages that are stable in the 
circulation(Rejmanova et al, 1985) but degradable (releasing free drug) 
intracellularly following pinocytotic inclusion by lysosomal thiol dependent (cysteine) 
proteases(Duncan et al,1983;Rejamanova et al, 1983). The aim of these studies was 
to evaluate the HPMA polymer in an animal model of colorectal metastases,and in 
addition to study the effect of regional delivery.
The serum levels following injection of the HPMA polymer follows a first order 
pharmacokinetic pattern,with a tmax of less than one minute and a t-j/2 of 3 
minutes. Interestingly this pattern was unaltered by regional administration,indicating 
that the hepatic extraction capacity is easily overwhelmed,further extraction 
occurring on recirculation. The total drug exposure following regional 
administration, as assessed by the AUC ratio, was minimally lower following 
regional administration which may indicate a minor degree of first pass uptake.
The distribution profile of the HPMA polymer shows excellent localisation 
with the liver,with up to 60% of the administered dose being present in the liver 
within 5 minutes.As expected there would appear to be a small benefit in the 
amount of polymer in tumour tissue when given by the intraarterial route over both 
systemic and intraportal administration. The overwhelming localisation within the 
normal hepatic parenchyma results in tumour levels a tenth of those of surrounding 
tissue,despite regional administration. This carrier molecule has therefore little to 
offer in the treatment of established metastases,but this may possibly have a role in 
the management of micrometastatic disease.
Whereas both the 5-FU/guarin and HPMA polymers were attempts at 
developing carrier systems for active drugs,the radiolabelled haematoporphyrin 
derivative was used as a potentially active component in its own right. When 
exposed to electromagnetic radiation of a suitable wavelength, the electrons of the
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photosensitiser molecule are stimulated into an "excited state" -the electrons having 
moved into an unstable higher energy plane. On decay, these electrons release 
their potential energy.forming cytotoxic radicals.the most important of which is 
singlet oxygen. Electromagnetic radiation within the visible spectrum (400-800nm) is 
most commonly used,but in theory radiation at other wavelengths has the potential 
for excitation.
Photodynamic therapy is established in the treatment of many superficial 
tumours. Two principle problems limit the application of photodynamic therapy in 
solid organ tumours such as hepatic metastases: firstly access difficulties and 
secondly the limitations posed by the poor penetration of visible light through solid 
tissue. By using radiation of much longer wavelength,such as x-rays,penetration 
and access cease to provide difficulties. These preliminary studies are being 
paralleled by in-vitro studies of xray sensitisation of HpD by T.Wheldon.Beatson 
Institute, Glasgow.
The first reported attempts at photodynamic therapy employed eosin and 
fluorescein to treat skin cancers in 1906 The natural affinity of porphyrins for tumour 
tissue was first noticed in 1924 when Policard observed red fluorescence from 
experimental animal sarcomas exposed to light,due to the accumulation of 
endogenous porphyrins within the tumour tissue. Auler in 1943 injected porphyrins 
into tumour bearing animals and confirmed subsequent fluorescence(Moan,1986). 
Biochemical manipulation of the composition of the injected porphyrin can further 
improve the tumour localising properties(Lipson et al, 1961;Dougherty et al,1984)
This affinity for tumour tissue provides positive tumour to host tissue ratios 
for most tumour sites in the body. Because of its inaccessibility for photodynamic 
therapy,the distribution for tumour within the liver was largely unknown. The natural 
metabolism of porphyrins results in the breakdown of the porphyrin ring in the
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reticuloendothelial system,and subsequent transhepatic excretion. The results from 
these experiments have shown that excellent tumour levels are achieved compared 
to most organs, but the reticuloendothelial localisation prevents the development of 
positive tumour to liver parenchymal ratios following administration.
There are two potential solutions to this problem: firstly to employ a 
photosensitiser that is not excreted by the hepatic route and secondly to further 
enhance the localisation within liver tumour. Unfortunately at present nearly all 
available photosensitisers are large molecules,loosely based on the porphyrin ring 
structure, undergoing hepatic breakdown. Prof. S Brown from Leeds,is at present 
developing photosensitisers from derivatives of methylene blue,whose size would 
potentially allow renal excretion (Personal communication). These are still 
experimental molecules and have not yet been evaluated adequately in-vitro,their 
affinity for tumour tissue being unknown.
An alternative strategy is to improve tumour localisation of the 
photosensitiser by using monoclonal antibodies linked to the photosensitiser. Dr 
S.Eccles of the Royal Marsden Hospital,has developed monoclonal antibodies to 
the HSN tumour cell line and this forms the basis of prospective future work.
Comparing the localisation of the HPMA molecule with that of the porphyrins 
indicates that both provide reasonable targeting to hepatic parenchymal tissue,but 
only porphyrins achieve significant tumour levels. The reliance of the HPMA 
molecule on the presence of the hepatocyte galactose receptor limits its potential 
clinical use in that the carrier targets normal cells in preference to tumour tissue.
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Second Order Targeting:
Despite accumulating clinical experience in the manipulation of hepatic blood 
flow to optimise the regional delivery to tumour tissue the rationale for using 
degradable emboli or vasoactive agents for regional targeting has not been fully 
evaluated at an experimental level.
Tumour vessels are immature and lack the smooth muscle elements to react 
with vasoconstrictor agents(Mattson et al,1977;Mattson et al,1978). Any response 
following the administration of a vasoconstricting agent therefore occurs 
predominately in the surrounding normal hepatic parenchyma. This results in 
temporary relative tumour hypervascularity with potentially improved regional 
delivery of drug to tumour tissue. We have previously demonstrated that vasoactive 
agents,such as angiotensin II or phenylephrine.can improve the delivery of a 
regionally administered drug to tumour tissue(Hemingway et al, 1991).
In addition.it has been shown that in both animals(Fujimoto et 
al,1985;Sigurdson et al,1986;Flowerdew et al, 1987;Nott et al,1989) and in 
man(Dakhil et al,1982;Gyves et al,1983;Mavor et al, 1987; Starkhammer et 
al,1987;Goldberg et al, 1988;Lorenz et al,1989;Hunt et al, 1990) regionally 
administered degradable starch microspheres reduce the hepatic arterial flow with 
improved retention of drugs or markers within tumour tissue. The aim of this study 
was to determine whether the combination of vasoactive agents with degradable 
microspheres could further enhance the delivery of a regionally delivered marker to 
tumour tissue.
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The administration of DSM results in temporary hepatic arterial stasis. The 
arterial vascular diversion as a result of the simultaneous or subsequent 
administration of angiotensin II will be negated if there is little or no flow along the 
vessel,thus explaining why the administration of angiotensin II prior to the DSM and 
marker provided the best results in the pilot experiments.
This study confirmed that DSM alone can significantly increase the retention 
of marker in tumour with a twelve fold increase over controls at one minute. In 
contrast to previous studiesfCooke and Chang, 1990) we have shown no immediate 
preferential delivery to tumour tissue. It has been previously suggested that the 
increased retention in tumour tissue was as a result of a redistribution of 
intrahepatic blood flow from hepatic parenchyma towards tumour tissue. The results 
of this study would suggest that the DSM is distributed according to blood 
flow,which initially results in retention of marker in both tumour and liver tissue at 
one minute without altering the tumour to liver ratio. By 90 minutes, we have 
demonstrated relatively greater retention in tumour tissue,with almost complete 
washout from normal liver tissue .probably as a result of continued portal flow to 
normal tissue.
Previous studies in our group have suggested that angiotensin II results in a 
redistribution of intrahepatic blood flow towards tumour tissue(Hemingway et 
al,1991). The prior administration of angiotensin II would therefore be expected to 
result in preferential delivery of the DSM and marker to the tumour tissue. Whilst we 
were unable to demonstrate an immediate advantage of combination targeting over 
DSM alone,by 90 minutes there was significantly greater retention of marker in 
tumour tissue compared to DSM alone,and a twelve fold increase over control 
animals. Moreover the tumour to liver ratio of retained marker was significantly 
improved using combined angiotensin II and DSM over DSM alone,with a 
concentration in tumour tissue five times that of surrounding liver parenchyma.The
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improved retention of marker in tumour may reflect prolonged blood flow stasis and 
lack of washout due to initial targeting of the DSM to tumour tissue.
The results of this study would suggest that the combination of angiotensin II 
and DSM can further improve the delivery of drug to intrahepatic tumour.whilst 
minimising the exposure of normal hepatic parenchyma to potentially hepatotoxic 
drugs.
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CHAPTER 5
CONCLUSIONS 
AND PROPOSED RESEARCH
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CONCLUSIONS
(1) The measurement of the Hepatic Perfusion Index using a high administered 
activity, is reproducible both between different observers and on reprocessing 
studies by a single observer.
(2) The HPI has a diagnostic sensitivity equal to that of computerised 
tomography.Intraoperative ultrasonography provides little additional information in 
the early detection of colorectal metastases over standard techniques. Rather than 
detection its principle role would appear to lie in the delineation of the intrahepatic 
vascular anatomy in the small number of patients in whom resection is being 
considered.
(3) The specificity of the HPI was poor,however if as suggested, those patients who 
are apparently disease free but with a raised HPI develop metachronous disease 
the specificity of the HPI will improve and the sensitivity and specificity of all other 
methods of detection will reduce.
(4) The HSN sarcoma cell model is a reliable model of colorectal 
metastases,producing tumours that are both slow growing and hypovascular.as in 
many human colorectal metastases.
(5) The change in the hepatic and splanchnic haemodynamics with the development 
of intrahepatic tumour in the HSN model,is due to a circulating vasoactive agent 
increasing splanchnic vascular resistance.
(6)Both extra-hepatic and intra-hepatic tumours are associated with reduced 
splanchnic vascular inflow.
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(7)The development of an abnormal HPI in animals with intravascular tumour is due 
to local preservation of hepatic arterial inflow despite splanchnic vasoconstriction.
(8 ) There is minimal hepatic targeting of 5-FU following injection of a 5-FU 
guarin/galactose polymer. This may be due to dissociation of the 5-FU from the 
polymer backbone.
(9)Excellent targeting to hepatic parenchyma is possible using a HPMA polymer 
backbone,but intrahepatic tumour levels are minimal.Regional delivery has little 
effect on polymer distribution. Small increases in tumour levels are possible using 
an intraarterial approach.
(10) Similar levels of hepatic targeting are possible with using haematoporphyrin 
derivatives,with improved tumour localisation. Despite this tumour: liver ratios 
remain less than 1 .
(11) Second order targeting of a chemotherapeutic marker using either degradable 
microspheres or vasoactive agents may be further improved by a combination 
approach. Administration of the vasoactive agent prior to the emboli provides the 
best results,producing a tumourliver ratio in excess of 5:1 at 90 minutes.
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FUTURE WORK
Although the work contained in this thesis has been successful in providing 
solutions for many of the questions for which the studies were designed,the work 
has generated more questions than answers. Many of the studies were in 
collaboration with other Departments,and fortunately these links are continuing,and 
a summary of the immediate projects to be carried out in our own Department and in 
other units is presented below:
(1) The reported ability of the HPI to predict the development of metachronous 
metastases in patients thought to be free of metastases should be prospectively 
evaluated.
(2) The role of the HPI in the investigation and management of patients with
tumours other than colorectal primaries should be assessed.
(3) The combination of angiotensin II and DSM in second order targeting of regional
chemotherapy requires evaluation in a phase one clinical study.
In conjunction with the University Department of Physiology:
(4) An attempt to identify the vasoactive agent responsible for the change in 
splanchnic vascular resistance is required,initially studying the response of vascular 
smooth muscle to tumour bearing plasma with sequential selective blockade in an 
in-vitro muscle ring organ bath experiment.
(5) The effect of tumour bearing plasma on the resistance vessels(Arterioles 
100-150nm diameter) of the splanchnic vascular bed,should be studied using an in- 
vitro isolated perfusion experiment and a in-vitro "Myograph" preparation.
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In conjunction with the University of Liverpool:
(6 ) The stability of the 5-FU guarin/galactose polymer in rat plasma should be 
assessed, and if as suspected there is rapid breakdown of the conjugate, further 
distribution studies may be performed with an improved preparation.
In conjunction with the University of Keele:
(7) The poor tumour levels achieved using the HPMA polymer do not undermine its 
potential for treating patients with micrometastatic disease. The effect of the 
excellent hepatic parenchymal targeting should be assessed a phase 1 clinical 
study in patients with colorectal carcinoma.
In conjunction with the Beatson Oncology Centre,Glasgow,and the Royal 
Marsdon Hospital,London.
(8 ) Alternative methods of improving tumour:liver ratios of the haematoporphyrin 
derivatives are required. The use of monoclonal antibodies to improve intratumour 
localisation should be assessed. The effect of using a photosensitiser of low 
molecular weight,allowing renal excretion may also prevent intrahepatic 
accumulation of the photosensitiser. These experiments are being paralleled by in- 
vitro work investigating stimulation of photo-sensitisers by non ionising radiation 
other than visible light.
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APPENDIX 1
CLINICAL STUDY on the REPRODUCIBILITY of the HPI
Patient number HPI values inter-observer
(first observer) (second observer) difference
Liver metastases:
1 0.89 0.90 0.89 0.90 0.91 +0 .0 2
2 0.58 0.53 0.54 0.51 0.59 +0.01
3 0.44 0.48 0.45 0.46 0.51 +0.07
4 0.43 0.43 0.43 0.41 0.47 +0.04
5 0.39 0.39 0.36 0.33 0.38 -0.01
6 0.52 0.53 0.55 0.55 0.52 0 .0 0
/er metastases:
7 0.33 0.37 0.34 0.34 0.39 +0.06
8 0.35 0.35 0.37 0.36 0.36 +0.01
9 0.40 0.41 0.36 0.36 0.38 -0 .0 2
10 0 .1 2 0.08 0.14 0.18 0.15 +0.03
11 0.19 0.21 0.21 0.18 0.27 +0.09
12 0.37 0.34 0.37 0.37 0.40 +0.03
13 0.33 0.33 0.34 0.34 0.40 +0.07
14 0.26 0.21 0.25 0.32 0.33 +0.07
15 0.54 0.59 0.60 0.50 0.50 -0.04
16 0.46 0.48 0.54 0.50 0.57 +0.11
17 0 .2 2 0.26 0.26 0 .2 0 0.30 +0.08
18 0.25 0.27 0.27 0.28 0.30 +0.05
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APPENDIX 2
PROSPECTIVE IMAGING RESULTS
Patient
No.
U/S CT HPI Static Palpn I.O.U/S CON!
1 N N 36 N N N _
2 N N 38 N N N -
3 N N 15 N N N -
4 N N 2 0 N N N -
5 N N 64 N N N -
6 POS POS 43 POS POS POS +
7 POS POS 38 N N N +
8 POS POS 54 POS POS POS +
9 N N 54 POS N N -
10 N N 49 N N N -
11 N N 27 N N N -
12 N N 31 N N N -
13 N N 42 POS N N -
14 POS POS 59 POS POS POS +
15 N N 46 POS POS N +
16 POS POS 29 POS POS POS +
17 N N 43 N N N -
18 N POS 41 N N N +
19 POS POS 52 POS POS POS +
2 0 N N focal POS N N -
21 N N 74 POS N N -
2 2 POS POS 52 POS POS POS +
23 POS POS 55 POS POS POS +
24 N N 12 N N N -
25 N POS 47 POS POS POS +
26 N N 40 N N N -
27 POS POS 56 POS POS POS +
28 N POS 39 POS N N +
29 POS POS 57 POS POS POS +
30 N N 62 N N N -
31 N N 39 N N N -
32 N N 31 N N N -
33 N N 30 N N N -
34 N N 57 N N N -
35 POS POS 55 POS POS POS +
36 N POS 67 N N N -
37 N POS 46 N N N -
38 POS POS 39 POS POS POS +
39 POS POS 38 POS POS POS +
40 N N 50 N N N -
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PATIENTS IN WHOM ALL INVESTIGATIONS WERE NOT COMPLETED:
Patient
No.
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26
27
28
29
30
31
32
33
U/S CT HPI Static Palpn I.O.U/S CONSENSUS
N N 47 N - - -
POS POS 51 POS - - +
N N 34 POS N - -
POS POS 89 POS POS - +
POS POS 54 POS POS - +
N N 46 POS N - -
N N 37 N - - -
N N 34 N N - -
N N 26 N N - -
N N 26 N N - -
POS POS 72 POS - - +
N POS 50 N - - +
N POS 27 N N - -
POS POS 79 N POS - +
POS POS 72 POS - - +
POS POS 82 POS POS - +
POS POS 53 N - - +
POS POS 79 POS - - +
N N 49 N - - -
N N 44 N - - -
N POS 40 N - - +
N N 54 POS - - -
N POS 40 POS - - +
N N 57 N - - -
N N 2 2 N - - -
N N 27 N - - -
POS POS 63 POS - - +
POS POS 43 POS - - +
POS POS 94 POS - - +
N N 54 POS POS - +
POS POS 57 POS POS - +
POS POS 48 POS POS - +
N POS 48 N POS - +
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APPENDIX 3
Cross perfusion 1
Segment Tumour Control
number
Press Flow Resist Press Flow Resist
1 100 1.4 71.4 105 1.8 58.3
100 1.2 83.3 100 1.7 52.6
100 1.0 100 100 2.0 50
2 85 1.9 44.7 100 2.2 45.4
90 2.0 45.0 105 2.0 52.5
95 2.4 39.6 95 2.4 39.6
3 95 1.4 67.8 110 1.0 110
90 1.6 56.2 110 1.0 110
95 1.4 67.8 105 0.8 131.2
4 95 2.8 33.9 105 2.8 33.9
95 1.8 31.2 105 3.6 27.8
95 2.0 35 105 3.2 32.8
5 95 2.8 33.9 105 3.4 30.9
100 3.2 31.2 105 3.6 29.2
105 3.0 35 105 3.6 29.2
6 100 3.8 26.3 100 3.8 26.3
95 3.4 28.2 95 3.8 25.3
100 3.8 26.3 105 4.2 25.0
7 100 1.9 52.6 90 2.6 34.6
90 2.1 42.8 85 2.4 35.4
100 1.9 52.6 90 2.6 34.6
8 115 1.2 95.8 90 1.3 69.2
115 1.2 95.8 95 1.2 79.2
110 1.1 100 95 1.5 63.3
9 100 0.4 250 105 1.6 60.0
100 0.4 255 110 1.8 60.0
100 0.5 200 110 1.6 68.7
10 95 0.4 240 110 1.6 68.7
100 0.4 245 105 2.0 53
100 0.4 245 110 2.4 45.8
11 125 0.8 156.3 100 1.5 66.7
120 1.2 100 100 1.8 55.6
120 1.2 100 110 1.7 64.7
12 100 1.8 55.6 100 3.4 29.2
110 1.7 64.7 105 3.2 32.8
100 1.6 76.9 100 3.5 28.6
Diff.in mean 
resistance
31.3
-2.7
-53.2
7.1
3.6
1.4
12.7
26.6
172.1
186.1
56.5
35.4
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Cross perfusion 2
Segment Tumour Control Diff.in mean
number resistance
Press Flow Resist Press Flow Resist
1 100 1.2 83.3 100 2.0 50
100 1.2 83.3 100 2.4 41.6 36.1
95 1.3 73.1 100 2.5 40
2 110 2.1 52.3 100 1.6 62.5
100 1.9 52.6 110 2.1 52.3 -8.4
100 1.8 55.5 85 1.2 70.8
3 95 1.0 95 110 0.9 122.2
100 1.2 83.3 110 1.3 84.6 -4.2
95 1.2 79.1 100 1.2 83.3
4 100 1.6 62.5 110 3.3 33.3
110 2.1 52.3 100 2.8 35.7 23.5
100 1.6 62.5 110 2.9 37.9
5 110 2.4 45.8 100 2.6 38.4
100 2.2 45.4 95 2.7 35.1 6.8
110 2.3 47.8 90 2.0 45
6 <80 not done
7 <80 not done
8 95 0.8 118.7 <80
95 0.9 105.5
100 0.7 142.8
9 100 0.4 250 100 0.9 111.1
100 0.6 166.6 100 0.9 111.1 111.
100 0.4 250 100 0.9 111.1
10 100 0.8 125 100 1.1 90.9
100 0.8 125 90 0.8 112.5 21.9
95 0.9 105.5 95 1.1 86.3
11 <80 120 0.4 300
115 0.6 191.6
100 0.2 500
12 100 1.2 83.3 100 2.6 38.4
110 1.6 68.7 100 2.4 41.6 29.1
110 1.7 64.7 110 2.2 50
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APPENDIX 4
Results of Reference Microsphere experiments:
Number 1 Tumour - none Reference counts(1 ml) = 3000
weight counts Blood Flow Flow/g
Liver 6.0 2467 0.82 0.13
Tumour
Kidney 1 0.8 12254 4.08 5.1
Kidney 2 0.8 11220 3.74 4.67
Spleen 0.5 1118 0.37 0.74
Heart 0.7 6848 2.28 3.25
Lung 1.0 2097 0.69 0.69
Stomach 1.7 1937 0.64 0.37
Pancreas 0.9 1061 0.35 0.38
Sm. Bowel 6.0 26566 8.85 1.48
Colon 3.0 3354 1.12 0.37
Liver Flow = 0.82
Splanchnic Flow = 11.34
Splanchnic weight = 12.1 0.94
Calculated HPI = 0.067
Number 2 Tumour - none Reference counts(lml) = 1403
weight counts Blood Flow Flow/g
Liver 6.8 1451 1.034 0.152
Tumour
Kidney 1 1.0 4954 3.53 3.53
Kidney 2 0.95 5278 3.76 3.95
Spleen 0.8 849 0.6 0.75
Heart 0.9 3418 2.43 2.7
Lung 1.3 1043 0.74 0.56
Stomach 1.4 1115 0.79 0.56
Pancreas 1.2 1350 0.96 0.80
Sm. Bowel 6.4 12287 8.75 1.36
Colon 3.2 1885 1.34 0.42
Liver Flow = 1.034
Splanchnic Flow = 12.48
Splanchnic Weight = 13.0 0.96
Calculated HPI = 0.076
217
Number 3 Tumour - none Reference counts(lml) = 3624
weight counts Blood Flow Flow/g
Liver 9.64 3316 0.91 0.094
Tumour
Kidney 1 1.05 18206 5.02 4.78
Kidney 2 1.00 16724 4.61 4.61
Spleen 0.8 3346 0.92 1.15
Heart 0.95 19737 5.44 5.72
Lung 1.58 2556 0.7 0.44
Stomach 1.74 2934 0.8 0.46
Pancreas 1.46 6963 1.92 1.31
Sm. Bowel 9.2 30538 8.42 0.91
Colon 4.26 4906 1.35 0.316
Liver Flow = 0.91
Splanchnic Flow = 13.42
Splanchnic Weight = 17.5 0.76
Calculated HPI = 0.063
Number 4 Tumour - none Reference counts(1 ml) = 5203
weight counts Blood Flow Flow/g
Liver 9.4 4789 0.91 0.096
Tumour
Kidney 1 1.1 25280 4.85 4.40
Kidney 2 1.1 26101 5.01 4.55
Spleen 1.0 5789 1.11 1.11
Heart 0.95 24835 4.77 5.02
Lung 1.45 2577 0.49 0.33
Stomach 1.85 2934 0.56 0.30
Pancreas 1.5 4406 0.84 0.56
Sm. Bowel 9.7 32251 6.19 0.66
Colon 4.7 6195 1.19 0.25
Liver Flow = 0.91
Splanchnic Flow = 9.91
Splanchnic Weight = 18.7 0.53
Calculated HPI = 0.087
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Number 5 Tumour - none Reference counts(lml) = 1363
weight counts Blood Flow Flow/g
Liver 6.1 1489 1.09 0.178
Tumour
Kidney 1 0.85 4912 3.63 4.27
Kidney 2 0.85 5356 3.92 4.64
Spleen 0.7 897 0.65 0.92
Heart 0.8 23860 17.5 21.8
Lung 1.25 1132 0.83 0.66
Stomach 1.7 1160 0.85 0.5
Pancreas 1.1 1387 1.01 0.91
Sm. Bowel 6.4 11771 8.63 1.34
Colon 2.9 1847 1.35 0.46
Liver Flow = 1.09
Splanchnic Flow = 12.51
Splanchnic Weight = 12.8 0.98
Calculated HPI = 0.08
Number 6 Tumour - none Reference counts(lml) = 1634
weight counts Blood Flow Flow/g
Liver 8.4 1217 0.74 0.09
Tumour
Kidney 1 0.85 5368 3.28 3.85
Kidney 2 0.85 4818 2.94 3.45
Spleen 0.6 482 0.29 0.48
Heart 1.0 4763 2.91 2.91
Lung 1.2 472 0.28 0.23
Stomach 1.5 1861 1.13 0.75
Pancreas 1.15 1425 0.87 0.76
Sm. Bowel 8.4 7566 4.63 0.55
Colon 3.2 2597 1.58 0.49
Liver Flow = 0.74
Splanchnic Flow = 8.52
Splanchnic Weight = 14.85 0.57
Calculated HPI = 0.079
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Number 7 Tumour - flank Reference counts(lml) = 2260
weight counts
Liver 9.4 1768
Tumour 1.9 631
Kidney 1 1.0 14440
Kidney 2 1.0 12738
Spleen 0.7 2497
Heart 0.9 8283
Lung 1.6 2549
Stomach 2.0 2839
Pancreas 1.5 2015
Sm. Bowel 9.8 13960
Colon 4.2 3110
Liver Flow =
Splanchnic Flow =
Splanchnic Weight =
Calculated HPI =
Number 8 Tumour - flank
weight counts
Liver 9.4 1288
Tumour 1.7 1269
Kidney 1 1.1 13806
Kidney 2 1.1 16636
Spleen 0.9 714
Heart 0.8 7019
Lung 1.4 4943
Stomach 1.6 1004
Pancreas 1.3 2421
Sm. Bowel 9.2 8468
Colon 4.6 2988
Liver Flow
Splanchnic Flow = 
Splanchnic Weight = 
Calculated HPI =
Blood Flow Flow/g
0.782 0.08
0.13 0.14
6.38 6.38
5.63 5.63
1.1 1.57
3.36 3.73
1.12 0.70
1.25 0.63
0.89 0.59
6.17 0.62
1.37 0.03
0.78
10.8
18.2 0.593
0.068
Reference counts(lml) = 2(
Blood Flow Flow/g
0.48 0.05
0.27 0.27
5.11 4.64
6.16 5.60
0.26 0.29
2.6 3.25
1.83 1.30
0.37 0.23
0.90 0.69
3.13 0.34
1.10 0.24
0.48
5.78
17.6 0.33
0.076
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Number 9 Tumour - flank Reference counts(lml) = 2037
weight counts Blood Flow Flow/g
Liver 9.4 2926 1.43 0.15
Tumour 2.3 1006 0.19 0.21
Kidney 1 1.0 9519 4.67 4.67
Kidney 2 1.05 10271 5.04 4.80
Spleen 0.7 1353 0.66 0.94
Heart 0.9 8472 4.15 4.61
Lung 1.6 1186 0.58 0.36
Stomach 2.0 2298 1.12 0.56
Pancreas 1.5 3606 1.77 1.18
Sm. Bowel 10.3 16002 7.85 0.76
Colon 4.2 2799 1.37 0.33
Liver Flow - 1.43
Splanchnic Flow = 14.22
Splanchnic Weight = 18.7 0.76
Calculated HPI = 0.10
Number 10 Tumour-flank Reference counts(lml) = 21
weight counts Blood Flow Flow/g
Liver 9.5 1354 0.50 0.05
Tumour 1.6 1379 0.28 0.31
Kidney 1 1.0 13685 5.04 5.04
Kidney 2 1.1 16184 5.96 5.41
Spleen 1.0 752 0.28 0.28
Heart 1.1 7147 2.63 2.39
Lung 1.6 4975 1.83 1.14
Stomach 1.7 952 0.35 0.21
Pancreas 1.7 2372 0.87 0.51
Sm. Bowel 10.9 8168 3.01 0.28
Colon 4.5 3007 1.10 0.24
Liver Flow = 0.5
Splanchnic Flow = 5.62
Splanchnic Weight = 19.5 0.29
Calculated HPI = 0.08
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Number 11 Tumour - flank Reference counts(lml) = 2349
weight counts Blood Flow Flow/g
Liver 10.1 1923 0.82 0.08
Tumour 1.6 474 0.13 0.12
Kidney 1 1.0 14620 6.22 6.22
Kidney 2 0.95 12183 5.18 5.45
Spleen 0.85 2453 1.04 1.22
Heart 0.85 8382 3.56 4.18
Lung 1.4 2619 1.11 0.79
Stomach 1.3 2821 1.2 0.92
Pancreas 1.1 2014 0.85 0.77
Sm. Bowel 9.7 14160 6.02 0.62
Colon 4.1 3023 1.28 0.31
Liver Flow 0.82
Splanchnic Flow = 10.41
Splanchnic Weight = 17.05 0.61
Calculated HPI = 0.073
Number 12 Tumour-flank Reference counts(lml) = 2\
weight counts Blood Flow Flow/g
Liver 8.1 1288 0.47 0.58
Tumour 1.4 712 0.26 0.19
Kidney 1 1.0 15539 5.68 5.68
Kidney 2 1.05 17175 6.28 5.98
Spleen 0.8 751 0.27 0.34
Heart 0.9 6795 2.48 2.75
Lung 1.4 4766 1.74 1.24
Stomach 1.7 991 0.36 0.21
Pancreas 1.3 2673 0.98 0.75
Sm. Bowel 7.2 7300 2.67 0.37
Colon 3.9 2887 1.05 0.27
Liver Flow = 0.47
Splanchnic Flow = 5.34
Splanchnic Weight = 14.9 0.36
Calculated HPI = 0.08
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Number 13 Tumour - liver Reference counts(lml) = 7878
weight counts
Liver 9.2 12447
Tumour 2.6 1543
Kidney 1 1.1 51104
Kidney 2 1.0 41898
Spleen 1.0 4517
Heart 0.9 71218
Lung 1.9 3515
Stomach 1.4 3218
Pancreas 1.7 6049
Sm. Bowel 8.2 30803
Colon 3.4 9857
Tumour/liver ratio 
Liver Flow
Splanchnic Flow
Splanchnic Weight =
Calculated HPI =
Blood Flow Flow/g
1.58 0.171
0.53 0.075
6.48 5.89
5.38 5.38
0.56 0.56
9.02 10.0
0.45 0.24
0.4 0.29
0.76 0.44
3.91 0.48
1.24 0.36
0.44
1.58
6.87
15.7 0.44
0.187
Number 14 Tumour - liver
weight counts
Liver 9.6 2482
Tumour 2.3 232
Kidney 1 1.2 9427
Kidney 2 1.2 9148
Spleen 0.9 1459
Heart 0.9 7270
Lung 1.6 1012
Stomach 2.0 364
Pancreas 1.8 2888
Sm. Bowel 10.3 8824
Colon 5.2 2809
Tumour/liver ratio 
Liver Flow
Splanchnic Flow
Splanchnic Weight = 
Calculated HPI =
Reference counts(lml) = 2086
Blood Flow Flow/g
1.19 0.12
0.28 0.04
4.51 3.76
4.37 3.53
0.69 0.77
3.49 3.87
0.49 0.28
0.17 0.08
1.38 0.76
4.23 0.41
1.35 0.25
0.39
1.19
7.82
20.2 0.39
0.132
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Number 15 Tumour - liver Reference counts(lml) = 3263
weight: counts
Liver 10.0 3393
Tumour 2.1 368
Kidney 1 1.2 17857
Kidney 2 1.1 14210
Spleen 0.9 1025
Heart 0.8 11463
Lung 1.5 2015
Stomach 1.6 1066
Pancreas 1.2 3909
Sm. Bowel 10.1 15238
Colon 4.7 7374
Tumour/liver ratio
Liver Flow
Splanchnic Flow
Splanchnic Weight
Calculated HPI
Number 16 Tumour - liver
weight counts
Liver 7.3 1627
Tumour 1.6 600
Kidney 1 1.0 9683
Kidney 2 1.0 10813
Spleen 0.55 1071
Heart 0.9 3402
Lung 1.3 1408
Stomach 1.7 1556
Pancreas 1.2 2070
Sm. Bowel 7.6 8640
Colon 4.2 2691
Tumour/liver ratio
Liver Flow
Splanchnic Flow
Splanchnic Weight = 
Calculated HPI =
Blood Flow Flow/g
1.04 0.10
0.35 0.05
5.47 4.56
4.35 3.95
0.31 0.34
3.51 4.39
0.61 0.40
0.32 0.19
1.19 0.95
4.67 0.46
2.26 0.48
0.55
1.04
8.77
18.5 0.47
0.106
Reference counts(lml) = 2176
Blood Flow Flow/g
0.75 0.10
0.27 0.17
4.44 4.44
4.96 4.96
0.49 0.89
1.56 1.73
0.64 0.49
0.71 0.42
0.95 0.79
3.97 0.52
1.23 0.29
1.7
0.75
7.36
15.3 0.48
0.093
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Number 17 Tumour - liver Reference counts(lml) = 2142
weight counts
Liver 8.1 2377
Tumour 1.2 118
Kidney 1 1.0 10701
Kidney 2 1.0 11678
Spleen 0.8 2164
Heart 0.9 5989
Lung 1.4 633
Stomach 1.7 12 77
Pancreas 1.3 2005
Sm. Bowel 7.2 8910
Colon 4.1 3092
Tumour/Liver ratio
Liver Flow
Splanchnic Flow
Splanchnic Weight
Calculated HPI
Number 18 Tumour - liver
weight counts
Liver 9.0 2204
Tumour 1.8 292
Kidney 1 0.9 10784
Kidney 2 0.9 11485
Spleen 0.8 2151
Heart 0.9 6017
Lung 1.3 618
Stomach 1.7 12 77
Pancreas 1.3 1954
Sm. Bowel 8.3 9976
Colon 4.5 3003
Tumour/liver ratio
Liver Flow =
Splanchnic Flow =
Splanchnic Weight =
Calculated HPI =
Blood Flow Flow/g
1.11 0.13
0.05 0.04
4.99 4.99
5.45 5.45
1.01 1.26
2.79 3.10
0.29 0.21
0.59 0.35
0.93 0.72
4.16 0.58
1.44 0.35
0.33
1.11
8.14
15.1 0.54
0.12
Reference counts(lml) = 2396
Blood Flow Flow/g
0.92 0.10
0.06 0.06
4.50 5.01
4.79 5.32
0.89 1.12
2.51 2.79
0.26 0.19
0.53 0.31
0.81 0.62
4.08 0.49
1.25 0.28
0.59
0.92
7.56
16.6 0.45
0.108
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SECTION 3
RESULTS OF EXPERIMENTS STUDYING 
METHODS OF FIRST AND SECOND ORDER 
HEPATIC TARGETING
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APPENDIX 5a
5FU ACETATE and 5FU/GUARIC ACID POLYMER DISTRIBUTION STUDIES
Recovery experiment of known amount of 5-FU injected into variable weights of liver 
parenchyma.
jmber Weight (mg) counts
recovered
1 96 240
2 206 4667
3 310 3755
4 398 4852
5 499 4911
6 603 5077
7 0 4684
8 115 4387
9 192 4765
10 320 3989
11 405 5142
12 496 4268
13 587 4643
14 0 4492
227
5-FU-ACETIC ACID BLOOD RESULTS
Results expressed as a percentage of the injected dose per ml blood
10 minutes
Animal number
time 1 2 3 4 5 6
2 0.528 0.628 0.423 0.763 0.391 0.467
4 0.964 1.092 0.863 0.932 0.743 1.156
6 0.436 0.536 0.632 0.396 0.564 0.643
8 0.173 0.289 0.309 0.201 0.276 0.342
10
30 minutes
0.062 0.079
Animal
0.127
number
0.097 0.151 0.119
time 1 2 3 4 5 6
5 0.643 0.743 0.436 0.546 0.876 0.549
10 0.125 0.097 0.076 0.098 0.135 0.084
15 0.062 0.051 0.042 0.056 0.078 0.042
20 0.056 0.046 0.036 0.042 0.065 0.046
25 0.043 0.048 0.039 0.048 0.067 0.037
30
60 minutes
0.041 0.039
Animal
0.038
number
0.040 0.069 0.036
time 1 2 3 4 5 6
10 0.097 0.132 0.088 0.118 0.198 0.114
20 0.050 0.063 0.041 0.058 0.103 0.063
30 0.041 0.044 0.032 0.041 0.078 0.052
40 0.039 0.035 0.030 0.039 0.080 0.051
50 0.040 0.040 0.031 0.039 0.076 0.049
60 0.042 0.039 0.034 0.038 0.082 0.052
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5-FU/GUARIC ACID POLYMER BLOOD RESULTS
Results expressed as a percentage of the injected dose per ml blood
10 minutes
Animal number
time 1 2 3 4 5 6
2 0.678 0.732 0.546 0.698 0.732 0.548
4 1.241 0.981 0.875 1.032 0.971 0.838
6 0.786 0.723 0.675 0.781 0.698 0.447
8 0.564 0.532 0.423 0.518 0.476 0.370
10 0.342 0.431 0.301 0.412 0.340 0.296
30 minutes 
time 1
Animal
2
number
3 4 5 6
5 0.670 0.743 0.562 0.819 0.480 0.651
10 0.406 0.399 0.259 0.488 0.200 0.218
15 0.167 0.122 0.098 0.210 0.087 0.093
20 0.078 0.069 0.051 0.120 0.048 0.057
25 0.056 0.054 0.044 0.111 0.044 0.051
30 0.055 0.048 0.049 0.119 0.047 0.044
60 minutes 
time 1
Animal
2
number
3 4 5 6
10 0.314 0.438 0.378 0.296 0.356 0.444
20 0.081 0.121 0.091 0.078 0.097 0.107
30 0.046 0.055 0.044 0.056 0.054 0.066
40 0.044 0.056 0.049 0.049 0.051 0.041
50 0.049 0.051 0.044 0.049 0.055 0.049
60 0.047 0.055 0.039 0.047 0.046 0.044
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5-FU ACETIC ACID DISTRIBUTION PROFILE
Results expressed as a percentage of the injected dose per gram tissue
10 minutes
Liver Tumour Kidney
0.131 0.023 0.314
0.124 0.028 0.179
0.113 0.032 0.270
0.178 0.238 1.554
0.243 0.106 0.958
0.334 0.338 1.069
Spleen Heart Lung
0.002 0.012 0.006
0.001 0.006 0.015
0.001 0.008 0.010
0.002 0.010 0.048
0.002 0.081 0.012
0.034 0.072 0.156
30 minutes
Liver Tumour Kidney
0.509 0.097 0.970
0.576 0.172 1.798
0.868 0.129 2.689
0.335 0.160 1.757
0.312 0.117 2.056
0.297 0.142 0.438
Spleen Heart Lung
0.004 0.045 0.071
0.066 0.047 0.088
0.015 0.060 0.075
0.004 0.026 0.048
0.016 0.051 0.030
0.003 0.025 0.004
60 minutes
Liver Tumour Kidney
0.639 0.156 3.042
0.545 0.172 3.410
0.731 0.164 3.415
0.421 0.107 3.478
0.227 0.092 2.992
0.452 0.173 2.225
Spleen Heart Lung
0.040 0.059 0.095
0.044 0.042 0.024
0.040 0.066 0.063
0.053 0.060 0.056
0.029 0.073 0.060
0.013 0.067 0.038
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5-FU/GUARIC ACID POLYMER DISTRIBUTION PROFILE
10 minutes
Liver Tumour Kidney
0.126 0.025 0.626
0.036 0.021 0.460
0.625 0.036 0.243
0.221 0.062 0.925
0.286 0.017 1.422
0.316 0.162 1.078
30 minutes
Liver Tumour Kidney
0.526 0.132 1.264
0.796 0.086 0.924
0.261 0.124 1.521
0.326 0.116 2.462
0.296 0.146 0.962
0.564 0.081 1.342
60 minutes
Liver Tumour Kidney
0.711 0.115 2.291
0.799 0.140 3.063
0.822 0.100 2.961
0.693 0.145 2.528
0.728 0.098 3.194
0.734 0.216 2.741
Spleen Heart Lung
0.002 0.007 0.006
0.001 0.006 0.013
0.002 0.012 0.008
0.001 0.082 0.022
0.002 0.062 0.136
0.002 0.007 0.048
Spleen Heart Lung
0.062 0.047 0.041
0.004 0.062 0.062
0.072 0.024 0.079
0.003 0.067 0.042
0.012 0.075 0.068
0.072 0.025 0.012
Spleen Heart Lung
0.059 0.020 0.102
0.025 0.022 0.039
0.034 0.019 0.026
0.029 0.025 0.079
0.027 0.023 0.121
0.022 0.019 0.064
231
APPENDIX 5b
N-(2-HYDR0XYPR0PYL)METHACRYLAMIDE POLYMER DISTRIBUTION
STUDIES.
lodination of HPMA polymer
(1) Thin layer chromatography (TLC) of free 125l to confirm an effective aqueous 
phase:
Solvent front: 14268 Origin: 19
14192 23
14421 27
i.e. 0.16% remains at origin
(2) Sequential centricom purification assessed on TLC:
First centrifugation:
Solvent front 23347 Origin: 13881
23418 13659
23397 13968
37.8% remains at origin - bound to HPMA
Second centrifugation:
Solvent front 9926 Origin: 18905
9778 18761
9771 19134
65.7% remains at origin
Third centrifugation:
Solvent front 4230 Origin 18662
4096 18823
4045 18878
82.0% remains at origin
Fourth centrifugation:
Solvent front: 1575 Origin 21306
1584 21198
1542 22268
93.1% remains at origin
232
Fifth centrifugation:
Solvent front: 956 Origin
897 
941
95.7% remains at origin
Sixth centrifugation:
Solvent front: 934 Origin
961 
921
95.9% remains at origin
22987
22563
22798
21987
22207
22067
The injected 125l was therefore >95% bound to the HPMA polymer.
N-(2-HYDR0XYPR0PYL)METHACRYLAMIDE POLYMER
BLOOD RESULTS
Results of studies examining the effect of regional administration:
Results expressed as a percentage of the recovered dose per 0.1ml blood. 
INTRA-VENOUS ADMINISTRATION
5 minutes
Rat number
Time 1 2 3 4 5 6
0.5 0.633 0.870 0.670 0.377 0.607 0.680
1 0.621 0.851 0.565 0.175 0.596 0.624
1.5 0.473 0.656 0.402 0.132 0.449 0.554
2 0.435 0.511 0.260 0.110 0.347 0.488
2.5 0.337 0.415 0.220 0.089 0.269 0.448
3 0.288 0.418 0.187 0.075 0.216 0.386
3.5 0.262 0.335 0.205 0.062 0.171 0.352
4 0.241 0.345 0.143 0.057 0.164 0.318
4.5 0.218 0.290 0.140 0.047 0.118 0.294
5 0.209 0.284 0.127 0.043 0.142 0.253
10 minutes 
Time 1 2
Rat number 
3 4 5 6
1 0.520 0.326 0.690 0.479 0.450 0.676
2 0.381 0.311 0.433 0.303 0.283 0.480
3 0.259 0.181 0.305 0.198 0.178 0.311
4 0.196 0.139 0.272 0.139 0.131 0.210
5 0.154 0.117 0.199 0.123 0.092 0.169
6 0.136 0.089 0.200 0.103 0.073 0.132
7 0.119 0.090 0.177 0.109 0.057 0.108
8 0.104 0.082 0.180 0.082 0.048 0.093
9 0.102 0.082 0.181 0.077 0.044 0.089
10 0.098 0.081 0.180 0.074 0.042 0.075
30 minutes
Rat number
Time 1 2 3 4 5 6
5 0.128 0.099 0.083 0.142 0.243 0.104
10 0.050 0.050 0.049 0.063 0.050 0.042
15 0.037 0.037 0.030 0.045 0.052 0.029
20 0.028 0.032 0.026 0.040 0.019 0.028
25 0.027 0.031 0.022 0.036 0.024 0.021
30 0.026 0.027 0.024 0.037 0.023 0.021
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INTRAARTERIAL ADMINISTRATION
5 minutes
Rat number
Time 1 2 3 4 5 6
0.5 0.444 1.018 0.783 0.192 0.273 0.264
1 0.527 0.795 1.208 0.380 0.236 0.431
1.5 0.455 0.548 1.060 0.339 0.215 0.377
2 0.359 0.466 0.901 0.247 0.162 0.285
2.5 0.324 0.419 0.802 0.217 0.136 0.283
3 0.284 0.297 0.751 0.194 0.124 0.262
3.5 0.261 0.267 0.725 0.171 0.100 0.249
4 0.265 0.265 0.747 0.150 0.085 0.288
4.5 0.231 0.234 0.619 0.173 0.090 0.210
5 0.217 0.207 0.615 0.134 0.097 0.213
10 minutes
Rat number
Time 1 2 3 4 5 6
1 0.747 0.390 0.526 0.335 0.320 0.665
2 0.535 0.236 0.331 0.225 0.201 0.450
3 0.329 0.190 0.240 0.155 0.147 0.241
4 0.274 0.139 0.220 0.127 0.100 0.187
5 0.167 0.111 0.212 0.081 0.086 0.158
6 0.154 0.085 0.191 0.088 0.065 0.128
7 0.130 0.093 0.172 0.083 0.059 0.100
8 0.106 0.081 0.160 0.082 0.065 0.093
9 0.112 0.084 0.150 0.071 0.054 0.079
10 0.109 0.054 0.139 0.068 0.056 0.076
30 minutes
Rat number
Time 1 2 3 4 5 6
5 0.109 0.081 0.110 0.076 0.105 0.167
10 0.058 0.056 0.078 0.033 0.047 0.057
15 0.047 0.052 0.065 0.031 0.050 0.037
20 0.045 0.048 0.057 0.025 0.043 0.038
25 0.044 0.039 0.058 0.026 0.037 0.027
30 0.043 0.042 0.064 0.025 0.036 0.034
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INTRAPORTAL ADMINISTRATION
5 minutes
Rat number
Time 1 2 3 4 5 6
0,5 0.564 0.572 0.653 0.491 0.546 0.783
1 0.454 0.510 0.603 0.384 0.484 0.620
1.5 0.364 0.364 0.425 0.355 0.361 0.513
2 0.304 0.308 0.387 0.294 0.342 0.411
2.5 0.247 0.286 0.304 0.277 0.342 0.377
3 0.196 0.249 0.260 0.275 0.321 0.326
3.5 0.189 0.244 0.248 0.233 0.296 0.302
4 0.170 0.181 0.228 0.206 0.266 0.291
4.5 0.157 0.203 0.182 0.219 0.259 0.256
5 0.118 0.179 0.195 0.179 0.250 0.244
10 minutes
Rat number
Time 1 2 3 4 5 6
1 0.365 0.447 0.402 0.436 0.311 0.539
2 0.239 0.442 0.231 0.331 0.237 0.386
3 0.178 0.349 0.168 0.248 0.157 0.272
4 0.132 0.282 0.115 0.218 0.137 0.259
5 0.117 0.256 0.103 0.173 0.099 0.192
6 0.097 0.241 0.087 0.164 0.088 0.209
7 0.080 0.204 0.083 0.147 0.082 0.168
8 0.095 0.210 0.079 0.132 0.065 0.155
9 0.074 0.182 0.079 0.143 0.060 0.136
10 0.074 0.170 0.070 0.117 0.053 0.143
30 minutes
Rat number
Time 1 2 3 4 5 6
5 0.262 0.129 0.343 0.080 0.040 0.091
10 0.176 0.085 0.286 0.048 0.031 0.047
15 0.112 0.055 0.188 0.036 0.018 0.032
20 0.124 0.055 0.175 0.030 0.021 0.036
25 0.112 0.067 0.142 0.030 0.019 0.036
30 0.108 0.061 0.126 0.027 0.021 0.028
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N-(2-HYDR0XYPR0PYL)METHACRYLAMIDE POLYMER 
DISTRIBUTION PROFILE
Effect of regional administration:
Results expressed as a percentage of the recovered dose(per gram). 
INTRA-VENOUS ADMINISTRATION 
5 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 54.2(5.06) 60.4(5.08) 67.1(5.89) 38.7(2.87) 57.5(5.58) 58.5(4.29)
Tumour 1.07(0.25) 1.65(0.32) 1.74(0.97) 1.30(0.21) 0.47(0.29) 0.91(0.16)
Heart 0.59(0.62) 0.35(0.35) 0.41(0.41) 2.90(1.90) 0.30(0.31) 0.82(0.83)
Lung 1.74(0.72) 0.91(0.37) 1.06(0.39) 22.0(6.11) 0.94(0.30) 5.43(2.69)
Kidney 3.20(1.64) 0.47(0.20) 7.56(3.35) 6.48(2.70) 6.62(3.31) 5.80(2.23)
Spleen 0.21(0.21) 0.12(0.09) 0.19(0.19) 0.41(0.30) 0.46(0.42) 0.50(0.71)
Carcass 38.9(0.15) 35.9(0.16) 21.9(0.08) 27.9(0.09) 33.6(0.13) 41.0(0.13)
10 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 57.9(5.31) 61.3(5.76) 56.7(3.83) 76.6(5.35) 69.5(7.02) 73.4(7.06)
Tumour 0.61(0.16) 0.51(0.13) 1.31(0.25) 1.24(0.12) 0.85(0.85) 1.14(0.67)
Heart 0.34(0.38) 0.34(0.42) 0.31(0.29) 0.68(0.49) 0.21(0.21) 0.47(0.43)
Lung 3.66(1.59) 0.56(0.22) 0.75(0.20) 0.92(0.29) 0.78(0.25) 11.3(2.94)
Kidney 0.77(0.38) 1.37(0.70) 3.08(1.23) 4.80(1.82) 6.93(3.47) 1.83(0.83)
Spleen 0.10(0.10) 0.20(0.20) 0.21(0.17) 0.06(0.05) 0.26(0.33) 0.28(0.32)
Carcass 36.4(0.14) 35.6(0.13) 37.5(0.15) 15.1(0.05) 19.6(0.08) 11.5(0.05)
30 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 62.5(6.51) 65.3(5.23) 76.0(7.70) 62.8(6.08) 70.1(4.87) 57.7(5.24)
Tumour 1.13(0.31) 2.15(0.42) 0.15(0.11) 1.42(0.57) 1.04(0.16) 0.36(0.48)
Heart 0.26(0.28) 0.31(0.31) 0.29(0.26) 0.10(0.08) 0.16(0.09) 0.14(0.15)
Lung 0.51(0.19) 0.95(0.39) 0.65(0.21) 0.38(0.14) 0.43(0.10) 0.64(0.20)
Kidney 5.29(2.64) 7.61(2.93) 2.02(1.01) 8.04(3.28) 0.89(0.31) 8.57(3.89)
Spleen 0.26(0.26) 0.40(0.67) 0.32(0.35) 0.27(0.24) 0.24(0.27) 0.36(0.40)
Carcass 29.9(0.13) 23.4(0.07) 20.5(0.08) 26.9(0.10) 27.1(0.08) 26.4(0.09)
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INTRA-ARTERIAL ADMINISTRATION
5 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 54.6(5.72) 49.2(5.23) 57.4(7.13) 55.7(5.67) 60.0(6.26) 58.9(7.46)
Tumour 3.92(1.36) 2.23(0.45) 1.84(0.54) 4.02(1.34) 4.31(1.27) 4.31(0.68)
Heart 0.89(0.74) 1.30(1.30) 0.99(1.10) 0.74(0.70) 0.70(0.74) 0.45(0.41)
Lung 1.60(0.84) 1.64(1.02) 1.11(0.92) 0.61(0.45) 0.86(0.59) 0.34(0.18)
Kidney 2.28(0.95) 6.60(2.87) 9.88(5.20) 5.10(1.96) 4.36(2.03) 9.34(4.76)
Spleen 0.65(0.59) 1.16(1.10) 1.11(1.48) 0.51(0.54) 3.69(4.10) 0.44(0.42)
Carcass 39.0(0.15) 38.8(0.15) 27.5(0.12) 33.2(0.12) 26.0(0.09) 26.1(0.09)
10 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver
Tumour
Heart
Lung
Kidney
Spleen
Carcass
61.6(7.33)
1.64(1.26)
0.70(0.70)
1.90(1.27)
3.71(1.76)
0.81(0.95)
29.5(0.12)
50.7(5.45)
10.4(2.67)
0.59(0.59)
1.12(0.83)
4.71(2.04)
0.59(0.82)
32.2(0.12)
49.9(4.92)
1.01(0.27)
1.03(1.12)
1.45(0.91)
6.10(2.59)
0.96(1.07)
39.4(0.14)
53.3(5.36)
2.75(0.60)
0.86(0.78)
0.97(0.61)
11.1(4.66)
0.81(0.70)
30.0(0.11)
61.9(4.76)
3.15(0.78)
0.53(0.48)
I.26(0.70)
II.5(4.79) 
0.90(0.94) 
21.2(0.07)
58.8(4.67)
1.20(0.27)
0.64(0.67)
0.91(0.53)
6.38(2.90)
0.71(0.79)
31.2(0.11)
30 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver
Tumour
Heart
Lung
Kidney
Spleen
Carcass
65.4(6.79)
1.12(0.20)
0.55(0.69)
0.68(0.52)
8.77(4.47)
0.51(0.57)
22.9(0.09)
64.0(6.10)
1.21(0.19)
0.75(0.83)
1.05(0.66)
2.74(1.24)
1.02(1.01)
29.1(0.10)
55.8(5.75)
1.80(0.54)
0.46(0.54)
0.70(0.44)
8.85(3.85)
0.44(0.63)
31.8(0.13)
73.8(7.77)
1.73(0.93)
0.45(0.41)
0.63(0.41)
9.70(4.41)
0.52(0.65)
13.1(0.05)
55.6(6.04)
1.01(1.26)
1.30(1.37)
0.49(0.31)
4.69(2.04)
0.67(0.89)
37.2(0.14)
56.3(5.66)
0.89(1.05)
0.34(0.31)
0.47(0.27)
16.1(7.00)
0.39(0.58)
25.4(0.09)
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INTRAPORTAL ADMINISTRATION
5 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 57.8(6.35) 57.5(5.64) 55.0(6.18) 62.4(7.34) 58.7(7.43) 54.4(5.72)
Tumour 1.93(0.33) 1.38(0.45) 1.49(0.29) 1.43(0.26) 0.61(0.31) 1.28(0.67)
Heart 0.64(0.71) 0.88(0.84) 0.53(0.50) 0.67(0.74) 1.07(1.19) 0.88(0.88)
Lung 0.86(0.61) 1.43(1.02) 1.09(1.13) 0.85(0.57) 1.08(0.98) 1.14(0.71)
Kidney 4.34(1.93) 5.09(2.55) 6.10(2.93) 3.00(1.59) 9.27(5.15) 4.81(2.18)
Spleen 0.83(0.92) 0.69(0.98) 0.53(0.56) 0.57(0.76) 0.62(0.77) 0.98(1.15)
Carcass 33.5(0.12) 32.9(0.11) 35.2(0.12) 31.1(0.14) 28.6(0.13) 36.5(0.15)
10 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 64.3(6.99) 58.5(5.73) 61.2(6.73) 60.4(6.16) 68.6(7.62) 57.9(6.43)
Tumour 0.77(0.39) 1.07(0.24) 1.25(1.25) 0.56(0.47) 0.32(0.53) 1.80(0.67)
Heart 0.63(0.66) 0.71(0.67) 0.34(0.37) 0.68(0.85) 0.48(0.53) 0.92(1.08)
Lung 0.76(0.54) 1.11(0.79) 0.61(0.47) 0.76(0.54) 0.48(0.30) 0.99(0.74)
Kidney 6.19(3.01) 1.69(0.70) 8.51(4.25) 3.05(1.38) 4.32(2.06) 2.72(1.29)
Spleen 0.45(0.60) 0.66(0.66) 0.49(0.49) 0.40(0.57) 0.47(0.59) 0.73(0.91)
Carcass 26.8(0.10) 36.2(0.13) 27.5(0.11) 34.0(0.13) 24.9(0.10) 34.8(0.14)
30 minutes
% R.D.(% R.D./gm)
Animal 1 2 3 4 5 6
Liver 66.1(5.55) 62.7(4.48) 59.5(5.67) 69.0(7.19) 59.3(6.52) 63.3(7.19)
Tumour 0.53(0.22) 1.06(0.25) 1.38(0.37) 1.70(0.28) 3.31(1.54) 4.51(1.07)
Heart 0.33(0.31) 0.45(0.43) 0.74(0.61) 0.35(0.44) 0.71(0.71) 0.34(0.32)
Lung 0.40(0.28) 0.69(0.38) 0.45(0.30) 0.38(0.32) 0.49(0.38) 0.51(0.33)
Kidney 0.81(0.34) 1.78(1.58) 1.47(0.61) 6.80(4.01) 15.2(6.91) 11.7(6.16)
Spleen 0.41(0.61) 0.42(0.37) 0.84(0.76) 0.23(0.38) 0.38(0.51) 0.42(0.47)
Carcass 31.3(0.11) 32.9(0.11) 35.5(0.13) 21.4(0.08) 20.4(0.08) 19.1(0.07)
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APPENDIX 5c
14C-HAEMATOPORPHYRIN DERIVATIVE DISTRIBUTION STUDIES.
EFFECT OF TIME ON DISTRIBUTION PROFILE
Results expressed as a percentage recovered dose(per gram)
Days following injection 1 mean recovered dose = 1104922cts
Animal 1 Animal 2 Mean % R.D./g
Liver 37.0(3.36) 18.4(1.51) 2.43
Tumour 2.99(1.91) 4.46(1.75) 1.82
Heart 0.55(0.73) 2.01(2.11) 1.42
Lung 1.89(0.70) 2.00(0.91) 0.80
Kidney 2.76(1.62) 4.89(2.44) 2.03
Spleen 3.26(4.34) 1.46(1.78) 3.06
Carcass 50.9(0.24) 66.2(0.27) 0.25
Skin 0.56(0.46) 0.48(0.40) 0.43
following injection 3 mean recovered dose = 773359
Animal 1 Animal 2 Mean % R.D./g
Liver 59.4(4.10) 48.8(3.23) 3.66
Tumour 7.59(1.58) 5.53(1.15) 1.37
Heart 0.82(0.97) 0.43(0.41) 0.69
Lung 0.61(0.32) 1.21(0.62) 0.47
Kidney 6.51(3.25) 3.27(1.64) 2.44
Spleen 3.93(3.93) 1.99(1.99) 2.96
Carcass 20.3(0.09) 38.1(0.16) 0.12
Skin 0.68(0.61) 0.48(0.30) 0.45
following injection 5 mean recovered dose = 666497
Animal 1 Animal 2 Mean % R.D./g
Liver 47.4(3.92) 54.1(4.36) 4.14
Tumour 6.76(1.05) 9.13(2.02) 1.53
Heart 0.23(0.23) 0.31(0.27) 0.25
Lung 0.60(0.19) 0.59(0.24) 0.21
Kidney 4.51(2.14) 3.42(1.59) 1.86
Spleen 2.11(1.92) 5.36(5.36) 3.64
Carcass 37.9(0.16) 26.8(0.11) 0.13
Skin 0.32(0.64) 0.19(0.32) 0.48
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Days following injection 7 mean recovered dose = 560425
Animal 1 Animal 2 Mean % R.D./g
Liver 48.0(3.38) 57.2(4.81) 4.01
Tumour 11.9(2.17) 2.50(2.00) 2.01
Heart 0.38(0.34) 0.31(0.28) 0.31
Lung 0.85(0.36) 0.74(0.23) 0.30
Kidney 4.02(1.91) 1.96(1.09) 1.49
Spleen 3.86(3.86) 3.32(3.32) 3.57
Carcass 30.4(0.12) 35.0(0.05) 0.08
Skin 0.46(0.48) 0.40(0.54) 0.51
Days following injection 9 mean recovered dose = 537791
Animal 1 Animal 2 Mean % R.D./g
Liver 43.0(4.30) 43.9(4.93) 4.61
Tumour 10.8(1.91) 11.3(2.01) 1.95
Heart 0.39(0.43) 0.45(0.37) 0.40
Lung 0.32(0.17) 0.74(0.34) 0.51
Kidney 5.00(2.94) 6.06(3.74) 3.34
Spleen 4.82(5.34) 5.76(6.40) 5.87
Carcass 34.4(0.14) 30.2(0.11) 0.12
Skin 1.16(1.93) 1.60(2.67) 2.31
Days following injection 11 mean recovered dose = 505761
Animal 1 Animal 2 Mean % R.D./g
Liver 43.1(4.19) 45.1(4.96) 4.57
Tumour 10.5(1.42) 6.66(2.22) 1.82
Heart 0.31(0.35) 0.56(0.56) 0.45
Lung 0.38(0.20) 0.47(0.20) 0.20
Kidney 4.28(2.44) 3.95(2.00) 2.22
Spleen 5.52(6.90) 4.76(5.29) 6.09
Carcass 33.9(0.13) 36.2(0.13) 0.13
Skin 1.83(1.66) 2.23(1.85) 1.75
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APPENDIX 6a
SECOND ORDER TARGETING EXPERIMENTS:
PILOT STUDY:
(Comparing variable sequences of administration of combined 
angiotensin II and degradable starch microspheres)
99mMDP + Angiotensin II + DSM simultaneously:
One minute:
Animal number 1
Weight total counts
Liver 8610 7702875
Tumour 760 116800
Tumour/liver ratio = 0.13 : 1
Animal number 2
Weight total counts
Liver 8770 20323287
Tumour 1270 1998223
Tumour /liver ratio = 0.68 : 1
Animal number 3
Weight total counts
Liver 11100 32320596
Tumour 1600 3127937
Tumour /liver ratio = 0.67 : 1
90 minutes:
Animal number 4
Weight total counts
Liver 9220 717950
Tumour 2160 285813
Tumour /liver ratio = 1.7 : 1
Animal number 5
Weight total counts
Liver 8770 392609
Tumour 1470 217250
Tumour /liver ratio = 3.3 : 1
Animal number 6 Reference = 1768521
Weight total counts % inj.dose % Inj.dose/g
Liver 9210 993909 0.562 0.061
Tumour 1250 465121 0.263 0.210
Tumour /liver ratio = 3.44 : 1
Reference = 974217
% inj.dose % Inj.dose/g 
0.403 0.046
0.223 0.152
Reference = 1367524
% inj.dose % Inj.dose/g 
0.525 0.057
0.209 0.097
Reference = 2124957
% inj.dose % Inj.dose/g 
15.21 1.37
1.472 0.92
Reference = 2186240
% inj.dose % Inj.dose/g 
9.296 1.06
0.914 0.72
Reference = 1344671 
% inj.dose % Inj.dose/g 
5.728 0.660
0.066 0.087
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DSM before 99mMDP + Angiotensin II
One minute:
Animal number 7
Weight total counts 
Liver 9320 13799745
Tumour 2310 2223607
Tumour /liver ratio = 0.65 : 1
Reference = 1715746
% inj.dose % Inj.dose/g
8.043 0.863
1.296 0.561
Animal number 8
Weight total counts 
Liver 10620 17531103
Tumour 1800 1804716
Tumour/liver ratio = 0.61 : 1
Reference = 1474441
% inj.dose % Inj.dose/g
11.89 1.12
1.224 0.68
Animal number 9
Weight total counts 
Liver 9450 9300927
Tumour 1540 1020250
Tumour /liver ratio = 0.67 : 1
Reference = 919973
% inj.dose % Inj.dose/g 
10.11 1.07
1.109 0.72
90 minutes:
Animal number 10 Reference = 1466721
Weight total counts % inj.dose % Inj.dose/g
Liver 8660 558821 0.381 0.044
Tumour 1550 363747 0.248 0.16
Tumour /liver ratio = 3.63 : 1
Animal number 11 Reference = 1107821
Weight total counts % inj.dose % Inj.dose/g
Liver 10870 625919 0.565 0.052
Tumour 2110 387737 0.35 0.166
Tumour /liver ratio = 3.19 : 1
Animal number 12 Reference = 987234
Weight total counts % inj.dose % Inj.dose/g
Liver 9270 448204 0.454 0.049
Tumour 1140 194485 0.197 0.173
Tumour /liver ratio = 3.53 : 1
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Angiotensin II before DSM + 99mMDP
One minute:
Animal number 13
Weight total counts 
Liver 7760 6451370
Tumour 1900 1212972
Tumour /liver ratio = 0.77 : 1
Reference = 831362
% inj.dose % Inj.dose/g
7.76 1.000
1.459 0.768
Animal number 14
Weight total counts 
Liver 7190 3985024
Tumour 960 529710
Tumour /liver ratio = 1.04 : 1
Reference = 507452
% inj.dose % Inj.dose/g
7.853 1.092
1.087 1.132
Animal number 15
Weight total counts 
Liver 12340 4246839
T umour 1980 464218
Tumour /liver ratio = 0.68 : 1
Reference = 577251
% inj.dose % Inj.dose/g
7.357 0.596
0.804 0.406
90 minutes:
Animal number 16 Reference = 2112317
Weight total counts % inj.dose % Inj.dose/g
Liver 7920 549202 0.26 0.033
Tumour 1750 1394129 0.66 0.377
Tumour /liver ratio = 11.4 : 1
Animal number 17 Reference = 713924
Weight total counts % inj.dose % Inj.dose/g
Liver 9410 388374 0.544 0.057
Tumour 850 92096 0.129 0.152
Tumour /liver ratio = 2.66 : 1
Animal number 18 Reference = 1348564
Weight total counts % inj.dose % Inj.dose/g
Liver 8730 734967 0.545 0.0624
Tumour 1490 797001 0.591 0.397
Tumour /liver ratio = 6.36 : 1
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APPENDIX 6b
SECOND ORDER TARGETING EXPERIMENTS:
COMPARATIVE STUDY:
(Comparing saline controls with the combination of DSM plus Angiotensin II and 
DSM alone.)
GROUP 1 - Control Animals (MDP + saline alone) 
One minute:
Animal number 1 Reference = 413801
Weight total counts % inj.dose % Inj.dose/g
Liver 8460 2174511 5.25 0.62
Tumour 3190 531907 1.28 0.40
Tumour /liver ratio = 0.65 : 1
Animal number 2 Reference = 3704971
Weight total counts % inj.dose % Inj.dose/g
Liver 9490 4377470 1.18 0.12
Tumour 7735 385297 0.10 0.012
T umour /liver ratio = 0.10: 1
Animal number 3 Reference = 3704971
Weight total counts % inj.dose % Inj.dose/g
Liver 9790 2283820 0.61 0.062
Tumour 7470 1707083 0.46 0.060
Tumour /liver ratio = 0.97 : 1
Animal number 4 Reference = 2472861
Weight total counts % inj.dose % Inj.dose/g
Liver 8970 2352371 0.95 0.10
Tumour 6400 985751 0.39 0.062
Tumour /liver ratio = 0.62 : 1
Animal number 5 Reference = 2556684
Weight total counts % inj.dose % Inj.dose/g
Liver 8210 2742258 1.072 0.13
Tumour 1290 296831 0.116 0.09
Tumour /liver ratio = 0.69 : 1
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Animal number 6
Weight total counts 
Liver 7600 593077
Tumour 2030 134059
Tumour /liver ratio = 0.85 : 1
Reference = 880590
% inj.dose % Inj.dose/g 
0.673 0.088
0.15 0.075
Animal number 7
Weight total counts 
Liver 10600 536737
Tumour 2690 97597
Tumour /liver ratio = 0.75 : 1
Reference = 400442
% inj.dose % Inj.dose/g
1.34 0.120
0.24 0.090
Animal number 8
Weight total counts 
Liver 9660 392849
Tumour 1140 36194
Tumour /liver ratio = 0.63 : 1
Reference = 844791
% inj.dose % Inj.dose/g 
0.46 0.048
0.037 0.033
90 minutes:
Animal number 1
Weight total counts 
Liver 9050 567237
Tumour 5460 298768
Tumour / liver ratio = 0.79 : 1
Reference = 819512
% inj.dose % Inj.dose/g 
0.69 0.076
0.36 0.060
Animal number 2
Weight total counts 
Liver 8140 872206
Tumour 3550 685659
Tumour/liver ratio = 0.18 : 1
Reference = 1567430
% inj.dose % Inj.dose/g 
0.55 0.068
0.43 0.012
Animal number 3
Weight total counts 
Liver 10090 1895919
Tumour 5231 1007076
Tumour /liver ratio = 1.02 : 1
Reference = 2846153
% inj.dose % Inj.dose/g 
0.666 0.066
0.35 0.067
Animal number 4
Weight total counts 
Liver 10370 1647389
Tumour 5180 896068
Tumour /liver ratio = 1.09 : 1
Reference = 2168735
% inj.dose % Inj.dose/g 
0.759 0.073
0.413 0.079
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Animal number 5 Reference = 518787
Weight total counts % inj.dose % Inj.dose/g
Liver 9780 858520 1.65 0.16
Tumour 3880 108329 0.20 0.053
Tumour /liver ratio = 0.33 : 1
Animal number 6 Reference = 1894343
Weight total counts % inj.dose % Inj.dose/g
Liver 7680 747855 0.394 0.051
Tumour 1950 88536 0.047 0.023
Tumour /liver ratio = 0.45 : 1
Animal number 7 Reference = 751534
Weight total counts % inj.dose % Inj.dose/g
Liver 7740 399959 0.53 0.068
Tumour 1750 48280 0.064 0.036
Tumour /liver ratio = 0.53 : 1
Animal number 8 Reference = 1580392
Weight total counts % inj.dose % Inj.dose/g
Liver 9720 818604 0.51 0.053
Tumour 5560 112875 0.071 0.012
Tumour /liver ratio = 0.23 : 1
GROUP 2 - DSM + MDP + Saline
One minute:
Animal number 1
Weight total counts 
Liver 11210 5159403
Tumour 3200 2506071
Tumour /liver ratio = 1.70 : 1
Reference = 389445
% inj.dose % Inj.dose/g 
13.25 1.182
6.434 2.01
Animal number 2
Weight total counts 
Liver 7930 3983625
Tumour 9200 451818
Tumour /liver ratio = 0.96 : 1
Reference = 432947
% inj.dose % Inj.dose/g 
9.201 1.16
1.043 0.113
Animal number 3
Weight total counts 
Liver 7120 2392003
Tumour 4540 510520
Tumour /liver ratio = 0.33 : 1
Reference = 412879
% inj.dose % Inj.dose/g 
5.79 0.813
1.23 0.272
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Animal number 4
Weight total counts 
Liver 10990 3878471
Tumour 3040 457067
Tumour /liver ratio = 0.43 : 1
Reference = 485706
% inj.dose % Inj.dose/g 
7.985 0.726
0.941 0.309
Animal number 5
Weight total counts 
Liver 10290 4721872
Tumour 2490 4849320
Tumour /liver ratio = 4.24 : 1
Reference = 427583
% inj.dose % Inj.dose/g
11.04 1.073
11.30 4.550
Animal number 6
Weight total counts 
Liver 11030 3603396
Tumour 220 19623
Tumour/liver ratio = 0.27 : 1
Reference = 414948
% inj.dose % Inj.dose/g 
8.68 0.787
0.047 0.210
Animal number 7
Weight total counts 
Liver 11760 4043294
Tumour 3470 4251543
Tumour /liver ratio = 3.56 : 1
Reference = 454815
% inj.dose % Inj.dose/g 
8.88 0.755
9.34 2.690
Animal number 8
Weight total counts 
Liver 9560 4527281
Tumour 2520 95489
Tumour /liver ratio = 0.08 : 1
Reference = 436549
% inj.dose % Inj.dose/g 
10.32 1.080
0.218 0.086
90 minutes:
Animal number 1
Weight total counts 
Liver 10660 577032
Tumour 2270 417712
Tumour /liver ratio = 3.41 : 1
Reference = 417071
% inj.dose % Inj.dose/g 
1.380 0.129
1.001 0.44
Animal number 2
Weight total counts 
Liver 9020 865616
Tumour 6170 1269935
Tumour /liver ratio = 2.14 : 1
Reference = 336314
% inj.dose % Inj.dose/g 
2.572 0.285
3.776 0.612
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Animal number 3
Weight total counts 
Liver 9120 279133
Tumour 3130 134386
Tumour /liver ratio = 1.41 : 1
Reference = 353685
% inj.dose % Inj.dose/g 
0.789 0.086
0.379 0.121
Animal number 4
Weight total counts 
Liver 8580 266439
Tumour 5240 554344
Tumour /liver ratio = 3.44 : 1
Reference = 502741
% inj.dose % Inj.dose/g 
0.529 0.061
1.102 0.21
Animal number 5
Weight total counts 
Liver 9490 197141
Tumour 3460 144113
Tumour /liver ratio = 2.00 : 1
Reference = 467544
% inj.dose % Inj.dose/g 
0.421 0.044
0.308 0.089
Animal number 6
Weight total counts 
Liver 13390 465730
Tumour 1590 53672
Tumour /liver ratio = 0.97 : 1
Reference = 420167
% inj.dose % Inj.dose/g 
1.108 0.0827
0.127 0.080
Animal number 7
Weight total counts 
Liver 10590 968566
Tumour 3370 981516
Tumour /liver ratio = 3.19: 1
Reference = 386257
% inj.dose % Inj.dose/g 
2.50 0.236
2.54 0.754
Animal number 8
Weight total counts 
Liver 11440 521717
Tumour 250 23234
Tumour /liver ratio = 2.03 : 1
Reference = 406747
% inj.dose % Inj.dose/g 
1.280 0.112
0.057 0.228
Animal number 9
Weight total counts 
Liver 12920 696120
Tumour 8070 1377771
Tumour /liver ratio = 3.17: 1
Reference = 448399
% inj.dose % Inj.dose/g 
1.552 0.12
3.073 0.380
Animal number 10 
Weight 
Liver 14220
Tumour 8590
total counts
472838
893918
Reference = 583161
% inj.dose % Inj.dose/g 
0.810 0.05
1.532 0.178
Tumour /liver ratio = 3.56 : 1
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Animal number 11
Weight total counts 
Liver 11080 532124
Tumour 12660 378852
Tumour /liver ratio = 0.06 : 1
Reference = 541348
% inj.dose % Inj.dose/g 
0.982 0.887
0.699 0.055
Animal number 12
Weight total counts 
Liver 11040 3391602
Tumour 2580 78675
Tumour /liver ratio = 0.01 : 1
Reference = 348627
% inj.dose % Inj.dose/g 
9.728 0.88
0.225 0.087
GROUP 3 - Angiotensin II followed by DSM and 99mMDP
One minute:
Animal number 1
Weight total counts 
Liver 7760 6451370
Tumour 1900 1212972
Tumour/liver ratio = 0.77 : 1
Reference = 831362
% inj.dose % Inj.dose/g
7.76 1.000
1.459 0.768
Animal number 2
Weight total counts 
Liver 7190 3985024
Tumour 960 529710
Tumour /liver ratio = 1.04 : 1
Reference = 507452
% inj.dose % Inj.dose/g
7.853 1.092
1.087 1.132
Animal number 3
Weight total counts
Liver 12340 4246839
Tumour 1980 464218
Tumour/liver ratio = 0.68 : 1
Animal number 4
Weight total counts
Liver 12420 8142463
Tumour 4930 7238411
Tumour /liver ratio = 2.24 : 1
Animal number 5
Weight total counts
Liver 11730 4392230
Tumour 5360 2843778
Tumour/liver ratio = 1.41 : 1
Reference = 577251
% inj.dose % Inj.dose/g
7.357 0.596
0.804 0.406
Reference = 735674
% inj.dose % Inj.dose/g
11.07 0.891
9.938 1.995
Reference = 825623
% inj.dose % Inj.dose/g
5.319 0.453
3.444 0.643
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Animal number 6
Weight total counts 
Liver 7780 3537546
Tumour 750 83329
Tumour /liver ratio = 0.24 : 1
Reference = 422348
% inj.dose % Inj.dose/g 
8.375 1.076
0.197 0.263
Animal number 7
Weight total counts 
Liver 10820 4662752
Tumour 1340 168515
Tumour /liver ratio = 0.29 : 1
Reference = 397343
% inj.dose % Inj.dose/g
11.73 1.085
0.424 0.316
Animal number 8
Weight total counts 
Liver 9710 3240041
Tumour 1500 200762
Tumour /liver ratio = 0.39 :1
Reference = 819557
% inj.dose % Inj.dose/g 
3.953 0.407
0.24 0.16
90 minutes:
Animal number 1
Weight total counts 
Liver 7920 549202
Tumour 1750 1394129
Tumour /liver ratio = 11.4 :1
Reference = 2112317
% inj.dose % Inj.dose/g 
0.26 0.033
0.66 0.377
Animal number 2
Weight total counts 
Liver 9410 388374
Tumour 850 92096
Tumour /liver ratio = 2.66 : 1
Reference = 713924
% inj.dose % Inj.dose/g 
0.544 0.057
0.129 0.152
Animal number 3
Weight total counts 
Liver 8730 734967
Tumour 1490 797001
Tumour /liver ratio = 6.36 :1
Reference = 1348564
% inj.dose % Inj.dose/g 
0.545 0.0624
0.591 0.397
Animal number 4
Weight total counts
Liver 12410 885688
Tumour 3850 2720052
Tumour /liver ratio = 9.90 :1
Reference = 764030
% inj.dose % Inj.dose/g 
1.159 0.0934
3.56 0.925
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Animal number 5
Weight total counts 
Liver 9650 1174918
Tumour 1810 1565789
Tumour /liver ratio = 7.11 : 1
Reference = 827469
% inj.dose % Inj.dose/g 
1.419 0.147
1.892 1.045
Animal number 6
Weight total counts 
Liver 15020 812602
Tumour 13060 3942415
Tumour /liver ratio = 5.57 : 1
Reference = 528325
% inj.dose % Inj.dose/g 
1.538 0.102
7.462 0.571
Animal number 7
Weight total counts 
Liver 15130 875742
Tumour 2850 694762
Tumour /liver ratio = 4.36 : 1
Reference = 508520
% inj.dose % Inj.dose/g 
1.722 0.11
1.366 0.4793
Animal number 8
Weight total counts 
Liver 10310 892723
Tumour 7560 1260722
Tumour/liver ratio = 1.92 : 1
Reference = 534494
% inj.dose % Inj.dose/g 
1.670 0.162
2.358 0.312
Animal number 9
Weight total counts 
Liver 8530 1207854
Tumour 3440 2989210
Tumour /liver ratio = 6.14 : 1
Reference = 794946
% inj.dose % Inj.dose/g 
1.519 0.178
3.76 1.093
Animal number 10
Weight total counts 
Liver 9600 1569671
Tumour 1360 768126
Tumour /liver ratio = 3.46 : 1
Reference = 776593
% inj.dose % Inj.dose/g
2.02 0.21
0.989 0.727
Animal number 11
Weight total counts 
Liver 11.76 1040108
Tumour 40 857681
Tumour /liver ratio = 4.33 : 1
Reference = 369589
% inj.dose % Inj.dose/g 
2.814 0.239
2.320 1.036
Animal number 12
Weight total counts 
Liver 12600 434431
Tumour 2970 498664
Tumour /liver ratio = 4.87 : 1
Reference = 565070
% inj.dose % Inj.dose/g 
0.768 0.061
0.882 0.297
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